


**CUMULATIVE
SUPPLEMENT 4
APRIL 2013**



**APPROVED
DRUG PRODUCTS**

**WITH
THERAPEUTIC EQUIVALENCE EVALUATIONS**

33rd EDITION

Department of Health and Human Services

**Food and Drug Administration
Center for Drug Evaluation and Research
Office of Generic Drugs**

2013

Prepared By
Office of Generic Drugs
Center for Drug Evaluation and Research
Food and Drug Administration

**APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS**

33rd EDITION

Cumulative Supplement 4

April 2013

CONTENTS

	<i>PAGE</i>
1.0 INTRODUCTION.....	iii
1.1 How to use the Cumulative Supplement	iii
1.2 Cumulative Supplement Content	iv
1.3 Applicant Name Changes	v
1.4 Levothyroxine Sodium.....	v
1.5 Availability of the Edition.....	vi
1.6 Report of Counts for the Prescription Drug Product List.....	vii
1.7 Cumulative Supplement Legend	viii
 DRUG PRODUCT LISTS	
Prescription Drug Product List	1-1
OTC Drug Product List	2-1
Drug Products with Approval under Section 505 of the Act	
Administered by the Center for Biologics Evaluation and Research List.....	3-1
Orphan Product Designations and Approvals List	4-1
Drug Products Which Must Demonstrate in vivo Bioavailability	
Only if Product Fails to Achieve Adequate Dissolution	5-1
 PATENT AND EXCLUSIVITY INFORMATION ADDENDUM	
A. Patent and Exclusivity Lists	A-1
B. Patent and Exclusivity Terms	B-1

**APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS**

33rd EDITION

**CUMULATIVE SUPPLEMENT 4
April 2013**

1.0 INTRODUCTION

1.1 HOW TO USE THE CUMULATIVE SUPPLEMENT

This Cumulative Supplement is one of a series of monthly updates to the Approved Drug Products with Therapeutic Equivalence Evaluations, 30th Edition (the List). The List is composed of four parts: approved prescription drug products with therapeutic equivalence evaluations; over-the-counter (OTC) drug products that require approved applications as a condition of marketing; drug products with approval under Section 505 of the Act administered by the Center for Biologics Evaluation and Research; and products that have never been marketed, are for exportation, are for military use, have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons.

The Cumulative Supplement provides, among other things, information on newly approved drugs and, if necessary, revised therapeutic equivalence evaluations and updated patent and exclusivity data. The Addendum contains appropriate drug patent and exclusivity information required of the Agency by the "Drug Price Competition and Patent Term Restoration Act of 1984" for the Prescription, OTC, and Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research Lists.

Because all parts of the publication are subject to changes, additions, or deletions, the List must be used in conjunction with the most current Cumulative Supplement. Users may wish to mark to the left of the ingredient(s) in the List to indicate that changes to that entry appear in the Cumulative Supplement. Drug product information is provided in each Cumulative Supplement for completeness to assist in locating the proper place in the List for the revision.

The presence of any therapeutic equivalence code indicates that the drug product is multisource; the deletion of a therapeutic equivalence code indicates that the drug product has become single source. (An infrequent exception exists when a therapeutic equivalence code is revised. In that case, the deletion of the therapeutic equivalence code is followed immediately by the addition of the revised one.)

Products that have never been marketed, are for exportation, are for military use, or have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons, will be flagged in this Cumulative Supplement with the "@" symbol to designate their non-marketed status. All products having a "@" symbol in the 12th Cumulative Supplement of the 32nd Edition List will then be added to the "Discontinued Drug Product List" appearing in the 33rd Edition. The current Edition Section 2., How To Use The Drug Product Lists, describes the layout and usage of the List.

New additions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >A>. The Patent and Exclusivity List new additions are indicated by the symbol >A> to the left of Patent Number or Exclusivity Code. The >A> symbol is then dropped in subsequent Cumulative Supplements for that item.

New deletions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >D> (DELETE) to the left of the line. The information line with the >D> symbol is dropped in subsequent Cumulative Supplements for that item.

The Patent and Exclusivity List is arranged in alphabetical order by active ingredient name(s) and trade name. The trade name will follow the active ingredient name separated by a dash symbol. Also shown is the application number and product number (FDA's internal file number) for reference purposes. All patents with their expiration dates are displayed for each application number. Drug substance and drug product patents are indicated as such with DS or DP in the Patent codes column. Use patents are indicated with the symbol "U" followed by a number representing a specific use. Exclusivity information for a specific drug is indicated by an abbreviation followed by the date upon which the exclusivity expires. Refer to the Exclusivity Terms, Section B, in the Patent and Exclusivity Information Addendum for an explanation of all codes and abbreviations. Refer to Section 1.3 for internet access to the most current list of Patent and Exclusivity terms.

1.2 CUMULATIVE SUPPLEMENT CONTENT

Since February 2005, we have been providing daily Electronic Orange Book (EOB) product information for new generic drug approvals. Daily generic updates provide the consumer with the current list of approved generic products which is important for substitution purposes. Previously, a first-time-generic product approved early in the month would not be published in the Cumulative Supplement (CS) for several weeks.

The CS monthly update publish goal is by the end of the following month's second work week (e.g., November's supplement will be updated by the end of the second full work week in December).

Currently, the monthly PDF CS includes:

- Generic product ANDA (Abbreviated New Drug Approval) approvals as of the date of publication.
- All product changes received and processed as of the date of publication.
 - Refer to CS Section 1.8 Cumulative Supplement Legend for types of changes
 - Discontinued products will be processed as of the date of publication. There will be circumstances where a product is discontinued in one month, however, it will be reported in a different month's CS. For example, the Orange Book Staff received a letter November 7 that the product has been discontinued from manufacturing and marketing. The Orange Book subsequently publishes the October CS on November 14. The product will show in the October CS that it is discontinued even though the date of discontinuance is the day that the Orange Book Staff receives notification (November 7).
- New Drug Application (NDA) approvals appear in the CS month they were approved.

- Patent information, also updated daily in the EOB, is current to the date of publication.
- Exclusivity information is updated monthly and current to the date of publication.

Every effort is made to ensure the Cumulative Supplement is current and accurate. Applicant holders are requested to inform the FDA Orange Book Staff (OBS) of any changes or corrections. The OBS can be contacted by email at drugproducts@fda.hhs.gov. Send Changes by FAX: 240-276-8974; mail to:

FDA/CDER Orange Book Staff
Office of Generic Drugs, HFD-610
7620 Standish Place
Rockville, MD 20855-2773

1.3 APPLICANT NAME CHANGES

It is not practical to identify in the Cumulative Supplement each and every product involved when an applicant transfers its entire line of approved drug products to another applicant, or when an applicant changes its name. Therefore, the cumulation of these transfers and name changes will be identified in this section only. Where only partial lines of approved products are transferred between applicants, each approved product involved will appear as an applicant name change entry in the Cumulative Supplement.

It is also not practical to identify each and every product involved when an applicant name is changed to meet internal publication standards (e.g., MSD or Zenith [Former Abbreviated Names] are changed, respectively to Merck Sharp Dohme or Zenith Labs [New Abbreviated Names]). When this occurs, each product involved (either currently in the Cumulative Supplement or in the following year's edition) will reflect the new abbreviated name. Consequently, it will not appear as an applicant name change entry in the Cumulative Supplement nor will the cumulation of these name changes appear in this section. The Electronic Orange Book Query, updated monthly, will contain the most current applicant holder name.

FORMER APPLICANT NAME
(FORMER ABBREVIATED NAME)

NEW APPLICANT NAME
(NEW ABBREVIATED NAME)

BIONICHE PHARMA USA LLC
(BIONICHE PHARMA USA)

MYLAN INSTITUTIONAL LLC
(MYLAN LLC)

1.4 LEVOTHYROXINE SODIUM

Because there are multiple reference listed drugs of levothyroxine sodium tablets and some reference listed drugs' sponsors have conducted studies to establish their drugs' therapeutic equivalence to other reference listed drugs, FDA has determined that its usual practice of assigning two or three character TE codes may be potentially confusing and inadequate for these drug products. Accordingly, FDA provides the following explanation and chart of therapeutic equivalence evaluations for levothyroxine sodium drug products.

Levothyroxine Sodium (Mylan ANDA 76187) and Levo-T (Alara NDA 21342) tablets have been determined to be therapeutically equivalent to corresponding strengths of Unithroid (Jerome Stevens NDA 021210) tablets. Levo-T (Alara NDA 021342), Levothyroxine Sodium (Mylan ANDA 76187), Unithroid (Jerome Stevens NDA 021210), and Levothyroxine Sodium (Merck

KGAA ANDA 76752)tablets have been determined to be therapeutically equivalent to corresponding strengths of Synthroid (Abbott NDA 021402) tablets.

Levo-T (Alara NDA 021342), Unithroid (Jerome Stevens NDA 021210), Levothyroxine Sodium (Mylan ANDA 076187), and Levothyroxine Sodium (Merck KGAA ANDA 76752) tablets have been determined to be therapeutically equivalent to corresponding strengths of Levoxyl (King Pharms NDA 021301) tablets.

Levothyroxine Sodium (Mylan ANDA 76187) tablets have been determined to be therapeutically equivalent to corresponding strengths of Levothroid (Lloyd NDA 021116) tablets.

The chart outlines TE codes for all 0.025mg products. Other product strengths may be similar. Therapeutic equivalence has been established between products that have the same AB+number TE code. More than one TE code may apply to some products. One common TE code indicates therapeutic equivalence between products.

Trade Name	Applicant	Potency	TE Code	Appl No	Product No
UNITHROID	STEVENS J	0.025MG	AB1	21210	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB1	76187	001
LEVOXYL	KING PHARMS	0.025MG	AB1	21301	001
SYNTHROID	ABBOTT	0.025MG	AB1	21402	001
LEVO-T	ALARA PHARM	0.025MG	AB1	21342	001
SYNTHROID	ABBOTT	0.025MG	AB2	21402	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB2	76187	001
LEVO-T	ALARA PHARM	0.025MG	AB2	21342	001
UNITHROID	STEVENS J	0.025MG	AB2	21210	001
LEVOTHYROXINE SODIUM	MERCK KGAA	0.025MG	AB2	76752	001
LEVOXYL	KUNG PHARMS	0.025MG	AB3	21301	001
LEVO-T	ALARA PHARM	0.025MG	AB3	21342	001
UNITHROID	STEVENS J	0.025MG	AB3	21210	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB3	76187	001
LEVOTHYROXINE SODIUM	MERCK KGAA	0.025MG	AB3	76752	001
LEVOTHROID	LLOYD	0.025MG	AB4	21116	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB4	76187	001

1.5 AVAILABILITY OF THE EDITION

Since 1997, the Electronic Orange Book Query (EOBQ) <http://www.accessdata.fda.gov/scripts/cder/ob/default.cfm>, has been available on the internet and has become the updated-every-month Orange Book. The Query provides searching of the approved drug list by active ingredient, proprietary name, applicant holder, applicant number or patent number. Product search categories are: prescription, over-the-counter, discontinued drugs. There are links to patent and exclusivity information that may be applicable to each product.

Commencing with the 25th edition, the Annual Edition and monthly Cumulative Supplements have been provided in downloadable Portable Document Format (PDF) at the EOB home page by clicking on Publications. The PDF annual and cumulative supplements duplicate previous paper

versions. Over time, there will be an archive for the annuals and each year's December Cumulative Supplement.

The downloaded Annual Edition and Cumulative Supplements are also available in a paper version (Approved Drug Products with Therapeutic Equivalence Evaluations, ADP) from the U.S. Government Printing Office: <http://bookstore.gpo.gov>; toll free 866-512-1800.

There are historical lists of Orange Book cumulative supplement product monthly changes at <http://www.fda.gov/Drugs/InformationOnDrugs/ucm086229.htm>. There are ASCII text files of the Orange Book drug product, patent, and exclusivity data at <http://www.fda.gov/Drugs/InformationOnDrugs/ucm129689.htm>. The drug product text files are provided in eobzip.zip format. The files are updated concurrently with the monthly cumulative supplements. The annual Orange Book Edition Appendices A, B, and C in PDF format are updated quarterly.

Effective August 18, 2003, patent submissions for publication in the Orange Book and Docket *95S-0117 need to be submitted on form FDA-3542 which may be downloaded from the FDA Forms List, <http://www.fda.gov/opacom/morechoices/fdaforms/default.html>.

The current listing of the Orphan Product Designations and Approvals is available at <http://www.fda.gov/orphan/designat/list.htm>.

1.6 REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

DESCRIPTION OF REPORT

This report provides summary counts derived from the product information in the Prescription Drug Product List and the current Cumulative Supplement. Products included in the counts are domestically marketed drug products approved for both safety and effectiveness under section 505 of the Federal Food, Drug, and Cosmetic Act. Excluded are approved drug products marketed by distributors; those marketed solely abroad; and those now regarded as medical devices, biologics or foods.

The baseline column (Dec 2011) refers to the products in the Prescription Drug Product List. For each three-month period, a column of quarterly data is added which incorporates counts of product activity from the previous quarter(s) with those in the baseline count.

DEFINITIONS

Drug Product

For this report, a drug product is the representation in the Prescription Drug Product List of an active moiety (molecular entity and its salts, esters and derivatives) either as a single ingredient or as a combination product provided in a specific dosage form and strength for a given route of administration with approval for marketing by a firm under a particular generic or trade name.

New Molecular Entity

A new molecular entity is considered an active moiety that has not previously been approved (either as the parent compound or as a salt, ester or derivative of the parent compound) in the United States for use in a drug product either as a single ingredient or as part of a combination.

REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST
COUNTS CUMULATIVE BY QUARTER

<u>CATEGORIES COUNTED</u>	<u>DEC 2012</u>	<u>MAR 2013</u>	<u>JUN 2013</u>	<u>SEPT 2013</u>	<u>DEC 2013</u>
DRUG PRODUCTS LISTED	15343	15445			
SINGLE SOURCE	2400 (15.9%)	2467 (16.0%)			
MULTISOURCE	12825 (83.6%)	12900 (83.5%)			
THERAPEUTICALLY EQUIVALENT	12683 (82.7%)	12758 (82.6%)			
NOT THERAPEUTICALLY EQUIVALENT	142 (0.9%)	142 (0.9%)			
EXCEPTIONS ¹	78 (0.5%)	78 (0.5%)			
NEW MOLECULAR ENTITIES APPROVED	17	9			
NUMBER OF APPLICANTS	835	844			

¹Amino acid-containing products of varying composition (see Introduction, page xx of the List).

1.7 CUMULATIVE SUPPLEMENT LEGEND

The List is sorted by Ingredient(s) and, within each grouping, by the Dosage Form; Route and then by trade name.

The individual product record contains the Therapeutic Equivalence Code, Reference Listed Drug symbol, applicant holder, strength(s), New Drug Application number, product number, and approval date. The application number preceded by "N" is a New Drug Application (NDA or innovator). The application number preceded by an "A" is an Abbreviated New Drug Application (ANDA or generic). The last two columns describe the action. The Action Month is the CS month the action occurred. The OB Action is the type of change that has occurred.

New ingredient(s), new dosage form; route(s), new trade names, and new product additions are preceded by >A> during the action month. The change month is the current CS month; the change code for new approvals is NEWA. Following months will display the same information without the >A>.

Changes to currently listed products will list two records. The deleted product record will be preceded by >D>. The product record change addition being made will be preceded by >A>. Following months will display only the >A> record without the >A>. All changes that occur to the product through the Annual year will be listed. The change month and change code will document the change.

The change code and description:

NEWA	New drug product approval usually in the supplement month.
CAHN	Applicant holder firm name has changed.
CAIN	Change. There has been a change in the Ingredient(s) name. All products will be deleted under the old name and all products will be added under the changed ingredient(s) name.
CDFR	Change. Dosage Form; Route of Administration.
CFTG	Change. A first time generic for the innovator product. A TE Code is added.
CMFD	Change. The product is moved from the Discontinued Section due to a change in marketing status.

CMS1	Change. Miscellaneous addition to list.
CMS2	Change. Miscellaneous deletion from list.
CPOT	Change. Potency amount/unit.
CRLD	Change. Reference Listed Drug.
CTEC	Change. Therapeutic Equivalence Code.
CTNA	Change. Trade Name.
DISC	Discontinued. The Rx or OTC listed product is not being marketed and will be moved to the discontinued section in the next edition.

PRESCRIPTION DRUG PRODUCT LIST - 33RD EDITION

RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 4 - April 2013

1-1

ACETAMINOPHEN; BUTALBITAL; CAFFEINE

TABLET; ORAL

BUTALBITAL, ACETAMINOPHEN AND CAFFEINE

@ MIRROR PHARMS LLC 500MG;50MG;40MG

A040883 001 Dec 23, 2008 Feb DISC

ACETAMINOPHEN; CAFFEINE; DIHYDROCODEINE BITARTRATE

CAPSULE; ORAL

ACETAMINOPHEN, CAFFEINE, AND DIHYDROCODEINE BITARTRATE

@ MIKART 356.4MG;30MG;16MG

A040109 001 Aug 26, 1997 Feb DISC

TABLET; ORAL

ACETAMINOPHEN, CAFFEINE, AND DIHYDROCODEINE BITARTRATE

@ MIKART 712.8MG;60MG;32MG

A040316 001 Apr 28, 1999 Feb DISC

ACETAMINOPHEN; CODEINE PHOSPHATE

TABLET; ORAL

ACETAMINOPHEN AND CODEINE PHOSPHATE

>A> AA AUROLIFE PHARMA LLC 300MG;15MG

A202800 001 Apr 15, 2013 Apr NEWA

>A> AA 300MG;30MG

A202800 002 Apr 15, 2013 Apr NEWA

>A> AA 300MG;60MG

A202800 003 Apr 15, 2013 Apr NEWA

@ MIKART 650MG;30MG

A089231 001 Mar 03, 1986 Feb DISC

@ 650MG;60MG

A089363 001 Sep 09, 1991 Feb DISC

ACETAMINOPHEN; HYDROCODONE BITARTRATE

CAPSULE; ORAL

HYDROCODONE BITARTRATE AND ACETAMINOPHEN

@ MIKART 500MG;5MG

A081067 001 Nov 30, 1989 Feb DISC

SOLUTION; ORAL

HYDROCODONE BITARTRATE AND ACETAMINOPHEN

>A> AA PAI 325MG/15ML;7.5MG/15ML

A040838 001 May 10, 2013 Apr NEWA

TABLET; ORAL

HYDROCODONE BITARTRATE AND ACETAMINOPHEN

@ MIKART 500MG;2.5MG

A089698 001 Aug 25, 1989 Feb DISC

@ 650MG;5MG

A040849 001 Jun 09, 2010 Feb DISC

AA TRIS PHARMA INC 325MG;5MG

A202214 001 Mar 27, 2013 Mar NEWA

AA 325MG;7.5MG

A202214 002 Mar 27, 2013 Mar NEWA

AA 325MG;10MG

A202214 003 Mar 27, 2013 Mar NEWA

ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE

TABLET; ORAL

OXYCODONE AND ACETAMINOPHEN

>A> AA ACTAVIS ELIZABETH 325MG;2.5MG

A201447 001 Apr 12, 2013 Apr NEWA

>A> AA 325MG;5MG

A201447 002 Apr 12, 2013 Apr NEWA

>A> AA 325MG;7.5MG

A201447 003 Apr 12, 2013 Apr NEWA

>A> AA 325MG;10MG

A201447 004 Apr 12, 2013 Apr NEWA

ACETAZOLAMIDE

TABLET; ORAL

ACETAZOLAMIDE

@ WATSON LABS 250MG

A088882 001 Oct 22, 1985 Jan DISC

ACETAZOLAMIDE SODIUM

INJECTABLE; INJECTION
ACETAZOLAMIDE SODIUM

AP	SAGENT AGILA	EQ 500MG BASE/VIAL	A200880 001	May 09, 2012	Jan	CAHN
----	--------------	--------------------	-------------	--------------	-----	------

ACITRETIN

CAPSULE; ORAL
ACITRETIN

AB	BARR LABS INC	10MG	A091455 001	Apr 04, 2013	Mar	NEWA
AB		25MG	A091455 002	Apr 04, 2013	Mar	NEWA
AB	TEVA PHARMS USA	17.5MG	A202897 001	Apr 04, 2013	Mar	NEWA
AB		22.5MG	A202897 002	Apr 04, 2013	Mar	NEWA

SORIATANE

AB	STIEFEL LABS INC	10MG	N019821 001	Oct 28, 1996	Mar	CFTG
AB		17.5MG	N019821 003	Aug 06, 2009	Mar	CFTG
AB		22.5MG	N019821 004	Aug 06, 2009	Mar	CFTG
AB	+	25MG	N019821 002	Oct 28, 1996	Mar	CFTG

ACYCLOVIR

OINTMENT; TOPICAL
ACYCLOVIR

AB	MYLAN PHARMS INC	5%	A202459 001	Apr 03, 2013	Mar	NEWA	
AB	+	ZOVIRAX					
AB	+	VALEANT INTL	5%	N018604 001	Mar 29, 1982	Mar	CFTG

>A> TABLET; BUCCAL

>A> SITAVIG

>A>	+	BIOALLIANCE PHARMA	50MG	N203791 001	Apr 12, 2013	Apr	NEWA
-----	---	--------------------	------	-------------	--------------	-----	------

ACYCLOVIR; HYDROCORTISONE

CREAM; TOPICAL
XERESE

>A>	+	VALEANT BERMUDA	5%;1%	N022436 001	Jul 31, 2009	Apr	CAHN
>D>	+	VALEANT INTL	5%;1%	N022436 001	Jul 31, 2009	Apr	CAHN

ADENOSINE

INJECTABLE; INJECTION
ADENOSINE

>D>	@	TEVA PARENTERAL	3MG/ML	A076564 001	Jun 16, 2004	Apr	CAHN
>D>	@		3MG/ML	A078676 001	Jul 31, 2008	Apr	CAHN
>A>	@	TEVA PHARMS USA	3MG/ML	A076564 001	Jun 16, 2004	Apr	CAHN
>A>	@		3MG/ML	A078676 001	Jul 31, 2008	Apr	CAHN

ALBENDAZOLE

TABLET; ORAL
ALBENZA

+	AMEDRA PHARMS	200MG	N020666 001	Jun 11, 1996	Feb	CAHN
---	---------------	-------	-------------	--------------	-----	------

ALBUTEROL SULFATE

AEROSOL, METERED; INHALATION
PROAIR HFA

>A>	BX	+	TEVA BRANDED PHARM	EQ 0.09MG BASE/INH	N021457 001	Oct 29, 2004	Apr	CAHN
>D>	BX	+	TEVA GLOBAL	EQ 0.09MG BASE/INH	N021457 001	Oct 29, 2004	Apr	CAHN

SOLUTION; INHALATIONALBUTEROL SULFATE

>D>	AN	APOTEX INC	EQ 0.021% BASE	A078623 001	Apr 05, 2010	Apr	DISC
>A>		@	EQ 0.021% BASE	A078623 001	Apr 05, 2010	Apr	DISC
>D>	AN		EQ 0.042% BASE	A078623 002	Apr 05, 2010	Apr	DISC
>A>		@	EQ 0.042% BASE	A078623 002	Apr 05, 2010	Apr	DISC
>D>	AN		EQ 0.083% BASE	A075717 001	Feb 02, 2007	Apr	DISC
>A>		@	EQ 0.083% BASE	A075717 001	Feb 02, 2007	Apr	DISC
>A>		@	EQ 0.5% BASE	A076391 001	Apr 01, 2003	Apr	DISC
	AN	+ MYLAN SPECLT	EQ 0.083% BASE	A072652 001	Feb 21, 1992	Jan	CAHN
>D>	AN	NOVEX	EQ 0.5% BASE	A076391 001	Apr 01, 2003	Apr	DISC
		@ WOCKHARDT EU OPERATN	EQ 0.083% BASE	A075394 001	Nov 22, 1999	Mar	DISC

ALBUTEROL SULFATE; IPRATROPIUM BROMIDESOLUTION; INHALATIONALBUTEROL SULFATE AND IPRATROPIUM BROMIDE

>D>	AN	APOTEX CORP	EQ 0.083% BASE;0.017%	A077117 001	Dec 31, 2007	Apr	DISC
>A>		@ APOTEX INC	EQ 0.083% BASE;0.017%	A077117 001	Dec 31, 2007	Apr	DISC

ALENDRONATE SODIUMSOLUTION; ORALALENDRONATE SODIUM

AA		ROXANE	EQ 70MG BASE/75ML	A090520 001	Feb 25, 2013	Feb	NEWA
		FOSAMAX					
AA	+	MERCK	EQ 70MG BASE/75ML	N021575 001	Sep 17, 2003	Feb	CFTG

ALFUZOSIN HYDROCHLORIDETABLET, EXTENDED RELEASE; ORALUROXATRAL

>A>	AB	+ COVIS PHARMA SARL	10MG	N021287 001	Jun 12, 2003	Apr	CAHN
>D>	AB	+ SANOFI AVENTIS US	10MG	N021287 001	Jun 12, 2003	Apr	CAHN

ALLOPURINOLTABLET; ORALALLOPURINOL

>A>	AB	ACCORD HLTHCARE	100MG	A203154 001	May 06, 2013	Apr	NEWA
>A>	AB		300MG	A203154 002	May 06, 2013	Apr	NEWA

ALOGLIPTIN BENZOATETABLET; ORALNESINA

		TAKEDA PHARMS USA	EQ 6.25MG BASE	N022271 001	Jan 25, 2013	Jan	NEWA
			EQ 12.5MG BASE	N022271 002	Jan 25, 2013	Jan	NEWA
	+		EQ 25MG BASE	N022271 003	Jan 25, 2013	Jan	NEWA

ALOGLIPTIN BENZOATE; METFORMIN HYDROCHLORIDETABLET; ORALKAZANO

		TAKEDA PHARMS USA	EQ 12.5MG BASE;500MG	N203414 001	Jan 25, 2013	Jan	NEWA
	+		EQ 12.5MG BASE;1GM	N203414 002	Jan 25, 2013	Jan	NEWA

ALOGLIPTIN BENZOATE; PIOGLITAZONETABLET; ORALOSENI

		TAKEDA PHARMS USA	EQ 12.5MG BASE;EQ 15MG BASE	N022426 004	Jan 25, 2013	Jan	NEWA
--	--	-------------------	-----------------------------	-------------	--------------	-----	------

TABLET; ORAL

OSEN

TAKEDA PHARMS USA	EQ 12.5MG BASE;EQ 30MG BASE	N022426 005	Jan 25, 2013	Jan	NEWA
	EQ 12.5MG BASE;EQ 45MG BASE	N022426 006	Jan 25, 2013	Jan	NEWA
	EQ 25MG BASE;EQ 15MG BASE	N022426 001	Jan 25, 2013	Jan	NEWA
	EQ 25MG BASE;EQ 30MG BASE	N022426 002	Jan 25, 2013	Jan	NEWA
+	EQ 25MG BASE;EQ 45MG BASE	N022426 003	Jan 25, 2013	Jan	NEWA

ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE

TABLET; ORAL

OSEN

TAKEDA PHARMS USA	EQ 12.5MG BASE;EQ 15MG BASE	N022426 004	Jan 25, 2013	Feb	CAIN
	EQ 12.5MG BASE;EQ 30MG BASE	N022426 005	Jan 25, 2013	Feb	CAIN
	EQ 12.5MG BASE;EQ 45MG BASE	N022426 006	Jan 25, 2013	Feb	CAIN
	EQ 25MG BASE;EQ 15MG BASE	N022426 001	Jan 25, 2013	Feb	CAIN
	EQ 25MG BASE;EQ 30MG BASE	N022426 002	Jan 25, 2013	Feb	CAIN
+	EQ 25MG BASE;EQ 45MG BASE	N022426 003	Jan 25, 2013	Feb	CAIN

ALPROSTADIL

INJECTABLE; INJECTION

ALPROSTADIL

>D>	AP	TEVA PARENTERAL	0.5MG/ML	A075196 001	Apr 30, 1999	Apr	CAHN
>A>	AP	TEVA PHARMS USA	0.5MG/ML	A075196 001	Apr 30, 1999	Apr	CAHN

AMIKACIN SULFATE

INJECTABLE; INJECTION

AMIKACIN SULFATE

@ HOSPIRA	EQ 250MG BASE/ML	A063264 001	Nov 30, 1994	Mar	DISC
-----------	------------------	-------------	--------------	-----	------

AMIODARONE HYDROCHLORIDE

INJECTABLE; INJECTION

AMIODARONE HYDROCHLORIDE

>A>	@	APOTEX INC	50MG/ML	A076394 001	Apr 25, 2003	Apr	DISC
>D>	AP	+ BIONICHE PHARMA	50MG/ML	A076217 001	Oct 15, 2002	Apr	CAHN
>D>	AP	+ CLARIS LIFESCIENCES	50MG/ML	A076394 001	Apr 25, 2003	Apr	DISC
>A>	AP	+ MYLAN INSTITUTIONAL	50MG/ML	A076217 001	Oct 15, 2002	Apr	CAHN
>D>	@	TEVA PARENTERAL	50MG/ML	A076163 001	Sep 05, 2003	Apr	CAHN
>A>	@	TEVA PHARMS USA	50MG/ML	A076163 001	Sep 05, 2003	Apr	CAHN

AMLODIPINE BESYLATE

TABLET; ORAL

AMLODIPINE BESYLATE

>A>	AB	ACCORD HLTHCARE	EQ 2.5MG BASE	A202553 001	Apr 29, 2013	Apr	NEWA
>A>	AB		EQ 5MG BASE	A202553 002	Apr 29, 2013	Apr	NEWA
>A>	AB		EQ 10MG BASE	A202553 003	Apr 29, 2013	Apr	NEWA

AMLODIPINE BESYLATE; VALSARTAN

TABLET; ORAL

AMLODIPINE BESYLATE AND VALSARTAN

AB	PAR PHARM INC	EQ 5MG BASE;160MG	A090011 001	Mar 28, 2013	Mar	NEWA
AB		EQ 5MG BASE;320MG	A090144 001	Mar 28, 2013	Mar	NEWA
AB		EQ 10MG BASE;160MG	A090011 002	Mar 28, 2013	Mar	NEWA
AB		EQ 10MG BASE;320MG	A090011 004	Mar 28, 2013	Mar	NEWA
	EXFORGE					
AB	NOVARTIS	EQ 5MG BASE;160MG	N021990 002	Jun 20, 2007	Mar	CFTG

TABLET; ORAL

EXFORGE

AB	NOVARTIS	EQ 5MG BASE;320MG	N021990 004	Jun 20, 2007	Mar	CFTG
AB	+	EQ 10MG BASE;160MG	N021990 003	Jun 20, 2007	Mar	CFTG
AB	+	EQ 10MG BASE;320MG	N021990 005	Jun 20, 2007	Mar	CFTG

AMMONIA N-13

INJECTABLE; INTRAVENOUS

AMMONIA N 13

AP	CARDINAL HEALTH 414	30MCI-300MCI/8ML (3.75-37.5MCI/ML)	A203700 001	Feb 25, 2013	Feb	NEWA
AP	+	FEINSTEIN 30MCI-300MCI/8ML (3.75-37.5MCI/ML)	N022119 001	Aug 23, 2007	Feb	CFTG
AP	MCPRF	30MCI-300MCI/8ML (3.75-37.5MCI/ML)	A203321 001	Feb 25, 2013	Feb	NEWA

AMOXICILLIN

FOR SUSPENSION; ORAL

AMOXICILLIN

@	RANBAXY	200MG/5ML	A065113 001	Nov 29, 2002	Feb	DISC
@		400MG/5ML	A065113 002	Nov 29, 2002	Feb	DISC

TABLET, CHEWABLE; ORAL

AMOXICILLIN

@	DAVA PHARMS INC	125MG	A064139 001	Jan 29, 1996	Mar	DISC
@		250MG	A064139 002	Jan 29, 1996	Mar	DISC
@	RANBAXY	200MG	A065060 001	Nov 29, 2000	Feb	DISC
@		400MG	A065060 002	Nov 29, 2000	Feb	DISC

AMOXIL

@	DR REDDYS LABS INC	200MG	N050761 001	Apr 15, 1999	Feb	DISC
@		400MG	N050761 002	Apr 15, 1999	Feb	DISC

TABLET, FOR SUSPENSION; ORAL

AMOXICILLIN

@	AUROBINDO PHARMA LTD	200MG	A065324 001	Jan 17, 2007	Jan	DISC
@		400MG	A065324 002	Jan 17, 2007	Jan	DISC

AMOXICILLIN; CLAVULANATE POTASSIUM

TABLET; ORAL

AMOXICILLIN AND CLAVULANATE POTASSIUM

>D>	AB	APOTEX	250MG;EQ 125MG BASE	A065333 001	Feb 24, 2009	Apr	DISC
>D>	AB		500MG;EQ 125MG BASE	A065333 002	Feb 24, 2009	Apr	DISC
>A>		@ APOTEX INC	250MG;EQ 125MG BASE	A065333 001	Feb 24, 2009	Apr	DISC
>A>		@	500MG;EQ 125MG BASE	A065333 002	Feb 24, 2009	Apr	DISC
>D>	AB		875MG;EQ 125MG BASE	A065317 003	Oct 20, 2008	Apr	DISC
>A>		@	875MG;EQ 125MG BASE	A065317 003	Oct 20, 2008	Apr	DISC
>D>	AB	RANBAXY	500MG;EQ 125MG BASE	A065109 001	Nov 04, 2002	Apr	DISC
>A>		@ RANBAXY LABS	500MG;EQ 125MG BASE	A065109 001	Nov 04, 2002	Apr	DISC
>D>	AB	+	TEVA 875MG;EQ 125MG BASE	A065096 001	Oct 29, 2002	Apr	CRLD
>A>	AB	TEVA PHARMS USA	875MG;EQ 125MG BASE	A065096 001	Oct 29, 2002	Apr	CRLD
		AUGMENTIN '250'					
>D>	AB	DR REDDYS LABS INC	250MG;EQ 125MG BASE	N050564 001	Aug 06, 1984	Apr	CRLD
>A>	AB	+	250MG;EQ 125MG BASE	N050564 001	Aug 06, 1984	Apr	CRLD
		AUGMENTIN '500'					
>D>	AB	DR REDDYS LABS INC	500MG;EQ 125MG BASE	N050564 002	Aug 06, 1984	Apr	CRLD
>A>	AB	+	500MG;EQ 125MG BASE	N050564 002	Aug 06, 1984	Apr	CRLD
		AUGMENTIN '875'					
>D>	AB	DR REDDYS LABS INC	875MG;EQ 125MG BASE	N050720 001	Feb 13, 1996	Apr	CRLD
>A>	AB	+	875MG;EQ 125MG BASE	N050720 001	Feb 13, 1996	Apr	CRLD

AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE

CAPSULE, EXTENDED RELEASE; ORAL

AMPHETAMINE ASP AMPHETAMINE SULF DEXTROAMPHET SACCHARATE & DEXTR SULF

>A>	AB	TEVA	1.25MG;1.25MG;1.25MG;1.25MG	A077488 001	Apr 29, 2013	Apr	NEWA
>A>	AB		2.5MG;2.5MG;2.5MG;2.5MG	A077488 002	Apr 29, 2013	Apr	NEWA
>A>	AB		3.75MG;3.75MG;3.75MG;3.75MG	A077488 003	Apr 29, 2013	Apr	NEWA
>A>	AB		5MG;5MG;5MG;5MG	A077488 004	Apr 29, 2013	Apr	NEWA
>A>	AB		6.25MG;6.25MG;6.25MG;6.25MG	A077488 005	Apr 29, 2013	Apr	NEWA
>A>	AB		7.5MG;7.5MG;7.5MG;7.5MG	A077488 006	Apr 29, 2013	Apr	NEWA

DEXTROAMP SACCHARATE,AMP ASPARTATE,DEXTROAMP SULFATE AND AMP SULFATE

AB	BARR LABS INC	1.25MG;1.25MG;1.25MG;1.25MG	A076536 001	Feb 12, 2013	Jan	NEWA
AB		2.5MG;2.5MG;2.5MG;2.5MG	A076536 002	Feb 12, 2013	Jan	NEWA
AB		3.75MG;3.75MG;3.75MG;3.75MG	A076536 003	Feb 12, 2013	Jan	NEWA
AB		5MG;5MG;5MG;5MG	A076536 004	Feb 12, 2013	Jan	NEWA
AB		6.25MG;6.25MG;6.25MG;6.25MG	A076536 005	Feb 12, 2013	Jan	NEWA
AB		7.5MG;7.5MG;7.5MG;7.5MG	A076536 006	Feb 12, 2013	Jan	NEWA

TABLET; ORAL

DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE

@	TEVA PHARMS	1.25MG;1.25MG;1.25MG;1.25MG	A040472 001	Sep 30, 2003	Jan	DISC
@		2.5MG;2.5MG;2.5MG;2.5MG	A040472 002	Sep 30, 2003	Jan	DISC
@		5MG;5MG;5MG;5MG	A040472 003	Sep 30, 2003	Jan	DISC
@		7.5MG;7.5MG;7.5MG;7.5MG	A040472 004	Sep 30, 2003	Jan	DISC

AMPICILLIN SODIUM

INJECTABLE; INJECTION

AMPICILLIN SODIUM

AP	ACS DOBFAR SPA	EQ 500MG BASE/VIAL	A090884 001	Apr 03, 2013	Mar	NEWA
AP		EQ 1GM BASE/VIAL	A090884 002	Apr 03, 2013	Mar	NEWA
AP		EQ 2GM BASE/VIAL	A090884 003	Apr 03, 2013	Mar	NEWA
AP		EQ 10GM BASE/VIAL	A090889 001	Apr 03, 2013	Mar	NEWA

ANASTROZOLE

TABLET; ORAL

ANASTROZOLE

>A>	AB	ACCORD HLTHCARE	1MG	A090568 001	Jun 28, 2010	Apr	CAHN
>D>	AB	ACCORD HLTHCARE INC	1MG	A090568 001	Jun 28, 2010	Apr	CAHN
	@	KUDCO IRELAND	1MG	A091331 001	Jan 05, 2011	Feb	DISC

ARIPIRAZOLE

FOR SUSPENSION, EXTENDED RELEASE; INTRAMUSCULAR

ABILIFY MAINTENA KIT

	OTSUKA PHARM CO LTD	300MG/VIAL	N202971 001	Feb 28, 2013	Feb	NEWA
+		400MG/VIAL	N202971 002	Feb 28, 2013	Feb	NEWA

ASPIRIN; CAFFEINE; ORPHENADRINE CITRATE

TABLET; ORAL

ORPHENGESIC

>A>	@	PRINSTON INC	385MG;30MG;25MG	A075141 001	May 29, 1998	Apr	CAHN
>D>	@	SOLCO HLTHCARE	385MG;30MG;25MG	A075141 001	May 29, 1998	Apr	CAHN
		ORPHENGESIC FORTE					
>A>	@	PRINSTON INC	770MG;60MG;50MG	A075141 002	May 29, 1998	Apr	CAHN
>D>	@	SOLCO HLTHCARE	770MG;60MG;50MG	A075141 002	May 29, 1998	Apr	CAHN

ATENOLOL

TABLET; ORAL

ATENOLOL

@ WATSON LABS

50MG

A073352 001 Dec 27, 1991 Mar DISC

@

100MG

A073353 001 Dec 27, 1991 Mar DISC

ATORVASTATIN CALCIUM

TABLET; ORAL

ATORVASTATIN CALCIUM

AB KUDCO IRELAND

EQ 10MG BASE

A091624 001 Apr 05, 2013 Mar NEWA

AB

EQ 20MG BASE

A091624 002 Apr 05, 2013 Mar NEWA

AB

EQ 40MG BASE

A091624 003 Apr 05, 2013 Mar NEWA

AB

EQ 80MG BASE

A091624 004 Apr 05, 2013 Mar NEWA

AZITHROMYCIN

INJECTABLE; INJECTION

AZITHROMYCIN

AP SUN PHARM INDS LTD

EQ 500MG BASE/VIAL

A090923 001 Apr 02, 2013 Mar NEWA

BACITRACIN

POWDER; FOR RX COMPOUNDING

BACI-RX

@ X GEN PHARMS

5,000,000 UNITS/BOT

A061580 001 Mar DISC

BENZOYL PEROXIDE; CLINDAMYCIN PHOSPHATE

GEL; TOPICAL

ACANYA

>A> + DOW PHARM

2.5%;1.2%

N050819 001 Oct 23, 2008 Apr CAHN

>D> + DOW PHARM SCI

2.5%;1.2%

N050819 001 Oct 23, 2008 Apr CAHN

BENZACLIN

>A> AB VALEANT BERMUDA

5%;EQ 1% BASE

N050756 001 Dec 21, 2000 Apr CAHN

>A> BT

+

5%;EQ 1% BASE

N050756 002 Apr 20, 2007 Apr CAHN

>D> AB

VALEANT INTL

5%;EQ 1% BASE

N050756 001 Dec 21, 2000 Apr CAHN

>D> BT

+

5%;EQ 1% BASE

N050756 002 Apr 20, 2007 Apr CAHN

BENZPHETAMINE HYDROCHLORIDE

TABLET; ORAL

BENZPHETAMINE HYDROCHLORIDE

@ COREPHARMA

50MG

A040714 001 Oct 29, 2007 Feb DISC

BENZTROPINE MESYLATE

INJECTABLE; INJECTION

BENZTROPINE MESYLATE

AP NAVINTA LLC

1MG/ML

A091525 001 Feb 05, 2013 Jan NEWA

TABLET; ORAL

BENZTROPINE MESYLATE

@ PROSAM LABS

0.5MG

A040699 001 Feb 14, 2008 Mar DISC

@

1MG

A040705 001 Feb 14, 2008 Mar DISC

@

2MG

A040706 001 Feb 14, 2008 Mar DISC

BETAMETHASONE

SYRUP; ORAL

CELESTONE

>A>

@ MERCK SHARP DOHME

0.6MG/5ML

N014215 002 Apr CAHN

SYRUP; ORAL									
CELESTONE									
>D>		@ SCHERING	0.6MG/5ML		N014215 002		Apr	CAHN	
<u>BETAMETHASONE ACETATE; BETAMETHASONE SODIUM PHOSPHATE</u>									
INJECTABLE; INJECTION									
CELESTONE SOLUSPAN									
>A>	AB	+	MERCK SHARP DOHME	3MG/ML;EQ 3MG BASE/ML	N014602 001		Apr	CAHN	
>D>	AB	+	SCHERING	3MG/ML;EQ 3MG BASE/ML	N014602 001		Apr	CAHN	
<u>BETAMETHASONE VALERATE</u>									
AEROSOL, FOAM; TOPICAL									
BETAMETHASONE VALERATE									
>D>	AB		PERRIGO	EQ 0.12% BASE	A078337 001	Nov 26, 2012	Apr	CPOT	
>A>	AB			0.12%	A078337 001	Nov 26, 2012	Apr	CPOT	
LUXIQ									
>D>	AB	+	STIEFEL	EQ 0.12% BASE	N020934 001	Feb 28, 1999	Apr	CPOT	
>A>	AB	+		0.12%	N020934 001	Feb 28, 1999	Apr	CPOT	
<u>BETAXOLOL HYDROCHLORIDE</u>									
SOLUTION/DROPS; OPHTHALMIC									
BETAXOLOL HYDROCHLORIDE									
>A>		@	APOTEX INC	EQ 0.5% BASE	A075446 001	Sep 28, 2000	Apr	DISC	
>D>	AT		NOVEX	EQ 0.5% BASE	A075446 001	Sep 28, 2000	Apr	DISC	
<u>BEXAROTENE</u>									
GEL; TOPICAL									
TARGRETIN									
		+	VALEANT PHARMS INC	1%	N021056 001	Jun 28, 2000	Feb	CAHN	
<u>BICALUTAMIDE</u>									
TABLET; ORAL									
BICALUTAMIDE									
>A>	AB		ACCORD HLTHCARE	50MG	A078917 001	Jul 06, 2009	Apr	CAHN	
>D>	AB		ACCORD HLTHCARE INC	50MG	A078917 001	Jul 06, 2009	Apr	CAHN	
<u>BLEOMYCIN SULFATE</u>									
INJECTABLE; INJECTION									
BLEOMYCIN SULFATE									
		@	PHARMACHEMIE BV	EQ 15 UNITS BASE/VIAL	A065201 001	Dec 13, 2007	Feb	DISC	
>A>	<u>BRIMONIDINE TARTRATE; BRINZOLAMIDE</u>								
>A>	SUSPENSION/DROPS; OPHTHALMIC								
>A>	SIMBRINZA								
>A>		+	ALCON RES LTD	0.2%;1%	N204251 001	Apr 19, 2013	Apr	NEWA	
<u>BROMFENAC SODIUM</u>									
SOLUTION/DROPS; OPHTHALMIC									
BROMDAY									
>D>		+	ISTA PHARMS INC	0.09%	N021664 002	Oct 16, 2010	Apr	CPOT	
>A>		+		EQ 0.09% ACID	N021664 002	Oct 16, 2010	Apr	CPOT	
BROMFENAC SODIUM									
>D>	AT		COASTAL PHARMS	0.09%	A201211 001	May 11, 2011	Apr	CPOT	
>A>	AT			EQ 0.09% ACID	A201211 001	May 11, 2011	Apr	CPOT	
>D>	AT		LUITPOLD	0.09%	A202030 001	Jan 09, 2013	Apr	CPOT	

SOLUTION/DROPS; OPHTHALMIC

BROMFENAC SODIUM

>A>	AT	LUITPOLD	EQ 0.09% ACID	A202030	001	Jan 09, 2013	Apr	CPOT
	AT		0.09%	A202030	001	Jan 09, 2013	Feb	CAHN
>A>		PROLENSA						
>A>	+	BAUSCH AND LOMB	EQ 0.07% ACID	N203168	001	Apr 05, 2013	Apr	NEWA
		XIBROM						
>D>		@ ISTA PHARMS INC	0.09%	N021664	001	Mar 24, 2005	Apr	CPOT
>A>		@	EQ 0.09% ACID	N021664	001	Mar 24, 2005	Apr	CPOT

BUDESONIDE

SUSPENSION; INHALATION

BUDESONIDE

>D>	AN	APOTEX	0.25MG/2ML	A078202	001	Mar 30, 2009	Apr	DISC
>D>	AN		0.5MG/2ML	A078202	002	Mar 30, 2009	Apr	DISC
>A>		@ APOTEX INC	0.25MG/2ML	A078202	001	Mar 30, 2009	Apr	DISC
>A>		@	0.5MG/2ML	A078202	002	Mar 30, 2009	Apr	DISC

TABLET, EXTENDED RELEASE; ORAL

UCERIS

	+	SANTARUS	9MG	N203634	001	Jan 14, 2013	Jan	NEWA
--	---	----------	-----	---------	-----	--------------	-----	------

BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE

TABLET; SUBLINGUAL

BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE DIHYDRATE

AB		ACTAVIS ELIZABETH	EQ 2MG BASE;EQ 0.5MG BASE	A091422	001	Feb 22, 2013	Feb	NEWA
>D>	AB		EQ 8MG BASE;EQ 2MG BASE	A091422	002	Feb 22, 2013	Apr	CRLD
>A>	AB	+	EQ 8MG BASE;EQ 2MG BASE	A091422	002	Feb 22, 2013	Apr	CRLD
	AB		EQ 8MG BASE;EQ 2MG BASE	A091422	002	Feb 22, 2013	Feb	NEWA
	AB	AMNEAL PHARMS	EQ 2MG BASE;EQ 0.5MG BASE	A203136	001	Feb 22, 2013	Feb	NEWA
	AB		EQ 8MG BASE;EQ 2MG BASE	A203136	002	Feb 22, 2013	Feb	NEWA
		SUBOXONE						
		@ RECKITT BENCKISER	EQ 2MG BASE;EQ 0.5MG BASE	N020733	001	Oct 08, 2002	Mar	DISC
	AB		EQ 2MG BASE;EQ 0.5MG BASE	N020733	001	Oct 08, 2002	Feb	CFTG
		@	EQ 8MG BASE;EQ 2MG BASE	N020733	002	Oct 08, 2002	Mar	DISC
	AB	+	EQ 8MG BASE;EQ 2MG BASE	N020733	002	Oct 08, 2002	Feb	CFTG

BUPROPION HYDROBROMIDE

TABLET, EXTENDED RELEASE; ORAL

APLENZIN

>A>		VALEANT BERMUDA	174MG	N022108	001	Apr 23, 2008	Apr	CAHN
>A>	+		348MG	N022108	002	Apr 23, 2008	Apr	CAHN
>A>			522MG	N022108	003	Apr 23, 2008	Apr	CAHN
>D>		VALEANT INTL	174MG	N022108	001	Apr 23, 2008	Apr	CAHN
>D>	+		348MG	N022108	002	Apr 23, 2008	Apr	CAHN
>D>			522MG	N022108	003	Apr 23, 2008	Apr	CAHN

BUPROPION HYDROCHLORIDE

TABLET; ORAL

BUPROPION HYDROCHLORIDE

		@ TEVA	75MG	A075310	001	Nov 29, 1999	Feb	CDFR
		@	100MG	A075310	002	Nov 29, 1999	Feb	DISC

TABLET, EXTENDED RELEASE; ORAL

BUPROPION HYDROCHLORIDE

>D>	AB1	ACTAVIS	100MG	A077455	001	Jul 19, 2010	Apr	CAHN
>D>	AB3		150MG	A077285	001	Nov 26, 2008	Apr	CAHN
>D>	AB1		150MG	A077455	002	Mar 12, 2008	Apr	CAHN

TABLET, EXTENDED RELEASE; ORAL

BUPROPION HYDROCHLORIDE

>D>	AB1	ACTAVIS	200MG	A077455	003	Jul 19, 2010	Apr	CAHN
>D>	AB3		300MG	A077285	002	Aug 15, 2008	Apr	CAHN
>D>	BX	IMPAX LABS	300MG	A077415	002	Dec 15, 2006	Apr	DISC
>A>	@		300MG	A077415	002	Dec 15, 2006	Apr	DISC
>A>	AB1	WATSON LABS INC	100MG	A077455	001	Jul 19, 2010	Apr	CAHN
>A>	AB3		150MG	A077285	001	Nov 26, 2008	Apr	CAHN
>A>	AB1		150MG	A077455	002	Mar 12, 2008	Apr	CAHN
>A>	AB1		200MG	A077455	003	Jul 19, 2010	Apr	CAHN
>A>	AB3		300MG	A077285	002	Aug 15, 2008	Apr	CAHN

BUTOCONAZOLE NITRATE

CREAM; VAGINAL

BUTOCONAZOLE NITRATE

+	PERRIGO ISRAEL	2%	A200923	001	May 18, 2012	Mar	CRLD
	GYNazole-1						
@	KV PHARM	2%	N019881	001	Feb 07, 1997	Mar	DISC

BUTORPHANOL TARTRATE

INJECTABLE; INJECTION

BUTORPHANOL TARTRATE

>A>	@	APOTEX INC	2MG/ML	A075697	001	Oct 23, 2001	Apr	DISC
>D>	AP	CLARIS LIFESCIENCES	2MG/ML	A075697	001	Oct 23, 2001	Apr	DISC
		BUTORPHANOL TARTRATE PRESERVATIVE FREE						
>A>	@	APOTEX INC	1MG/ML	A075695	001	Oct 23, 2001	Apr	DISC
>A>	@		2MG/ML	A075695	002	Oct 23, 2001	Apr	DISC
>D>	AP	CLARIS LIFESCIENCES	1MG/ML	A075695	001	Oct 23, 2001	Apr	DISC
>D>	AP		2MG/ML	A075695	002	Oct 23, 2001	Apr	DISC

CABERGOLINE

TABLET; ORAL

CABERGOLINE

AB	APOTEX CORP	0.5MG	A201503	001	Mar 08, 2013	Feb	NEWA
----	-------------	-------	---------	-----	--------------	-----	------

CAFFEINE; ERGOTAMINE TARTRATE

TABLET; ORAL

ERGOTAMINE TARTRATE AND CAFFEINE

AA	MIKART	100MG;1MG	A040590	001	Sep 16, 2005	Mar	CMFD
	@	100MG;1MG	A040590	001	Sep 16, 2005	Jan	DISC

CALCIUM ACETATE

CAPSULE; ORAL

CALCIUM ACETATE

AB	INVAGEN PHARMS	EQ 169MG CALCIUM	A203135	001	Feb 07, 2013	Jan	NEWA
----	----------------	------------------	---------	-----	--------------	-----	------

TABLET; ORAL

CALCIUM ACETATE

AB	INVAGEN PHARMS	EQ 169MG CALCIUM	A202420	001	Feb 05, 2013	Jan	NEWA
----	----------------	------------------	---------	-----	--------------	-----	------

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM CITRATE

INJECTABLE; INJECTION

ISOLYTE E IN DEXTROSE 5% IN PLASTIC CONTAINER

@ B BRAUN

35MG/100ML;5GM/100ML;30MG/100ML;7	N019867	001	Dec 20, 1993	Mar	DISC
4MG/100ML;640MG/100ML;500MG/100ML					
;74MG/100ML					

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

SOLUTION; INTRAPERITONEAL

INPERSOL-LC/LM W/ DEXTROSE 1.5% IN PLASTIC CONTAINER

@ FRESenius	18.4MG/100ML;1.5GM/100ML;5.08MG/100ML;538MG/100ML;448MG/100ML	N020374 001	Jun 13, 1994	Feb	DISC
-------------	---	-------------	--------------	-----	------

INPERSOL-LC/LM W/ DEXTROSE 2.5% IN PLASTIC CONTAINER

@ FRESenius	18.4MG/100ML;2.5GM/100ML;5.08MG/100ML;538MG/100ML;448MG/100ML	N020374 002	Jun 13, 1994	Feb	DISC
-------------	---	-------------	--------------	-----	------

INPERSOL-LC/LM W/ DEXTROSE 3.5% IN PLASTIC CONTAINER

@ FRESenius	18.4MG/100ML;3.5GM/100ML;5.08MG/100ML;538MG/100ML;448MG/100ML	N020374 003	Jun 13, 1994	Feb	DISC
-------------	---	-------------	--------------	-----	------

INPERSOL-LC/LM W/ DEXTROSE 4.25% IN PLASTIC CONTAINER

@ FRESenius	18.4MG/100ML;4.25GM/100ML;5.08MG/100ML;538MG/100ML;448MG/100ML	N020374 004	Jun 13, 1994	Feb	DISC
-------------	--	-------------	--------------	-----	------

CANAGLIFLOZIN

TABLET; ORAL

INVOKANA

>A>	JANSSEN PHARMS	100MG	N204042 001	Mar 29, 2013	Apr	CAHN
>A>	+	300MG	N204042 002	Mar 29, 2013	Apr	CAHN
>D>	JANSSEN RES AND DEV	100MG	N204042 001	Mar 29, 2013	Apr	CAHN
		100MG	N204042 001	Mar 29, 2013	Mar	NEWA
>D>	+	300MG	N204042 002	Mar 29, 2013	Apr	CAHN
	+	300MG	N204042 002	Mar 29, 2013	Mar	NEWA

CANDESARTAN CILEXETIL

TABLET; ORAL

ATACAND

>D>	ASTRAZENECA	4MG	N020838 001	Jun 04, 1998	Apr	CFTG
>A>	AB	4MG	N020838 001	Jun 04, 1998	Apr	CFTG
>D>		8MG	N020838 002	Jun 04, 1998	Apr	CFTG
>A>	AB	8MG	N020838 002	Jun 04, 1998	Apr	CFTG
>D>		16MG	N020838 003	Jun 04, 1998	Apr	CFTG
>A>	AB	16MG	N020838 003	Jun 04, 1998	Apr	CFTG
>D>	+	32MG	N020838 004	Jun 04, 1998	Apr	CFTG
>A>	AB	32MG	N020838 004	Jun 04, 1998	Apr	CFTG
>A>	CANDESARTAN CILEXETIL					
>A>	AB	4MG	A078702 001	May 03, 2013	Apr	NEWA
>A>	AB	8MG	A078702 002	May 03, 2013	Apr	NEWA
>A>	AB	16MG	A078702 003	May 03, 2013	Apr	NEWA
>A>	AB	32MG	A078702 004	May 03, 2013	Apr	NEWA

CARBIDOPA; LEVODOPA

TABLET, EXTENDED RELEASE; ORAL

CARBIDOPA AND LEVODOPA

AB	ACCORD HLTHCARE	25MG;100MG	A202323 001	Feb 08, 2013	Jan	NEWA
AB		50MG;200MG	A202323 002	Feb 08, 2013	Jan	NEWA

CARBINOXAMINE MALEATE

SUSPENSION, EXTENDED RELEASE; ORAL

KARBINAL ER

+	TRIS PHARMA INC	4MG/5ML	N022556 001	Mar 28, 2013	Mar	NEWA
---	-----------------	---------	-------------	--------------	-----	------

CARBOPLATIN

INJECTABLE; INJECTION

CARBOPLATIN

@ PLIVA	50MG/VIAL	A076602 001	Nov 16, 2004	Feb	DISC
@	150MG/VIAL	A076602 002	Nov 16, 2004	Feb	DISC
@	450MG/VIAL	A076602 003	Nov 16, 2004	Feb	DISC

INJECTABLE; IV (INFUSION)

CARBOPLATIN

	@ FRESenius KABI USA	50MG/5ML (10MG/ML)	A077266 001	Feb 15, 2006	Mar	DISC
	@	150MG/15ML (10MG/ML)	A077266 002	Feb 15, 2006	Mar	DISC
>D>	AP	PHARMACHEMIE BV	50MG/5ML (10MG/ML)	A077679 001	Feb 25, 2009	Apr DISC
>A>	@	50MG/5ML (10MG/ML)	A077679 001	Feb 25, 2009	Apr	DISC
>D>	AP	150MG/15ML (10MG/ML)	A077679 002	Feb 25, 2009	Apr	DISC
>A>	@	150MG/15ML (10MG/ML)	A077679 002	Feb 25, 2009	Apr	DISC
>D>	AP	450MG/45ML (10MG/ML)	A077679 003	Feb 25, 2009	Apr	DISC
>A>	@	450MG/45ML (10MG/ML)	A077679 003	Feb 25, 2009	Apr	DISC

PARAPLATIN

@ CORDENPHARMA	50MG/5ML (10MG/ML)	N020452 001	Jul 14, 2003	Mar	CAHN
@	150MG/15ML (10MG/ML)	N020452 002	Jul 14, 2003	Mar	CAHN
@	450MG/45ML (10MG/ML)	N020452 003	Jul 14, 2003	Mar	CAHN
@	600MG/60ML (10MG/ML)	N020452 004	Jan 15, 2004	Mar	CAHN

CARISOPRODOL

TABLET; ORAL

CARISOPRODOL

@ COREPHARMA	350MG	A040397 001	Sep 21, 2000	Feb	DISC
--------------	-------	-------------	--------------	-----	------

CARMUSTINE

IMPLANT; INTRACRANIAL

GLIADEL

+	ARBOR PHARMS LLC	7.7MG	N020637 001	Sep 23, 1996	Mar CAHN
---	------------------	-------	-------------	--------------	----------

INJECTABLE; INJECTION

BICNU

+	EMCURE PHARMS LTD	100MG/VIAL	N017422 001		Jan CAHN
---	-------------------	------------	-------------	--	----------

CARTEOLOL HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

CARTEOLOL HYDROCHLORIDE

>A>	@ APOTEX INC	1%	A076097 001	Feb 06, 2002	Apr DISC
>D>	AT	NOVEX	A076097 001	Feb 06, 2002	Apr DISC

CARVEDILOL

TABLET; ORAL

CARVEDILOL

@ WOCKHARDT LTD	3.125MG	A078786 001	Dec 22, 2009	Feb	DISC
@	6.25MG	A078786 002	Dec 22, 2009	Feb	DISC
@	12.5MG	A078786 003	Dec 22, 2009	Feb	DISC
@	25MG	A078786 004	Dec 22, 2009	Feb	DISC

CEFADROXIL/CEFADROXIL HEMIHYDRATE

FOR SUSPENSION; ORAL

CEFADROXIL

>A>	AB	AUROBINDO	EQ 250MG BASE/5ML	A065349 001	Apr 25, 2013	Apr NEWA
>A>	AB		EQ 500MG BASE/5ML	A065349 002	Apr 25, 2013	Apr NEWA

FOR SUSPENSION; ORAL

CEFADROXIL

@ TEVA PHARMS USA

EQ 250MG BASE/5ML

A065278 001 Jan 20, 2006 Mar DISC

@

EQ 500MG BASE/5ML

A065278 002 Jan 20, 2006 Mar DISC

CEFAZOLIN SODIUM

INJECTABLE; INJECTION

CEFAZOLIN SODIUM

AP + HOSPIRA INC

EQ 500MG BASE/VIAL

A065226 001 Apr 21, 2005 Feb CRLD

AP +

EQ 1GM BASE/VIAL

A065244 001 Aug 12, 2005 Feb CRLD

AP +

EQ 1GM BASE/VIAL

A065226 002 Apr 21, 2005 Feb CRLD

AP +

EQ 10GM BASE/VIAL

A065247 001 Aug 12, 2005 Feb CRLD

CEFEPIME HYDROCHLORIDE

INJECTABLE; INJECTION

CEFEPIME HYDROCHLORIDE

@ SANDOZ

EQ 500MG BASE/VIAL

A090291 001 Dec 21, 2010 Mar DISC

@

EQ 1GM BASE/VIAL

A090291 002 Dec 21, 2010 Mar DISC

@

EQ 2GM BASE/VIAL

A090291 003 Dec 21, 2010 Mar DISC

CEFIXIME

FOR SUSPENSION; ORAL

SUPRAX

+ LUPIN LTD

500MG/5ML

N202091 001 Feb 20, 2013 Feb CDFR

LUPIN PHARMS

100MG/5ML

A065129 001 Feb 23, 2004 Feb CDFR

200MG/5ML

A065355 001 Apr 10, 2007 Feb CDFR

CEPHALEXIN

CAPSULE; ORAL

CEPHALEXIN

ALKEM LABS LTD

EQ 333MG BASE

A090836 003 Mar 29, 2013 Mar NEWA

AB

EQ 750MG BASE

A090836 004 Mar 29, 2013 Mar NEWA

KEFLEX

AB + SHIONOGI INC

EQ 750MG BASE

N050405 005 May 12, 2006 Mar CTEC

CETIRIZINE HYDROCHLORIDE

SYRUP; ORAL

CETIRIZINE HYDROCHLORIDE

>D> AA

APOTEX INC

5MG/5ML

A078412 001 Jun 18, 2008 Apr DISC

>A>

@

5MG/5ML

A078412 001 Jun 18, 2008 Apr DISC

@ AUROBINDO PHARMA LTD

5MG/5ML

A090751 001 Dec 16, 2009 Feb DISC

CHLORHEXIDINE GLUCONATE

SOLUTION; DENTAL

CHLORHEXIDINE GLUCONATE

>A>

@ APOTEX INC

0.12%

A075561 001 Nov 14, 2000 Apr DISC

>D>

AT

JOHN O BUTLER CO

0.12%

A076434 001 Nov 29, 2005 Apr CTNA

>D>

AT

NOVEX

0.12%

A075561 001 Nov 14, 2000 Apr DISC

>A>

PAROEX

>A>

AT

SUNSTAR AMERICAS

0.12%

A076434 001 Nov 29, 2005 Apr CTNA

CHLOROTHIAZIDE

TABLET; ORAL

DIURIL

@ OAK PHARMS AKORN

250MG

N011145 004

Jan CAHN

TABLET; ORAL

DIURIL

@ OAK PHARMS AKORN

500MG

N011145 002

Jan CAHN

CHLOROTHIAZIDE SODIUM

INJECTABLE; INJECTION

CHLOROTHIAZIDE SODIUM

>A>

AP

PHARMAFORCE

EQ 500MG BASE/VIAL

A202561 001 Apr 22, 2013 Apr NEWA

DIURIL

AP

+

OAK PHARMS AKORN

EQ 500MG BASE/VIAL

N011145 005

Jan CAHN

CHLORPHENIRAMINE MALEATE; HYDROCODONE BITARTRATE

SOLUTION; ORAL

VITUZ

+ CYPRESS PHARM

4MG/5ML; 5MG/5ML

N204307 001 Feb 20, 2013 Feb NEWA

CHLORPROPAMIDE

TABLET; ORAL

CHLORPROPAMIDE

@ WATSON LABS INC

100MG

A088852 001 Sep 26, 1984 Jan DISC

@

250MG

A088826 001 Sep 26, 1984 Jan DISC

CHOLINE FENOFIBRATE

CAPSULE, DELAYED RELEASE; ORAL

FENOFIBRIC ACID

AB

MYLAN PHARMS INC

EQ 45MG FENOFIBRIC ACID

A200913 001 Mar 25, 2013 Mar NEWA

AB

EQ 135MG FENOFIBRIC ACID

A200913 002 Mar 25, 2013 Mar NEWA

TRILIPIX

AB

ABBVIE

EQ 45MG FENOFIBRIC ACID

N022224 001 Dec 15, 2008 Mar CFTG

AB

+

EQ 135MG FENOFIBRIC ACID

N022224 002 Dec 15, 2008 Mar CFTG

CICLOPIROX

SOLUTION; TOPICAL

CICLOPIROX

>D>

AT

APOTEX CORP

8%

A078172 001 Sep 18, 2007 Apr DISC

>A>

@ APOTEX INC

8%

A078172 001 Sep 18, 2007 Apr DISC

@ TEVA PHARMS

8%

A078079 001 Sep 18, 2007 Jan DISC

PENLAC

AT

+

VALEANT INTL

8%

N021022 001 Dec 17, 1999 Feb CAHN

CIMETIDINE HYDROCHLORIDE

SOLUTION; ORAL

CIMETIDINE HYDROCHLORIDE

>A>

@ APOTEX INC

EQ 300MG BASE/5ML

A075560 001 Mar 15, 2000 Apr DISC

>D>

AA

NOVEX

EQ 300MG BASE/5ML

A075560 001 Mar 15, 2000 Apr DISC

CIPROFLOXACIN

INJECTABLE; INJECTION

CIPROFLOXACIN

>D>

@ TEVA PARENTERAL

400MG/40ML (10MG/ML)

A077782 002 Aug 28, 2006 Apr CAHN

>D>

@

200MG/20ML (10MG/ML)

A077782 001 Aug 28, 2006 Apr CAHN

>A>

@ TEVA PHARMS USA

400MG/40ML (10MG/ML)

A077782 002 Aug 28, 2006 Apr CAHN

>A>

@

200MG/20ML (10MG/ML)

A077782 001 Aug 28, 2006 Apr CAHN

CIPROFLOXACIN HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

CIPROFLOXACIN HYDROCHLORIDE

>D>	AT	APOTEX	EQ 0.3% BASE	A075928 001	Jun 09, 2004	Apr	DISC
>A>		@ APOTEX INC	EQ 0.3% BASE	A075928 001	Jun 09, 2004	Apr	DISC

CISPLATIN

INJECTABLE; INJECTION

PLATINOL

@ HQ SPCLT PHARMA	10MG/VIAL	N018057 001		Jan	CAHN
@	50MG/VIAL	N018057 002		Jan	CAHN

PLATINOL-AQ

@ HQ SPCLT PHARMA	0.5MG/ML	N018057 003	Jul 18, 1984	Jan	CAHN
@	1MG/ML	N018057 004	Nov 08, 1988	Jan	CAHN

CITALOPRAM HYDROBROMIDE

SOLUTION; ORAL

CITALOPRAM HYDROBROMIDE

>D>		@ APOTEX INC	EQ 10MG BASE/5ML	A077601 001	Nov 15, 2005	Apr	DISC
>A>		@	EQ 10MG BASE/5ML	A077601 001	Nov 15, 2005	Apr	DISC

TABLET; ORAL

CITALOPRAM HYDROBROMIDE

@ COREPHARMA	EQ 10MG BASE	A077036 001	Oct 28, 2004	Feb	DISC
@	EQ 20MG BASE	A077036 002	Oct 28, 2004	Feb	DISC
@	EQ 40MG BASE	A077036 003	Oct 28, 2004	Feb	DISC

CLEMASTINE FUMARATE

SYRUP; ORAL

CLEMASTINE FUMARATE

>A>		@ APOTEX INC	EQ 0.5MG BASE/5ML	A075703 001	Nov 27, 2000	Apr	DISC
>D>	AA	NOVEX	EQ 0.5MG BASE/5ML	A075703 001	Nov 27, 2000	Apr	DISC
		@ SILARX	EQ 0.5MG BASE/5ML	A074884 001	Dec 17, 1997	Mar	DISC

CLEVIDIPINE

EMULSION; INTRAVENOUS

CLEVIPREX

+	MEDICINES CO	25MG/50ML (0.5MG/ML)	N022156 001	Aug 01, 2008	Feb	CAIN
+		50MG/100ML (0.5MG/ML)	N022156 002	Aug 01, 2008	Feb	CAIN

CLINDAMYCIN PALMITATE HYDROCHLORIDE

FOR SOLUTION; ORAL

CLINDAMYCIN PALMITATE HYDROCHLORIDE

>A>	AA	AUROBINDO PHARMA LTD	EQ 75MG BASE/5ML	A202409 001	Apr 30, 2013	Apr	NEWA
-----	----	----------------------	------------------	-------------	--------------	-----	------

CLINDAMYCIN PHOSPHATE

INJECTABLE; INJECTION

CLINDAMYCIN PHOSPHATE IN 5% DEXTROSE IN PLASTIC CONTAINER

AP	AKORN INC	EQ 6MG BASE/ML	A203048 001	Apr 04, 2013	Mar	NEWA
AP		EQ 12MG BASE/ML	A203048 002	Apr 04, 2013	Mar	NEWA
AP		EQ 18MG BASE/ML	A203048 003	Apr 04, 2013	Mar	NEWA

SOLUTION; TOPICAL

CLINDAMYCIN PHOSPHATE

@ PERRIGO NEW YORK	EQ 1% BASE	A064050 001	Nov 30, 1995	Feb	DISC
--------------------	------------	-------------	--------------	-----	------

CLONAZEPAM

TABLET; ORAL

CLONAZEPAM

>A>	AB	ACCORD HLTHCARE	0.5MG	A077147 001	May 02, 2005	Apr	CAHN
>A>	AB		1MG	A077147 002	May 02, 2005	Apr	CAHN
>A>	AB		2MG	A077147 003	May 02, 2005	Apr	CAHN
>D>	AB	ACCORD HLTHCARE INC	0.5MG	A077147 001	May 02, 2005	Apr	CAHN
>D>	AB		1MG	A077147 002	May 02, 2005	Apr	CAHN
>D>	AB		2MG	A077147 003	May 02, 2005	Apr	CAHN
		@ APOTEX INC	0.5MG	A075468 001	Oct 06, 2000	Feb	DISC
		@	1MG	A075468 002	Oct 06, 2000	Feb	DISC
		@	2MG	A075468 003	Oct 06, 2000	Feb	DISC

CLOPIDOGREL BISULFATE

TABLET; ORAL

CLOPIDOGREL BISULFATE

AB	ACCORD HLTHCARE	EQ 75MG BASE	A202925 001	Mar 27, 2013	Mar	NEWA
AB		EQ 300MG BASE	A202925 002	Mar 27, 2013	Mar	NEWA

CLOZAPINE

SUSPENSION; ORAL

VERSACLOZ

+	DOUGLAS PHARMS	50MG/ML	N203479 001	Feb 06, 2013	Feb	NEWA
+	JAZZ PHARMS III	50MG/ML	N203479 001	Feb 06, 2013	Mar	CAHN

CODEINE PHOSPHATE; PROMETHAZINE HYDROCHLORIDE

SYRUP; ORAL

PROMETHAZINE HYDROCHLORIDE AND CODEINE PHOSPHATE

>A>	AA	AMNEAL PHARMS	10MG/5ML; 6.25MG/5ML	A200894 001	Apr 24, 2013	Apr	NEWA
-----	----	---------------	----------------------	-------------	--------------	-----	------

COSYNTROPIN

INJECTABLE; INJECTION

COSYNTROPIN

AP	MYLAN LLC	0.25MG/VIAL	A090574 001	Dec 17, 2009	Feb	CAHN
----	-----------	-------------	-------------	--------------	-----	------

CROMOLYN SODIUM

CONCENTRATE; ORAL

CROMOLYN SODIUM

AA	MICRO LABS LTD INDIA	100MG/5ML	A202745 001	Apr 04, 2013	Mar	NEWA
----	----------------------	-----------	-------------	--------------	-----	------

SOLUTION; INHALATION

CROMOLYN SODIUM

>A>		@ APOTEX INC	10MG/ML	A075333 001	Apr 30, 2002	Apr	DISC
>D>	AN	NOVEX	10MG/ML	A075333 001	Apr 30, 2002	Apr	DISC

SOLUTION/DROPS; OPHTHALMIC

CROMOLYN SODIUM

>A>		@ APOTEX INC	4%	A075615 001	Jan 26, 2001	Apr	DISC
>D>	AT	NOVEX	4%	A075615 001	Jan 26, 2001	Apr	DISC

CYCLOBENZAPRINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

AMRIX

AB	IVAX INTL	15MG	N021777 001	Feb 01, 2007	Jan	CAHN
AB	+	30MG	N021777 002	Feb 01, 2007	Jan	CAHN

CAPSULE, EXTENDED RELEASE; ORAL

CYCLOBENZAPRINE HYDROCHLORIDE

AB	TWI PHARMS INC	15MG	A091281	001	Jan 31, 2013	Jan	NEWA
AB		30MG	A091281	002	Jan 31, 2013	Jan	NEWA

TABLET; ORAL

CYCLOBENZAPRINE HYDROCHLORIDE

AB	MYLAN PHARMS INC	7.5MG	A073144	003	Mar 25, 2013	Mar	NEWA
	@ PROSAM LABS	5MG	A077291	001	Feb 03, 2006	Mar	DISC
>D>	AB	SANDOZ	A072854	002	Feb 03, 2006	Apr	DISC
>A>	@	5MG	A072854	002	Feb 03, 2006	Apr	DISC
>D>	AB	10MG	A072854	001	Nov 19, 1991	Apr	DISC
>A>	@	10MG	A072854	001	Nov 19, 1991	Apr	DISC

CYCLOPENTOLATE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

AKPENTOLATE

@ AKORN	2%	A040165	001	Jan 13, 1997	Mar	DISC
---------	----	---------	-----	--------------	-----	------

CYCLOGYL

+ ALCON LABS INC	2%	A084108	001		Mar	CTEC
------------------	----	---------	-----	--	-----	------

CYCLOPHOSPHAMIDE

INJECTABLE; INJECTION

CYTOXAN (LYOPHILIZED)

AP	+	BAXTER HLTHCARE	500MG/VIAL	N012142	003		Mar	CTNA
	@		500MG/VIAL	N012142	008	Jan 04, 1984	Jan	CTNA
AP	+		1GM/VIAL	N012142	004	Aug 30, 1982	Mar	CTNA
	@		1GM/VIAL	N012142	010	Sep 24, 1985	Jan	CTNA
AP	+		2GM/VIAL	N012142	005	Aug 30, 1982	Mar	CTNA
	@		2GM/VIAL	N012142	009	Dec 10, 1985	Jan	CTNA

CYCLOSPORINE

SOLUTION; ORAL

CYCLOSPORINE

>A>	@ APOTEX INC	100MG/ML	A065167	001	Jan 05, 2005	Apr	DISC
>D>	AB1	NOVEX	A065167	001	Jan 05, 2005	Apr	DISC

CYPROHEPTADINE HYDROCHLORIDE

SYRUP; ORAL

CYPROHEPTADINE HYDROCHLORIDE

AA	PHARM ASSOC	2MG/5ML	A091295	001	Mar 28, 2013	Mar	NEWA
----	-------------	---------	---------	-----	--------------	-----	------

CYSTEAMINE BITARTRATE

CAPSULE, DELAYED RELEASE; ORAL

PROCYSBI

>A>	RAPTOR PHARMS	EQ 25MG BASE	N203389	001	Apr 30, 2013	Apr	NEWA
>A>	+	EQ 75MG BASE	N203389	002	Apr 30, 2013	Apr	NEWA

DACARBAZINE

INJECTABLE; INJECTION

DACARBAZINE

>D>	AP	TEVA PARENTERAL	200MG/VIAL	A075259	002	Aug 27, 1998	Apr	CAHN
>D>	AP	+	500MG/VIAL	A075259	001	Sep 22, 2000	Apr	CAHN
>A>	AP	TEVA PHARMS USA	200MG/VIAL	A075259	002	Aug 27, 1998	Apr	CAHN
>A>	AP	+	500MG/VIAL	A075259	001	Sep 22, 2000	Apr	CAHN

DAUNORUBICIN HYDROCHLORIDE

INJECTABLE; INJECTION

DAUNORUBICIN HYDROCHLORIDE

>D>	AP	TEVA PARENTERAL	EQ 5MG BASE/ML	A065035 001	Jan 24, 2000	Apr	CAHN
>A>	AP	TEVA PHARMS USA	EQ 5MG BASE/ML	A065035 001	Jan 24, 2000	Apr	CAHN

DESMOPRESSIN ACETATE

INJECTABLE; INJECTION

DESMOPRESSIN ACETATE

	AP	SUN PHARM INDS LTD	0.004MG/ML	A091280 001	Jan 25, 2013	Jan	NEWA
>D>	AP	TEVA PARENTERAL	0.004MG/ML	A074888 001	Oct 15, 1997	Apr	CAHN
>A>	AP	TEVA PHARMS USA	0.004MG/ML	A074888 001	Oct 15, 1997	Apr	CAHN

DESOGESTREL; ETHINYL ESTRADIOL

TABLET; ORAL-28

ENSKYCE

	AB	LUPIN LTD	0.15MG;0.03MG	A201887 001	Mar 07, 2013	Feb	NEWA
--	----	-----------	---------------	-------------	--------------	-----	------

DESOXIMETASONE

>A>		SPRAY; TOPICAL					
>A>		TOPICORT					
>A>	+	TARO	0.25%	N204141 001	Apr 11, 2013	Apr	NEWA

DESVENLAFAXINE

TABLET, EXTENDED RELEASE; ORAL

DESVENLAFAXINE

>D>		ALEMBIC PHARMS LTD	50MG	N204150 001	Mar 04, 2013	Apr	CRLD
>A>	+		50MG	N204150 001	Mar 04, 2013	Apr	CRLD
			50MG	N204150 001	Mar 04, 2013	Mar	NEWA
	+		100MG	N204150 002	Mar 04, 2013	Mar	NEWA

DEXAMETHASONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

SUSPENSION/DROPS; OPHTHALMIC

NEOMYCIN AND POLYMYXIN B SULFATES AND DEXAMETHASONE

	@	ALCON PHARMS LTD	0.1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	A062721 001	Nov 17, 1986	Jan	DISC
--	---	------------------	---------------------------------------	-------------	--------------	-----	------

DEXMEDETOMIDINE HYDROCHLORIDE

INJECTABLE; INJECTION

PRECEDEX

+	HOSPIRA	EQ 200MCG BASE/50ML (EQ 4MCG BASE/ML)	N021038 002	Mar 13, 2013	Mar	NEWA
+		EQ 400MCG BASE/100ML (EQ 4MCG BASE/ML)	N021038 003	Mar 13, 2013	Mar	NEWA

DEXTROSE; POTASSIUM CHLORIDE

INJECTABLE; INJECTION

POTASSIUM CHLORIDE 0.22% IN DEXTROSE 5% IN PLASTIC CONTAINER

	@	B BRAUN	5GM/100ML;220MG/100ML	N018744 003	Nov 09, 1982	Jan	DISC
--	---	---------	-----------------------	-------------	--------------	-----	------

DIAZOXIDE

SUSPENSION; ORAL

PROGLYCEM

>A>	+	TEVA BRANDED PHARM	50MG/ML	N017453 001		Apr	CAHN
>D>	+	TEVA GLOBAL	50MG/ML	N017453 001		Apr	CAHN

DICLOFENAC SODIUM

SOLUTION/DROPS; OPHTHALMIC

DICLOFENAC SODIUM

>D>	AT	APOTEX INC	0.1%	A077600 001	Nov 13, 2008	Apr	DISC
>A>		@	0.1%	A077600 001	Nov 13, 2008	Apr	DISC

DICLOFENAC SODIUM; MISOPROSTOL

TABLET, DELAYED RELEASE; ORAL

DICLOFENAC SODIUM AND MISOPROSTOL

>A>	AB	SANDOZ	50MG;0.2MG	A200158 001	May 09, 2013	Apr	NEWA
>A>	AB		75MG;0.2MG	A200158 002	May 09, 2013	Apr	NEWA

DIDANOSINE

>D> TABLET, CHEWABLE; ORAL

>D> DIDANOSINE

>D>		AUROBINDO	100MG	A077275 001	Aug 14, 2012	Apr	CDFR
-----	--	-----------	-------	-------------	--------------	-----	------

>D>			150MG	A077275 002	Aug 14, 2012	Apr	CDFR
-----	--	--	-------	-------------	--------------	-----	------

>D>	+		200MG	A077275 003	Aug 14, 2012	Apr	CDFR
-----	---	--	-------	-------------	--------------	-----	------

>A> TABLET, FOR SUSPENSION; ORAL

>A> DIDANOSINE

>A>		AUROBINDO	100MG	A077275 001	Aug 14, 2012	Apr	CDFR
-----	--	-----------	-------	-------------	--------------	-----	------

>A>			150MG	A077275 002	Aug 14, 2012	Apr	CDFR
-----	--	--	-------	-------------	--------------	-----	------

>A>	+		200MG	A077275 003	Aug 14, 2012	Apr	CDFR
-----	---	--	-------	-------------	--------------	-----	------

DILTIAZEM HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

DILTIAZEM HYDROCHLORIDE

AB3		PAR PHARM	120MG	A074984 001	Dec 20, 1999	Jan	CAHN
-----	--	-----------	-------	-------------	--------------	-----	------

AB3			180MG	A074984 002	Dec 20, 1999	Jan	CAHN
-----	--	--	-------	-------------	--------------	-----	------

AB3			240MG	A074984 003	Dec 20, 1999	Jan	CAHN
-----	--	--	-------	-------------	--------------	-----	------

AB3			300MG	A074984 004	Dec 20, 1999	Jan	CAHN
-----	--	--	-------	-------------	--------------	-----	------

AB4		SANDOZ	120MG	A091022 001	Sep 28, 2012	Feb	CAHN
-----	--	--------	-------	-------------	--------------	-----	------

AB4			180MG	A091022 002	Sep 28, 2012	Feb	CAHN
-----	--	--	-------	-------------	--------------	-----	------

AB4			240MG	A091022 003	Sep 28, 2012	Feb	CAHN
-----	--	--	-------	-------------	--------------	-----	------

AB4			300MG	A091022 004	Sep 28, 2012	Feb	CAHN
-----	--	--	-------	-------------	--------------	-----	------

AB4			360MG	A091022 005	Sep 28, 2012	Feb	CAHN
-----	--	--	-------	-------------	--------------	-----	------

AB4			420MG	A091022 006	Sep 28, 2012	Feb	CAHN
-----	--	--	-------	-------------	--------------	-----	------

INJECTABLE; INJECTION

DILTIAZEM HYDROCHLORIDE

>D>	AP	AGILA SPECLTS	5MG/ML	A075375 001	Sep 30, 1999	Apr	DISC
-----	----	---------------	--------	-------------	--------------	-----	------

>A>	AP	APOTEX INC	5MG/ML	A075375 001	Sep 30, 1999	Apr	DISC
-----	----	------------	--------	-------------	--------------	-----	------

>D>		@ TEVA PARENTERAL	5MG/ML	A074894 001	Aug 26, 1997	Apr	CAHN
-----	--	-------------------	--------	-------------	--------------	-----	------

>D>	+		10MG/ML	A074894 002	Apr 19, 2002	Apr	CAHN
-----	---	--	---------	-------------	--------------	-----	------

>A>		@ TEVA PHARMS USA	5MG/ML	A074894 001	Aug 26, 1997	Apr	CAHN
-----	--	-------------------	--------	-------------	--------------	-----	------

>A>	+		10MG/ML	A074894 002	Apr 19, 2002	Apr	CAHN
-----	---	--	---------	-------------	--------------	-----	------

TABLET; ORAL

DILTIAZEM HYDROCHLORIDE

@ DAVA PHARMS INC 30MG

A074093 001	Nov 05, 1992	Jan	DISC
-------------	--------------	-----	------

@ 60MG

A074093 002	Nov 05, 1992	Jan	DISC
-------------	--------------	-----	------

@ 90MG

A074093 003	Nov 05, 1992	Jan	DISC
-------------	--------------	-----	------

@ 120MG

A074093 004	Nov 05, 1992	Jan	DISC
-------------	--------------	-----	------

DIMENHYDRINATE

INJECTABLE; INJECTION

DIMENHYDRINATE

>D>	AP	FRESENIUS KABI USA	50MG/ML	A040519	001	Jun 23, 2004	Apr	CRLD
>A>		+	50MG/ML	A040519	001	Jun 23, 2004	Apr	CRLD
>D>	AP	+	WATSON LABS	50MG/ML	A080615	001	Apr	DISC
>A>		@	50MG/ML	A080615	001		Apr	DISC

DIMETHYL FUMARATE

CAPSULE, DELAYED RELEASE; ORAL

TECFIDERA

		BIOGEN IDEC INC	120MG	N204063	001	Mar 27, 2013	Mar	NEWA
		+	240MG	N204063	002	Mar 27, 2013	Mar	NEWA

DIPHENHYDRAMINE HYDROCHLORIDE

INJECTABLE; INJECTION

DIPHENHYDRAMINE HYDROCHLORIDE

		@ WATSON LABS INC	10MG/ML	A080873	001		Mar	DISC
		@	50MG/ML	A080873	002		Mar	DISC

DIPHENHYDRAMINE HYDROCHLORIDE PRESERVATIVE FREE

AP		BD RX	50MG/ML	A091526	001	Mar 26, 2013	Mar	NEWA
		@ WATSON LABS INC	50MG/ML	A080873	003		Mar	DISC

DIPYRIDAMOLE

INJECTABLE; INJECTION

DIPYRIDAMOLE

>A>		@ APOTEX INC	5MG/ML	A075769	001	Nov 27, 2002	Apr	DISC
>D>	AP	CLARIS LIFESCIENCES	5MG/ML	A075769	001	Nov 27, 2002	Apr	DISC

DIVALPROEX SODIUM

TABLET, EXTENDED RELEASE; ORAL

DIVALPROEX SODIUM

		@ TEVA PHARMS USA	EQ 500MG VALPROIC ACID	A078700	001	Aug 03, 2009	Mar	DISC
--	--	-------------------	------------------------	---------	-----	--------------	-----	------

DOCETAXEL

INJECTABLE; INJECTION

DOCETAXEL

>A>	AP	ACTAVIS INC	20MG/ML (20MG/ML)	N203551	001	Apr 12, 2013	Apr	NEWA
>A>	AP		80MG/4ML (20MG/ML)	N203551	002	Apr 12, 2013	Apr	NEWA
>A>			140MG/7ML (20MG/ML)	N203551	003	Apr 12, 2013	Apr	NEWA

DONEPEZIL HYDROCHLORIDE

TABLET; ORAL

DONEPEZIL HYDROCHLORIDE

		@ ACCORD HLTHCARE	5MG	A201335	001	Aug 29, 2011	Jan	DISC
		@	10MG	A201335	002	Aug 29, 2011	Jan	DISC
>A>	AB	ACTAVIS GRP PTC	5MG	A090551	001	May 31, 2011	Apr	CAHN
>A>	AB		10MG	A090551	002	May 31, 2011	Apr	CAHN
>D>	AB	ACTAVIS PHARMA	5MG	A090551	001	May 31, 2011	Apr	CAHN
>D>	AB		10MG	A090551	002	May 31, 2011	Apr	CAHN
	AB	ALEMBIC PHARMS LTD	5MG	A201724	001	Feb 25, 2013	Feb	NEWA
	AB		10MG	A201724	002	Feb 25, 2013	Feb	NEWA

DORZOLAMIDE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

DORZOLAMIDE HYDROCHLORIDE

>D>	AT	APOTEX INC	EQ 2% BASE	A078395	001	Oct 28, 2008	Apr	DISC
>A>		@	EQ 2% BASE	A078395	001	Oct 28, 2008	Apr	DISC

DORZOLAMIDE HYDROCHLORIDE; TIMOLOL MALEATE

SOLUTION/DROPS; OPHTHALMIC

DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE

>D>	AT	APOTEX INC	EQ 2% BASE;EQ 0.5% BASE	A078201	001	Oct 28, 2008	Apr	DISC
>A>		@	EQ 2% BASE;EQ 0.5% BASE	A078201	001	Oct 28, 2008	Apr	DISC

DOXAZOSIN MESYLATE

TABLET; ORAL

DOXAZOSIN MESYLATE

@ WATSON LABS INC

EQ 1MG BASE

A075426 001 Oct 18, 2000 Jan DISC

@

EQ 2MG BASE

A075426 002 Oct 18, 2000 Jan DISC

@

EQ 4MG BASE

A075426 003 Oct 18, 2000 Jan DISC

@

EQ 8MG BASE

A075426 004 Oct 18, 2000 Jan DISC

DOXEPIH HYDROCHLORIDE

CONCENTRATE; ORAL

DOXEPIH HYDROCHLORIDE

@ PHARM ASSOC

EQ 10MG BASE/ML

A075924 001 Jan 15, 2004 Mar DISC

TABLET; ORAL

SILENOR

>A>		PERNIX THERAPS LLC	EQ 3MG BASE	N022036	001	Mar 17, 2010	Apr	CAHN
>A>	+		EQ 6MG BASE	N022036	002	Mar 17, 2010	Apr	CAHN
>D>		SOMAXON	EQ 3MG BASE	N022036	001	Mar 17, 2010	Apr	CAHN
>D>	+		EQ 6MG BASE	N022036	002	Mar 17, 2010	Apr	CAHN

DOXORUBICIN HYDROCHLORIDE

INJECTABLE; INJECTION

DOXORUBICIN HYDROCHLORIDE

AP

SAGENT PHARMS

2MG/ML

A091495 001 Mar 18, 2013 Mar NEWA

INJECTABLE, LIPOSOMAL; INJECTION

>D>		DOXIL						
>D>	AB	+	JANSSEN RES AND DEV	20MG/10ML (2MG/ML)	N050718	001	Nov 17, 1995	Apr CTNA
	AB	+		20MG/10ML (2MG/ML)	N050718	001	Nov 17, 1995	Jan CFTG
>D>	AB	+		50MG/25ML (2MG/ML)	N050718	002	Jun 13, 2000	Apr CTNA
	AB	+		50MG/25ML (2MG/ML)	N050718	002	Jun 13, 2000	Jan CFTG
>A>			DOXIL (LIPOSOMAL)					
>A>	AB	+	JANSSEN RES AND DEV	20MG/10ML (2MG/ML)	N050718	001	Nov 17, 1995	Apr CTNA
>A>	AB	+		50MG/25ML (2MG/ML)	N050718	002	Jun 13, 2000	Apr CTNA
>D>			DOXORUBICIN HYDROCHLORIDE					
>D>	AB		SUN PHARMA GLOBAL	20MG/10ML (2MG/ML)	A203263	001	Feb 04, 2013	Apr CTNA
	AB			20MG/10ML (2MG/ML)	A203263	001	Feb 04, 2013	Jan NEWA
>D>	AB			50MG/25ML (2MG/ML)	A203263	002	Feb 04, 2013	Apr CTNA
	AB			50MG/25ML (2MG/ML)	A203263	002	Feb 04, 2013	Jan NEWA
>A>			DOXORUBICIN HYDROCHLORIDE (LIPOSOMAL)					
>A>	AB		SUN PHARMA GLOBAL	20MG/10ML (2MG/ML)	A203263	001	Feb 04, 2013	Apr CTNA
>A>	AB			50MG/25ML (2MG/ML)	A203263	002	Feb 04, 2013	Apr CTNA

DOXYCYCLINE

FOR SUSPENSION; ORAL

DOXYCYCLINE

AB	LUPIN LTD	EQ 25MG BASE/5ML	A201678	001	Mar 18, 2013	Mar	NEWA
----	-----------	------------------	---------	-----	--------------	-----	------

DOXYCYCLINE HYCLATE

TABLET; ORAL

DOXYCYCLINE HYCLATE

@	BLU CARIBE INC	EQ 50MG BASE	A062269	003		Mar	CAHN
---	----------------	--------------	---------	-----	--	-----	------

@		EQ 100MG BASE	A062269	002	Nov 08, 1982	Mar	CAHN
---	--	---------------	---------	-----	--------------	-----	------

TABLET, DELAYED RELEASE; ORAL

DORYX

>A>	MAYNE PHARMA	EQ 80MG BASE	N050795	004	Apr 11, 2013	Apr	NEWA
-----	--------------	--------------	---------	-----	--------------	-----	------

>A>		EQ 200MG BASE	N050795	005	Apr 11, 2013	Apr	NEWA
-----	--	---------------	---------	-----	--------------	-----	------

DOXYCYCLINE HYCLATE

>A>	AB	HERITAGE PHARMS INC	EQ 75MG BASE	A200856	001	Apr 30, 2013	Apr	NEWA
-----	----	---------------------	--------------	---------	-----	--------------	-----	------

>A>	AB		EQ 100MG BASE	A200856	002	Apr 30, 2013	Apr	NEWA
-----	----	--	---------------	---------	-----	--------------	-----	------

>A>	AB		EQ 150MG BASE	A200856	003	Apr 30, 2013	Apr	NEWA
-----	----	--	---------------	---------	-----	--------------	-----	------

DOXYLAMINE SUCCINATE; PYRIDOXINE HYDROCHLORIDE

>A> TABLET, DELAYED RELEASE; ORAL

>A> DICLEGIS

>A>	+	DUCHESNAY	10MG;10MG	N021876	001	Apr 08, 2013	Apr	NEWA
-----	---	-----------	-----------	---------	-----	--------------	-----	------

ECONAZOLE NITRATE

CREAM; TOPICAL

ECONAZOLE NITRATE

AB	IGI LABS INC	1%	A076574	001	Dec 17, 2004	Mar	CAHN
----	--------------	----	---------	-----	--------------	-----	------

ENTACAPONE

TABLET; ORAL

ENTACAPONE

>A>	AB	MYLAN PHARMS INC	200MG	A202394	001	May 13, 2013	Apr	NEWA
-----	----	------------------	-------	---------	-----	--------------	-----	------

EPIRUBICIN HYDROCHLORIDE

INJECTABLE; INJECTION

EPIRUBICIN HYDROCHLORIDE

@	MYLAN LLC	50MG/25ML (2MG/ML)	A065371	001	Nov 28, 2007	Feb	DISC
---	-----------	--------------------	---------	-----	--------------	-----	------

@		200MG/100ML (2MG/ML)	A065371	002	Nov 28, 2007	Feb	DISC
---	--	----------------------	---------	-----	--------------	-----	------

>D>	AP	TEVA PARENTERAL	50MG/25ML (2MG/ML)	A065331	001	Aug 09, 2007	Apr	CAHN
-----	----	-----------------	--------------------	---------	-----	--------------	-----	------

>D>	AP		200MG/100ML (2MG/ML)	A065331	002	Aug 09, 2007	Apr	CAHN
-----	----	--	----------------------	---------	-----	--------------	-----	------

>A>	AP	TEVA PHARMS USA	200MG/100ML (2MG/ML)	A065331	002	Aug 09, 2007	Apr	CAHN
-----	----	-----------------	----------------------	---------	-----	--------------	-----	------

>A>	AP		50MG/25ML (2MG/ML)	A065331	001	Aug 09, 2007	Apr	CAHN
-----	----	--	--------------------	---------	-----	--------------	-----	------

EPOPROSTENOL SODIUM

INJECTABLE; INJECTION

EPOPROSTENOL SODIUM

>D>	AP	TEVA PARENTERAL	EQ 0.5MG BASE/VIAL	A078396	001	Apr 23, 2008	Apr	CAHN
-----	----	-----------------	--------------------	---------	-----	--------------	-----	------

>D>	AP		EQ 1.5MG BASE/VIAL	A078396	002	Apr 23, 2008	Apr	CAHN
-----	----	--	--------------------	---------	-----	--------------	-----	------

>A>	AP	TEVA PHARMS USA	EQ 0.5MG BASE/VIAL	A078396	001	Apr 23, 2008	Apr	CAHN
-----	----	-----------------	--------------------	---------	-----	--------------	-----	------

>A>	AP		EQ 1.5MG BASE/VIAL	A078396	002	Apr 23, 2008	Apr	CAHN
-----	----	--	--------------------	---------	-----	--------------	-----	------

ERYTHROMYCIN

CAPSULE, DELAYED REL PELLETS; ORAL

ERYC

AB	+	MAYNE PHARMA	250MG	N050536	001		Mar	CAHN
>D>	AB	WARNER CHILCOTT LLC	250MG	A062338	001		Apr	DISC
>A>		@	250MG	A062338	001		Apr	DISC

SOLUTION; TOPICAL

SANSAC

>A>		@ DOW PHARM	2%	A062522	001	Jan 24, 1985	Apr	CAHN
>D>		@ DOW PHARM SCIENCES	2%	A062522	001	Jan 24, 1985	Apr	CAHN

ESOMEPRAZOLE SODIUM

INJECTABLE; INTRAVENOUS

ESOMEPRAZOLE SODIUM

AP		SUN PHARMA GLOBAL	EQ 20MG BASE/VIAL	A200882	001	Mar 18, 2013	Mar	NEWA
AP			EQ 40MG BASE/VIAL	A200882	002	Mar 18, 2013	Mar	NEWA
		NEXIUM IV						
AP	+	ASTRAZENECA	EQ 20MG BASE/VIAL	N021689	001	Mar 31, 2005	Mar	CFTG
AP	+		EQ 40MG BASE/VIAL	N021689	002	Mar 31, 2005	Mar	CFTG

ESTROPIPATE

TABLET; ORAL

ORTHO-EST

>A>		@ CARACO	0.75MG	A089567	001	Feb 27, 1991	Apr	DISC
>A>		@	1.5MG	A089582	001	Jul 17, 1991	Apr	DISC
>D>	AB	SUN PHARM INDS (IN)	0.75MG	A089567	001	Feb 27, 1991	Apr	DISC
>D>	AB		1.5MG	A089582	001	Jul 17, 1991	Apr	DISC

ESZOPICLONE

TABLET; ORAL

ESZOPICLONE

AB		MYLAN PHARMS INC	1MG	A091151	001	Mar 26, 2013	Mar	NEWA
AB			2MG	A091151	002	Mar 26, 2013	Mar	NEWA
AB			3MG	A091151	003	Mar 26, 2013	Mar	NEWA
AB		SUN PHARMA GLOBAL	1MG	A091103	001	Apr 03, 2013	Mar	NEWA
AB			2MG	A091103	002	Apr 03, 2013	Mar	NEWA
AB			3MG	A091103	003	Apr 03, 2013	Mar	NEWA
		LUNESTA						
AB		SUNOVION PHARMS INC	1MG	N021476	001	Dec 15, 2004	Mar	CTEC
AB			2MG	N021476	002	Dec 15, 2004	Mar	CTEC
AB	+		3MG	N021476	003	Dec 15, 2004	Mar	CTEC

ETHINYL ESTRADIOL; LEVONORGESTREL

TABLET; ORAL

DAYSEE

AB		LUPIN LTD	0.03MG,0.01MG;0.15MG,N/A	A091467	001	Apr 10, 2013	Mar	NEWA
		QUARTETTE						
	+	TEVA BRANDED PHARM	0.02MG,0.15MG;0.025MG,0.15MG;0.03MG,0.15MG;0.01MG,N/A	N204061	001	Mar 28, 2013	Mar	NEWA

TABLET; ORAL-28

LEVONORGESTREL AND ETHINYL ESTRADIOL

AB1		LUPIN LTD	0.02MG;0.1MG	A091425	001	Jan 18, 2013	Jan	NEWA
-----	--	-----------	--------------	---------	-----	--------------	-----	------

ETHINYL ESTRADIOL; NORETHINDRONE

	TABLET; ORAL-28						
>A>		PIRMELLA 1/35					
>A>	AB	LUPIN LTD	0.035MG;1MG	A201512	001	Apr 24, 2013	Apr NEWA
>A>		PIRMELLA 7/7/7					
>A>	AB	LUPIN LTD	0.035MG,0.035MG,0.035MG;0.5MG,0.75MG,1MG	A201510	001	Apr 24, 2013	Apr NEWA

ETHINYL ESTRADIOL; NORETHINDRONE ACETATE

>A>	CAPSULE; ORAL						
>A>	MINASTRIN 24 FE						
>A>	+	WARNER CHILCOTT	0.02MG;1MG	N204426	001	Apr 19, 2013	Apr NEWA
	TABLET; ORAL						
	FEMHRT						
	@	WARNER CHILCOTT LLC	0.005MG;1MG	N021065	002	Oct 15, 1999	Jan DISC
	NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL						
	+	BARR LABS INC	0.005MG;1MG	A076221	001	Nov 06, 2009	Jan CRLD

ETHINYL ESTRADIOL; NORGESTIMATE

	TABLET; ORAL-28						
	ESTARYLLA						
	AB	SANDOZ	0.035MG;0.25MG	A090794	001	Jan 30, 2013	Jan NEWA
>D>	TRI LO SPRINTC						
>D>	AB	BARR	0.025MG,0.025MG,0.025MG;0.18MG,0.215MG,0.25MG	A076784	001	Jun 29, 2009	Apr DISC
>A>	@	BARR LABS INC	0.025MG,0.025MG,0.025MG;0.18MG,0.215MG,0.25MG	A076784	001	Jun 29, 2009	Apr DISC
	TRI-ESTARYLLA						
	AB	SANDOZ	0.035MG,0.035MG,0.035MG;0.18MG,0.215MG,0.25MG	A090793	001	Jan 30, 2013	Jan NEWA

ETODOLAC

	TABLET; ORAL						
	ETODOLAC						
	@	PROSAM LABS	400MG	A074819	001	Feb 28, 1997	Mar DISC
	@		500MG	A074819	002	Apr 28, 1998	Mar DISC

ETOPOSIDE

	INJECTABLE; INJECTION						
	ETOPOSIDE						
>A>	AP	ACCORD HLTHCARE	20MG/ML	A074513	001	Mar 14, 1996	Apr CAHN
>D>	AP	ACCORD HLTHCARE INC	20MG/ML	A074513	001	Mar 14, 1996	Apr CAHN
>D>	AP	PHARMACHEMIE	20MG/ML	A074227	001	Feb 22, 1996	Apr DISC
>A>	@		20MG/ML	A074227	001	Feb 22, 1996	Apr DISC
>D>	AP	TEVA PARENTERAL	20MG/ML	A074529	001	Jul 24, 1996	Apr CAHN
>A>	AP	TEVA PHARMS USA	20MG/ML	A074529	001	Jul 24, 1996	Apr CAHN

FAMOTIDINE

	INJECTABLE; INJECTION						
	FAMOTIDINE						
>D>	@	APOTEX INC	10MG/ML	A075942	001	Aug 02, 2002	Apr DISC
>A>	@		10MG/ML	A075942	001	Aug 02, 2002	Apr DISC
	FAMOTIDINE PRESERVATIVE FREE						
>D>	AP	AKORN INC	10MG/ML	A076324	001	Nov 27, 2002	Apr DISC
	AP		10MG/ML	A076324	001	Nov 27, 2002	Mar CAHN
>A>	@	APOTEX INC	10MG/ML	A076324	001	Nov 27, 2002	Apr DISC

INJECTABLE; INJECTION

>D>	FAMOTIDINE PRESERVATIVE FREE (PHARMACY BULK)						
>D>	AP	AKORN INC	10MG/ML	A076322	001	Nov 27, 2002	Apr DISC
	AP		10MG/ML	A076322	001	Nov 27, 2002	Mar CAHN
>A>	@	APOTEX INC	10MG/ML	A076322	001	Nov 27, 2002	Apr DISC
	PEPCID PRESERVATIVE FREE IN PLASTIC CONTAINER						
>D>	@	MERCK	0.4MG/ML	N020249	001	Feb 18, 1994	Apr CAHN
>A>	@	MERCK SHARP DOHME	0.4MG/ML	N020249	001	Feb 18, 1994	Apr CAHN

FENOFIBRIC ACID

TABLET; ORAL

FIBRICOR

	MUTUAL PHARM CO INC	35MG	N022418	001	Aug 14, 2009	Feb CAHN
+		105MG	N022418	002	Aug 14, 2009	Feb CAHN

FENOPROFEN CALCIUM

TABLET; ORAL

FENOPROFEN CALCIUM

@	IVAX SUB TEVA PHARMS	EQ 600MG BASE	A072557	001	Aug 29, 1988	Mar DISC
+	MYLAN PHARMS INC	EQ 600MG BASE	A072267	001	Aug 17, 1988	Mar CTEC

FENTANYL CITRATE

TABLET; BUCCAL, SUBLINGUAL

FENTORA

AB	CEPHALON	EQ 0.1MG BASE	N021947	001	Sep 25, 2006	Feb CDFR
AB		EQ 0.2MG BASE	N021947	002	Sep 25, 2006	Feb CDFR
	@	EQ 0.3MG BASE	N021947	006	Mar 02, 2007	Feb CDFR
AB	+	EQ 0.4MG BASE	N021947	003	Sep 25, 2006	Feb CDFR
AB		EQ 0.6MG BASE	N021947	004	Sep 25, 2006	Feb CDFR
AB		EQ 0.8MG BASE	N021947	005	Sep 25, 2006	Feb CDFR

FERUMOXSI

SUSPENSION; ORAL

GASTROMARK

@	AMAG PHARMS INC	EQ 0.175MG IRON/ML	N020410	001	Dec 06, 1996	Feb DISC
---	-----------------	--------------------	---------	-----	--------------	----------

FINASTERIDE

TABLET; ORAL

FINASTERIDE

>A>	AB	ACCORD HLTHCARE	5MG	A090121	001	Feb 23, 2010	Apr CAHN
>D>	AB	ACCORD HLTHCARE INC	5MG	A090121	001	Feb 23, 2010	Apr CAHN
>D>	AB	HETERO DRUGS LTD	5MG	A090061	001	Jun 07, 2010	Apr CAHN
>A>	AB	HETERO LABS LTD III	5MG	A090061	001	Jun 07, 2010	Apr CAHN

FLECAINIDE ACETATE

TABLET; ORAL

FLECAINIDE ACETATE

>D>	AB	APOTEX INC	50MG	A079164	001	Jul 09, 2009	Apr DISC
>A>	@		50MG	A079164	001	Jul 09, 2009	Apr DISC
>D>	AB		100MG	A079164	002	Jul 09, 2009	Apr DISC
>A>	@		100MG	A079164	002	Jul 09, 2009	Apr DISC
>D>	AB		150MG	A079164	003	Jul 09, 2009	Apr DISC
>A>	@		150MG	A079164	003	Jul 09, 2009	Apr DISC

FLUCONAZOLE

FOR SUSPENSION; ORAL

FLUCONAZOLE

@ TARO PHARM INDS	50MG/5ML	A076918 001	Dec 18, 2006	Mar	DISC
-------------------	----------	-------------	--------------	-----	------

@	200MG/5ML	A076918 002	Dec 18, 2006	Mar	DISC
---	-----------	-------------	--------------	-----	------

INJECTABLE; INJECTION

FLUCONAZOLE IN DEXTROSE 5% IN PLASTIC CONTAINER

>D>	AP	AGILA SPECLTS	200MG/100ML (2MG/ML)	A076888 001	Mar 25, 2005	Apr	DISC
-----	----	---------------	----------------------	-------------	--------------	-----	------

>D>	AP		400MG/200ML (2MG/ML)	A076888 002	Mar 25, 2005	Apr	DISC
-----	----	--	----------------------	-------------	--------------	-----	------

>A>		@ APOTEX INC	200MG/100ML (2MG/ML)	A076888 001	Mar 25, 2005	Apr	DISC
-----	--	--------------	----------------------	-------------	--------------	-----	------

>A>		@	400MG/200ML (2MG/ML)	A076888 002	Mar 25, 2005	Apr	DISC
-----	--	---	----------------------	-------------	--------------	-----	------

FLUCONAZOLE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

>D>		@ AGILA SPECLTS	200MG/100ML (2MG/ML)	A076889 001	Mar 25, 2005	Apr	DISC
-----	--	-----------------	----------------------	-------------	--------------	-----	------

>D>		@	400MG/200ML (2MG/ML)	A076889 002	Mar 25, 2005	Apr	DISC
-----	--	---	----------------------	-------------	--------------	-----	------

>A>		@ APOTEX INC	200MG/100ML (2MG/ML)	A076889 001	Mar 25, 2005	Apr	DISC
-----	--	--------------	----------------------	-------------	--------------	-----	------

>A>		@	400MG/200ML (2MG/ML)	A076889 002	Mar 25, 2005	Apr	DISC
-----	--	---	----------------------	-------------	--------------	-----	------

FLUDARABINE PHOSPHATE

INJECTABLE; INJECTION

FLUDARABINE PHOSPHATE

AP	+	FRESENIUS KABI USA	50MG/2ML (25MG/ML)	A078393 001	Oct 15, 2007	Jan	CRLD
----	---	--------------------	--------------------	-------------	--------------	-----	------

>D>	AP	TEVA PARENTERAL	50MG/VIAL	A076349 001	Aug 28, 2003	Apr	CAHN
-----	----	-----------------	-----------	-------------	--------------	-----	------

>D>	AP		50MG/2ML (25MG/ML)	A076661 001	Apr 28, 2004	Apr	CAHN
-----	----	--	--------------------	-------------	--------------	-----	------

	AP		50MG/2ML (25MG/ML)	A076661 001	Apr 28, 2004	Jan	CRLD
--	----	--	--------------------	-------------	--------------	-----	------

>A>	AP	TEVA PHARMS USA	50MG/2ML (25MG/ML)	A076661 001	Apr 28, 2004	Apr	CAHN
-----	----	-----------------	--------------------	-------------	--------------	-----	------

>A>	AP		50MG/VIAL	A076349 001	Aug 28, 2003	Apr	CAHN
-----	----	--	-----------	-------------	--------------	-----	------

FLUDEOXYGLUCOSE F-18

INJECTABLE; INTRAVENOUS

FLUDEOXYGLUCOSE F18

+	FEINSTEIN	20-300mCi/ML	N021870 002	Nov 21, 2008	Jan	CFTG
---	-----------	--------------	-------------	--------------	-----	------

	HOUSTON CYCLOTRON	20-500mCi/ML	A203665 001	Feb 14, 2013	Jan	NEWA
--	-------------------	--------------	-------------	--------------	-----	------

FLUMAZENIL

INJECTABLE; INJECTION

FLUMAZENIL

>A>		@ APOTEX INC	0.5MG/5ML (0.1MG/ML)	A076755 002	Oct 12, 2004	Apr	DISC
-----	--	--------------	----------------------	-------------	--------------	-----	------

>A>		@	1MG/10ML (0.1MG/ML)	A076755 001	Oct 12, 2004	Apr	DISC
-----	--	---	---------------------	-------------	--------------	-----	------

>D>	AP	CLARIS LIFESCIENCES	0.5MG/5ML (0.1MG/ML)	A076755 002	Oct 12, 2004	Apr	DISC
-----	----	---------------------	----------------------	-------------	--------------	-----	------

>D>	AP		1MG/10ML (0.1MG/ML)	A076755 001	Oct 12, 2004	Apr	DISC
-----	----	--	---------------------	-------------	--------------	-----	------

>D>		@ TEVA PARENTERAL	0.5MG/5ML (0.1MG/ML)	A076589 002	Oct 12, 2004	Apr	CAHN
-----	--	-------------------	----------------------	-------------	--------------	-----	------

>D>		@	1MG/10ML (0.1MG/ML)	A076589 001	Oct 12, 2004	Apr	CAHN
-----	--	---	---------------------	-------------	--------------	-----	------

>A>		@ TEVA PHARMS USA	0.5MG/5ML (0.1MG/ML)	A076589 002	Oct 12, 2004	Apr	CAHN
-----	--	-------------------	----------------------	-------------	--------------	-----	------

>A>		@	1MG/10ML (0.1MG/ML)	A076589 001	Oct 12, 2004	Apr	CAHN
-----	--	---	---------------------	-------------	--------------	-----	------

FLUOCINONIDE

CREAM; TOPICAL

LIDEX

@ CNTY LINE PHARMS	0.05%	N016908 002		Jan	CAHN
--------------------	-------	-------------	--	-----	------

LIDEX-E

@ CNTY LINE PHARMS	0.05%	N016908 003		Jan	CAHN
--------------------	-------	-------------	--	-----	------

GEL; TOPICAL

FLUOCINONIDE

AB	+	TARO	0.05%	A074935 001	Jul 29, 1997	Jan	CRLD
----	---	------	-------	-------------	--------------	-----	------

GEL; TOPICAL

LIDEX

@ CNTY LINE PHARMS

0.05%

N017373 001

Jan CAHN

OINTMENT; TOPICAL

FLUOCINONIDE

AB + TARO

0.05%

A075008 001 Jun 30, 1999 Jan CRLD

LIDEX

@ CNTY LINE PHARMS

0.05%

N016909 002

Jan CAHN

SOLUTION; TOPICAL

FLUOCINONIDE

AT + TARO

0.05%

A074799 001 Dec 31, 1996 Jan CRLD

LIDEX

@ MEDICIS

0.05%

N018849 001 Apr 06, 1984 Jan DISC

FLUOROURACIL

INJECTABLE; INJECTION

FLUOROURACIL

AP + MYLAN LLC

500MG/10ML (50MG/ML)

A040743 002 Apr 26, 2007 Feb CAHN

AP +

1GM/20ML (50MG/ML)

A040743 001 Apr 26, 2007 Feb CAHN

FLUOXETINE HYDROCHLORIDE

CAPSULE; ORAL

FLUOXETINE HYDROCHLORIDE

@ CARLSBAD

EQ 10MG BASE

A076022 001 Jan 30, 2002 Mar DISC

@

EQ 20MG BASE

A076022 002 Jan 30, 2002 Mar DISC

>D> AB1 CR DOUBLE CRANE

EQ 10MG BASE

A076165 001 Feb 01, 2002 Apr DISC

>A> @

EQ 10MG BASE

A076165 001 Feb 01, 2002 Apr DISC

AB1

EQ 10MG BASE

A076165 001 Feb 01, 2002 Mar CAHN

>D> AB1

EQ 20MG BASE

A076165 002 Feb 01, 2002 Apr DISC

>A> @

EQ 20MG BASE

A076165 002 Feb 01, 2002 Apr DISC

AB1

EQ 20MG BASE

A076165 002 Feb 01, 2002 Mar CAHN

@ WOCKHARDT LTD

EQ 10MG BASE

A078143 001 Jan 16, 2008 Feb DISC

@

EQ 20MG BASE

A078143 002 Jan 16, 2008 Feb DISC

@

EQ 40MG BASE

A078143 003 Jan 16, 2008 Feb DISC

SOLUTION; ORAL

FLUOXETINE HYDROCHLORIDE

>A> @ APOTEX INC

EQ 20MG BASE/5ML

A075292 001 Feb 07, 2002 Apr DISC

>D> AA

NOVEX

EQ 20MG BASE/5ML

A075292 001 Feb 07, 2002 Apr DISC

FLUOXETINE HYDROCHLORIDE; OLANZAPINE

CAPSULE; ORAL

OLANZAPINE AND FLUOXETINE HYDROCHLORIDE

AB TEVA PHARMS

EQ 25MG BASE;EQ 3MG BASE

A202074 001 Mar 25, 2013 Mar NEWA

FLUPHENAZINE DECANOATE

INJECTABLE; INJECTION

FLUPHENAZINE DECANOATE

>A> @ APOTEX INC

25MG/ML

A075918 001 Aug 17, 2001 Apr DISC

>D> AO

CLARIS LIFESCIENCES

25MG/ML

A075918 001 Aug 17, 2001 Apr DISC

FLUVOXAMINE MALEATE

CAPSULE, EXTENDED RELEASE; ORAL

FLUVOXAMINE MALEATE

>A> AB ACTAVIS ELIZABETH

100MG

A091482 001 Apr 23, 2013 Apr NEWA

AB

ANCHEN PHARMS

100MG

A091476 001 Mar 13, 2013 Mar NEWA

AB

150MG

A091476 002 Mar 13, 2013 Mar NEWA

CAPSULE, EXTENDED RELEASE; ORAL

LUVOX CR

AB	JAZZ PHARMS	100MG	N022033 001	Feb 28, 2008	Mar	CFTG
AB	+	150MG	N022033 002	Feb 28, 2008	Mar	CFTG

FOSINOPRIL SODIUM

TABLET; ORAL

FOSINOPRIL SODIUM

@	WATSON LABS	10MG	A076987 001	Dec 23, 2004	Mar	DISC
@		20MG	A076987 002	Dec 23, 2004	Mar	DISC
@		40MG	A076987 003	Dec 23, 2004	Mar	DISC

FOSPHENYTOIN SODIUM

INJECTABLE; INJECTION

FOSPHENYTOIN SODIUM

>D>	AP	APOTEX INC	EQ 50MG PHENYTOIN NA/ML	A078126 001	Aug 06, 2007	Apr	DISC
>A>		@	EQ 50MG PHENYTOIN NA/ML	A078126 001	Aug 06, 2007	Apr	DISC

FUROSEMIDE

INJECTABLE; INJECTION

FUROSEMIDE

@	INTL MEDICATION	10MG/ML	N018025 001		Jan	DISC
---	-----------------	---------	-------------	--	-----	------

TABLET; ORAL

FUROSEMIDE

@	DAVA PHARMS INC	20MG	N018415 001	Jul 27, 1982	Feb	DISC
@		40MG	N018415 002	Jul 27, 1982	Feb	DISC
@		80MG	N018415 003	Nov 26, 1984	Feb	DISC

GADOTERATE MEGLUMINE

SOLUTION; INTRAVENOUS

DOTAREM

+	GUERBET	37.69GM/100ML (376.9MG/ML)	N204781 001	Mar 20, 2013	Mar	NEWA
+		3.769GM/10ML (376.9MG/ML)	N204781 002	Mar 20, 2013	Mar	NEWA
+		5.6535GM/15ML (376.9MG/ML)	N204781 003	Mar 20, 2013	Mar	NEWA
+		7.538GM/20ML (376.9MG/ML)	N204781 004	Mar 20, 2013	Mar	NEWA

GADOXETATE DISODIUM

SOLUTION; INTRAVENOUS

EOVIST

BAYER HLTHCARE	2.72145GM/15ML (181.43MG/ML)	N022090 002	Feb 04, 2013	Feb	NEWA
----------------	------------------------------	-------------	--------------	-----	------

GATIFLOXACIN

SOLUTION/DROPS; OPHTHALMIC

GATIFLOXACIN

>D>	AT	APOTEX CORP	0.3%	A079084 001	Aug 19, 2011	Apr	DISC
>A>		@ APOTEX INC	0.3%	A079084 001	Aug 19, 2011	Apr	DISC

GEMCITABINE HYDROCHLORIDE

INJECTABLE; INJECTION

GEMCITABINE HYDROCHLORIDE

>A>	AP	DR REDDYS LABS LTD	EQ 2GM BASE/VIAL	A202997 001	May 07, 2013	Apr	NEWA
>A>	AP	JIANGSU HANSON PHARM	EQ 200MG BASE/VIAL	A202485 001	May 07, 2013	Apr	NEWA
>A>	AP		EQ 1GM BASE/VIAL	A202485 002	May 07, 2013	Apr	NEWA
>A>	AP	PHARMAFORCE	EQ 200MG BASE/VIAL	A202031 001	May 07, 2013	Apr	NEWA
>A>	AP		EQ 1GM BASE/VIAL	A202031 002	May 07, 2013	Apr	NEWA

INJECTABLE; INJECTION

GEMCITABINE HYDROCHLORIDE

>A>	AP	SAGENT PHARMS	EQ 200MG BASE/VIAL	A091597 001	May 07, 2013	Apr	NEWA
>A>	AP		EQ 1GM BASE/VIAL	A091597 002	May 07, 2013	Apr	NEWA

GLATIRAMER ACETATE

FOR SOLUTION; SUBCUTANEOUS

COPAXONE

>D>	@	TEVA	20MG/VIAL	N020622 001	Dec 20, 1996	Apr	CAHN
>A>	@	TEVA PHARMS USA	20MG/VIAL	N020622 001	Dec 20, 1996	Apr	CAHN

INJECTABLE; SUBCUTANEOUS

COPAXONE

>D>	+	TEVA	20MG/ML	N020622 002	Feb 12, 2002	Apr	CAHN
>A>	+	TEVA PHARMS USA	20MG/ML	N020622 002	Feb 12, 2002	Apr	CAHN

GLIMEPIRIDE

TABLET; ORAL

GLIMEPIRIDE

	@	COREPHARMA	1MG	A077274 001	Oct 06, 2005	Feb	DISC
	@		2MG	A077274 002	Oct 06, 2005	Feb	DISC
	@		4MG	A077274 003	Oct 06, 2005	Feb	DISC
>A>	AB	INDOCO REMEDIES	1MG	A202112 001	Apr 17, 2013	Apr	NEWA
>A>	AB		2MG	A202112 002	Apr 17, 2013	Apr	NEWA
>A>	AB		4MG	A202112 003	Apr 17, 2013	Apr	NEWA

GLIPIZIDE

TABLET; ORAL

GLIPIZIDE

>A>	AB	ACCORD HLTHCARE	5MG	A074550 001	Sep 11, 1997	Apr	CAHN
>A>	AB		10MG	A074550 002	Sep 11, 1997	Apr	CAHN
>D>	AB	ACCORD HLTHCARE INC	5MG	A074550 001	Sep 11, 1997	Apr	CAHN
>D>	AB		10MG	A074550 002	Sep 11, 1997	Apr	CAHN

GLYCEROL PHENYLBUTYRATE

LIQUID; ORAL

RAVICTI

+	HYPERION THERAP INC	1.1GM/ML	N203284 001	Feb 01, 2013	Feb	NEWA
---	---------------------	----------	-------------	--------------	-----	------

GLYCOPYRROLATE

INJECTABLE; INJECTION

ROBINUL

>D>	AP	+	BAXTER HLTHCARE	0.2MG/ML	N017558 001		Apr	CAHN
>A>	AP	+	HIKMA MAPLE	0.2MG/ML	N017558 001		Apr	CAHN

TABLET; ORAL

GLYCOPYRROLATE

>A>	AA	AUROLIFE PHARMA LLC	1MG	A202675 001	Apr 15, 2013	Apr	NEWA
		@ COREPHARMA	1MG	A040568 001	Dec 22, 2004	Mar	DISC
		@	2MG	A040568 002	Dec 22, 2004	Mar	DISC

GRANISETRON HYDROCHLORIDE

INJECTABLE; INJECTION

GRANISETRON HYDROCHLORIDE

>A>	@	APOTEX INC	EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)	A078197 001	Dec 31, 2007	Apr	DISC
>A>	@		EQ 1MG BASE/ML (EQ 1MG BASE/ML)	A078198 001	Jun 30, 2008	Apr	DISC
>A>	@		EQ 4MG BASE/4ML (EQ 1MG BASE/ML)	A078198 002	Jun 30, 2008	Apr	DISC

INJECTABLE; INJECTION

GRANISETRON HYDROCHLORIDE

>D>	AP	CLARIS LIFESCIENCES	EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)	A078197	001	Dec 31, 2007	Apr	DISC
>D>	AP		EQ 1MG BASE/ML (EQ 1MG BASE/ML)	A078198	001	Jun 30, 2008	Apr	DISC
>D>	AP		EQ 4MG BASE/4ML (EQ 1MG BASE/ML)	A078198	002	Jun 30, 2008	Apr	DISC
		@ EBEWE PHARMA	EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)	A078808	001	Apr 29, 2008	Feb	DISC

GRISEOFULVIN, MICROSIZE

SUSPENSION; ORAL

GRIFULVIN V

>A>	AB	+	VALEANT LUXEMBOURG	125MG/5ML	A062483	001	Jan 26, 1984	Apr	CAHN
>D>	AB	+	VALEANT PHARM NORTH	125MG/5ML	A062483	001	Jan 26, 1984	Apr	CAHN

HALOBETASOL PROPIONATE

OINTMENT; TOPICAL

>D>			HALOBETASOL PROPIONATE						
>D>	AB		FOUGERA PHARMS	0.05%	A076903	001	Dec 16, 2004	Apr	DISC
>A>		@		0.05%	A076903	001	Dec 16, 2004	Apr	DISC
		@ TARO		0.05%	A076994	001	Dec 16, 2004	Mar	DISC

HALOPERIDOL DECANOATE

INJECTABLE; INJECTION

HALOPERIDOL DECANOATE

>A>		@	APOTEX INC	EQ 50MG BASE/ML	A075440	001	Feb 28, 2000	Apr	DISC
>A>		@		EQ 100MG BASE/ML	A075440	002	Feb 28, 2000	Apr	DISC
>D>	AO		CLARIS LIFESCIENCES	EQ 50MG BASE/ML	A075440	001	Feb 28, 2000	Apr	DISC
>D>	AO			EQ 100MG BASE/ML	A075440	002	Feb 28, 2000	Apr	DISC

HALOPERIDOL LACTATE

INJECTABLE; INJECTION

HALOPERIDOL

>A>		@	APOTEX INC	EQ 5MG BASE/ML	A076828	001	Aug 25, 2004	Apr	DISC
>A>		@		EQ 5MG BASE/ML	A076791	001	Aug 25, 2004	Apr	DISC
>D>	AP		CLARIS LIFESCIENCES	EQ 5MG BASE/ML	A076828	001	Aug 25, 2004	Apr	DISC
>D>	AP			EQ 5MG BASE/ML	A076791	001	Aug 25, 2004	Apr	DISC

HYDRALAZINE HYDROCHLORIDE

INJECTABLE; INJECTION

HYDRALAZINE HYDROCHLORIDE

	AP		NAVINTA LLC	20MG/ML	A202938	001	Mar 28, 2013	Mar	NEWA
--	----	--	-------------	---------	---------	-----	--------------	-----	------

TABLET; ORAL

HYDRALAZINE HYDROCHLORIDE

>A>	AA		ACTAVIS GRP PTC	10MG	A091679	001	Mar 04, 2013	Apr	CAHN
>A>	AA			25MG	A091679	002	Mar 04, 2013	Apr	CAHN
>A>	AA			50MG	A091679	003	Mar 04, 2013	Apr	CAHN
>A>	AA			100MG	A091679	004	Mar 04, 2013	Apr	CAHN
>D>	AA		ACTAVIS PHARMA	10MG	A091679	001	Mar 04, 2013	Apr	CAHN
	AA			10MG	A091679	001	Mar 04, 2013	Feb	NEWA
>D>	AA			25MG	A091679	002	Mar 04, 2013	Apr	CAHN
	AA			25MG	A091679	002	Mar 04, 2013	Feb	NEWA
>D>	AA			50MG	A091679	003	Mar 04, 2013	Apr	CAHN
	AA			50MG	A091679	003	Mar 04, 2013	Feb	NEWA
>D>	AA			100MG	A091679	004	Mar 04, 2013	Apr	CAHN
	AA			100MG	A091679	004	Mar 04, 2013	Feb	NEWA

TABLET; ORAL

HYDRALAZINE HYDROCHLORIDE

>D>	AB	ALKEM LABS LTD	10MG	A200737	001	Dec 07, 2012	Apr	CTEC
>A>	AA		10MG	A200737	001	Dec 07, 2012	Apr	CTEC
>D>	AB		25MG	A200737	002	Dec 07, 2012	Apr	CTEC
>A>	AA		25MG	A200737	002	Dec 07, 2012	Apr	CTEC
>D>	AB		50MG	A200737	003	Dec 07, 2012	Apr	CTEC
>A>	AA		50MG	A200737	003	Dec 07, 2012	Apr	CTEC
>D>	AB		100MG	A200737	004	Dec 07, 2012	Apr	CTEC
>A>	AA		100MG	A200737	004	Dec 07, 2012	Apr	CTEC
>A>	AA	HETERO LABS LTD III	10MG	A040901	001	Sep 12, 2008	Apr	CAHN
>A>	AA		25MG	A040901	002	Sep 12, 2008	Apr	CAHN
>A>	AA		50MG	A040901	003	Sep 12, 2008	Apr	CAHN
>A>	AA		100MG	A040901	004	Sep 12, 2008	Apr	CAHN
>D>	AA	HETERO LABS UNIT III	10MG	A040901	001	Sep 12, 2008	Apr	CAHN
>D>	AA		25MG	A040901	002	Sep 12, 2008	Apr	CAHN
>D>	AA		50MG	A040901	003	Sep 12, 2008	Apr	CAHN
>D>	AA		100MG	A040901	004	Sep 12, 2008	Apr	CAHN
>A>	AA	STRIDES ARCOLAB LTD	25MG	A200770	001	May 03, 2013	Apr	NEWA
>A>	AA		50MG	A200770	002	May 03, 2013	Apr	NEWA
>A>	AA		100MG	A200770	003	May 03, 2013	Apr	NEWA

HYDROCHLOROTHIAZIDE

TABLET; ORAL

HYDROCHLOROTHIAZIDE

@	WATSON LABS	25MG	A081189	001	Jan 24, 1992	Mar	DISC
---	-------------	------	---------	-----	--------------	-----	------

HYDROCHLOROTHIAZIDE; IRBESARTAN

TABLET; ORAL

IRBESARTAN AND HYDROCHLOROTHIAZIDE

AB	AUROBINDO PHARMA LTD	12.5MG;150MG	A203630	001	Feb 22, 2013	Feb	NEWA
AB		12.5MG;300MG	A203630	002	Feb 22, 2013	Feb	NEWA
AB	LUPIN LTD	12.5MG;150MG	A201524	001	Feb 27, 2013	Feb	NEWA
AB		12.5MG;300MG	A201524	002	Feb 27, 2013	Feb	NEWA

HYDROCHLOROTHIAZIDE; LOSARTAN POTASSIUM

TABLET; ORAL

LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE

AB	IPCA LABS LTD	12.5MG;50MG	A201682	001	Mar 01, 2013	Feb	NEWA
AB		12.5MG;100MG	A201682	002	Mar 01, 2013	Feb	NEWA
AB		25MG;100MG	A201682	003	Mar 01, 2013	Feb	NEWA

HYDROCHLOROTHIAZIDE; QUINAPRIL HYDROCHLORIDE

TABLET; ORAL

QUINAPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

AB	APOTEX CORP	12.5MG;EQ 10MG BASE	A091524	001	Mar 12, 2013	Mar	NEWA
AB		12.5MG;EQ 20MG BASE	A091524	002	Mar 12, 2013	Mar	NEWA
AB		25MG;EQ 20MG BASE	A091524	003	Mar 12, 2013	Mar	NEWA

HYDROCHLOROTHIAZIDE; TRIAMTERENE

TABLET; ORAL

TRIAMTERENE AND HYDROCHLOROTHIAZIDE

@	WATSON LABS	50MG;75MG	A071969	001	Apr 17, 1988	Jan	DISC
---	-------------	-----------	---------	-----	--------------	-----	------

HYDROCHLOROTHIAZIDE; VALSARTAN

TABLET; ORAL

VALSARTAN AND HYDROCHLOROTHIAZIDE

AB	ALEMBIC LTD	12.5MG;80MG	A201662	001	Mar 21, 2013	Mar	NEWA
AB		12.5MG;160MG	A201662	002	Mar 21, 2013	Mar	NEWA
AB		12.5MG;320MG	A201662	003	Mar 21, 2013	Mar	NEWA
AB		25MG;160MG	A201662	004	Mar 21, 2013	Mar	NEWA
AB		25MG;320MG	A201662	005	Mar 21, 2013	Mar	NEWA
AB	APOTEX INC	12.5MG;80MG	A203026	001	Mar 21, 2013	Mar	NEWA
AB		12.5MG;160MG	A203026	002	Mar 21, 2013	Mar	NEWA
AB		12.5MG;320MG	A203026	003	Mar 21, 2013	Mar	NEWA
AB		25MG;160MG	A203026	004	Mar 21, 2013	Mar	NEWA
AB		25MG;320MG	A203026	005	Mar 21, 2013	Mar	NEWA
AB	AUROBINDO PHARMA LTD	12.5MG;80MG	A202519	001	Mar 21, 2013	Mar	NEWA
AB		12.5MG;160MG	A202519	002	Mar 21, 2013	Mar	NEWA
AB		12.5MG;320MG	A202519	003	Mar 21, 2013	Mar	NEWA
AB		25MG;160MG	A202519	004	Mar 21, 2013	Mar	NEWA
AB		25MG;320MG	A202519	005	Mar 21, 2013	Mar	NEWA
AB	LUPIN LTD	12.5MG;80MG	A078946	003	Mar 21, 2013	Mar	NEWA
AB		12.5MG;160MG	A078946	004	Mar 21, 2013	Mar	NEWA
AB		12.5MG;320MG	A078946	001	Mar 21, 2013	Mar	NEWA
AB		25MG;160MG	A078946	005	Mar 21, 2013	Mar	NEWA
AB		25MG;320MG	A078946	002	Mar 21, 2013	Mar	NEWA
>A>	AB	MACLEODS PHARMS LTD	A203145	001	Apr 19, 2013	Apr	NEWA
>A>	AB		A203145	002	Apr 19, 2013	Apr	NEWA
>A>	AB		A203145	003	Apr 19, 2013	Apr	NEWA
>A>	AB		A203145	004	Apr 19, 2013	Apr	NEWA
>A>	AB		A203145	005	Apr 19, 2013	Apr	NEWA
AB	WATSON LABS INC	12.5MG;80MG	A091519	001	Mar 21, 2013	Mar	NEWA
AB		12.5MG;160MG	A091519	002	Mar 21, 2013	Mar	NEWA
AB		12.5MG;320MG	A091519	003	Mar 21, 2013	Mar	NEWA
AB		25MG;160MG	A091519	004	Mar 21, 2013	Mar	NEWA
AB		25MG;320MG	A091519	005	Mar 21, 2013	Mar	NEWA

HYDROCORTISONE

LOTION; TOPICAL

STIE-CORT

@ PERRIGO CO

1%

A089066 001 Nov 25, 1985 Feb DISC

OINTMENT; TOPICAL

HYDROCORTISONE

@ TARO

2.5%

A040310 001 Dec 29, 2000 Mar DISC

HYDROCORTISONE ACETATE

PASTE; TOPICAL

ORABASE HCA

@ COLGATE

0.5%

A083205 001 Mar DISC

HYDROCORTISONE VALERATE

OINTMENT; TOPICAL

HYDROCORTISONE VALERATE

@ FOUGERA PHARMS

0.2%

A075085 001 Jul 31, 2001 Feb DISC

+ TARO

0.2%

A075043 001 Aug 25, 1998 Feb CRLD

WESTCORT

@ RANBAXY

0.2%

N018726 001 Aug 08, 1983 Feb DISC

HYDROMORPHONE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL
EXALGO

MALLINCKRODT INC 16MG
+ 32MG

N021217 003 Mar 01, 2010 Jan CRLD

N021217 004 Aug 24, 2012 Jan CRLD

HYDROXYZINE HYDROCHLORIDE

TABLET; ORAL

HYDROXYZINE HYDROCHLORIDE

>A> AB HETERO LABS LTD III 10MG

A040805 001 May 29, 2008 Apr CAHN

>A> AB 25MG

A040805 002 May 29, 2008 Apr CAHN

>A> AB 50MG

A040805 003 May 29, 2008 Apr CAHN

>D> AB HETERO LABS UNIT III 10MG

A040805 001 May 29, 2008 Apr CAHN

>D> AB 25MG

A040805 002 May 29, 2008 Apr CAHN

>D> AB 50MG

A040805 003 May 29, 2008 Apr CAHN

IDARUBICIN HYDROCHLORIDE

INJECTABLE; INJECTION

IDARUBICIN HYDROCHLORIDE PFS

>D> AP TEVA PARENTERAL 1MG/ML

A065036 001 May 01, 2002 Apr CAHN

>A> AP TEVA PHARMS USA 1MG/ML

A065036 001 May 01, 2002 Apr CAHN

IMIPRAMINE HYDROCHLORIDE

TABLET; ORAL

IMIPRAMINE HYDROCHLORIDE

@ PROSAM LABS 10MG

A040753 001 Feb 28, 2008 Mar DISC

@ 25MG

A040752 001 Feb 28, 2008 Mar DISC

@ 50MG

A040751 001 Feb 28, 2008 Mar DISC

INDOMETHACIN

CAPSULE; ORAL

INDOCIN

@ ICEUTICA OPERATIONS 25MG

N016059 001 Mar CAHN

@ 50MG

N016059 002 Mar CAHN

INDOMETHACIN

>A> AB HETERO LABS LTD III 25MG

A091240 001 Apr 12, 2011 Apr CAHN

>A> AB 50MG

A091240 002 Apr 12, 2011 Apr CAHN

>D> AB HETERO LABS UNIT III 25MG

A091240 001 Apr 12, 2011 Apr CAHN

>D> AB 50MG

A091240 002 Apr 12, 2011 Apr CAHN

AB SUN PHARM INDS INC 25MG

A091401 001 Mar 28, 2013 Mar NEWA

AB 50MG

A091401 002 Mar 28, 2013 Mar NEWA

IPRATROPIUM BROMIDE

SOLUTION; INHALATION

IPRATROPIUM BROMIDE

>A> @ APOTEX INC 0.02%

A075441 001 Mar 28, 2001 Apr DISC

>D> AN NOVEX 0.02%

A075441 001 Mar 28, 2001 Apr DISC

@ TEVA PHARMS USA 0.02%

A075313 001 Feb 07, 2000 Mar DISC

SPRAY, METERED; NASAL

IPRATROPIUM BROMIDE

>A> @ APOTEX INC 0.021MG/SPRAY

A076156 001 Apr 18, 2003 Apr DISC

>A> @ 0.042MG/SPRAY

A076155 001 Apr 18, 2003 Apr DISC

>D> AB NOVEX 0.021MG/SPRAY

A076156 001 Apr 18, 2003 Apr DISC

>D> AB 0.042MG/SPRAY

A076155 001 Apr 18, 2003 Apr DISC

IRON SUCROSE

INJECTABLE; INTRAVENOUS

VENOFER

LUITPOLD

EQ 65MG BASE/3.25ML (EQ 20MG
BASE/ML)

N021135 005 Mar 29, 2013 Mar NEWA

ISONIAZID; RIFAMPIN

CAPSULE; ORAL

RIFAMATE

>D> AB + SANOFI AVENTIS US 150MG;300MG
 >A> + 150MG;300MG

A061884 001 Apr CTEC
 A061884 001 Apr CTEC

RIFAMPIN AND ISONIAZID

>A> @ WEST WARD PHARM CORP 150MG;300MG
 >D> AB WESTWARD 150MG;300MG

A065221 001 Jul 29, 2005 Apr DISC
 A065221 001 Jul 29, 2005 Apr DISC

ISOPROTERENOL HYDROCHLORIDE

INJECTABLE; INJECTION

ISOPROTERENOL HYDROCHLORIDE

@ INTL MEDICATION 0.2MG/ML

A083724 001 Mar DISC

ISUPREL

+ HOSPIRA 0.2MG/ML

N010515 001 Mar CTEC

ISOSORBIDE DINITRATE

TABLET; ORAL

ISORDIL

>A> AB VALEANT BERMUDA 5MG N012093 007 Jul 29, 1988 Apr CAHN
 >A> AB 10MG N012093 002 Jul 29, 1988 Apr CAHN
 >A> AB 20MG N012093 006 Jul 29, 1988 Apr CAHN
 >A> AB + 30MG N012093 005 Jul 29, 1988 Apr CAHN
 >A> + 40MG N012093 001 Jul 29, 1988 Apr CAHN
 >D> AB VALEANT PHARM NORTH 5MG N012093 007 Jul 29, 1988 Apr CAHN
 AB 5MG N012093 007 Jul 29, 1988 Mar CAHN
 >D> AB 10MG N012093 002 Jul 29, 1988 Apr CAHN
 AB 10MG N012093 002 Jul 29, 1988 Mar CAHN
 >D> AB 20MG N012093 006 Jul 29, 1988 Apr CAHN
 AB 20MG N012093 006 Jul 29, 1988 Mar CAHN
 >D> AB + 30MG N012093 005 Jul 29, 1988 Apr CAHN
 AB + 30MG N012093 005 Jul 29, 1988 Mar CAHN
 >D> + 40MG N012093 001 Jul 29, 1988 Apr CAHN
 + 40MG N012093 001 Jul 29, 1988 Mar CAHN

ISOSORBIDE DINITRATE

>D> @ PAR PHARM 5MG A086923 001 Mar 12, 1987 Apr CMFD
 >A> AB 5MG A086923 001 Mar 12, 1987 Apr CMFD
 @ 5MG A086923 001 Mar 12, 1987 Feb DISC
 >D> AB WATSON LABS 5MG A086034 001 Jan 06, 1988 Apr DISC
 >A> @ 5MG A086034 001 Jan 06, 1988 Apr DISC
 >D> AB 10MG A086032 001 Jan 07, 1988 Apr DISC
 >A> @ 10MG A086032 001 Jan 07, 1988 Apr DISC

ISOTRETINOIN

CAPSULE; ORAL

ABSORICA

BX RANBAXY 10MG N021951 001 May 25, 2012 Feb CAHN
 BX 20MG N021951 002 May 25, 2012 Feb CAHN
 BX 30MG N021951 003 May 25, 2012 Feb CAHN

CAPSULE; ORALABSORICA

BX		RANBAXY	40MG	N021951	004	May 25, 2012	Feb	CAHN
----	--	---------	------	---------	-----	--------------	-----	------

AMNESTEEM

>D>	AB	+	MYLAN	20MG	A075945	002	Nov 08, 2002	Apr	CRLD
-----	----	---	-------	------	---------	-----	--------------	-----	------

>A>	AB		MYLAN PHARMS INC	20MG	A075945	002	Nov 08, 2002	Apr	CRLD
-----	----	--	------------------	------	---------	-----	--------------	-----	------

CLARAVIS

>D>	AB		BARR	30MG	A076135	003	May 11, 2006	Apr	CRLD
-----	----	--	------	------	---------	-----	--------------	-----	------

>D>	AB			40MG	A076135	001	Apr 11, 2003	Apr	CRLD
-----	----	--	--	------	---------	-----	--------------	-----	------

>A>	AB		TEVA PHARMS USA	30MG	A076135	003	May 11, 2006	Apr	CRLD
-----	----	--	-----------------	------	---------	-----	--------------	-----	------

>A>	AB	+		40MG	A076135	001	Apr 11, 2003	Apr	CRLD
-----	----	---	--	------	---------	-----	--------------	-----	------

ZENATANE

AB			DR REDDYS LABS LTD	10MG	A202099	001	Mar 25, 2013	Mar	NEWA
----	--	--	--------------------	------	---------	-----	--------------	-----	------

AB				20MG	A202099	002	Mar 25, 2013	Mar	NEWA
----	--	--	--	------	---------	-----	--------------	-----	------

AB				40MG	A202099	003	Mar 25, 2013	Mar	NEWA
----	--	--	--	------	---------	-----	--------------	-----	------

KETOROLAC TROMETHAMINEINJECTABLE; INJECTIONKETOROLAC TROMETHAMINE

>A>		@	APOTEX INC	15MG/ML	A075631	002	Jun 29, 2001	Apr	DISC
-----	--	---	------------	---------	---------	-----	--------------	-----	------

>D>		@		30MG/ML	A075626	001	Jul 24, 2001	Apr	DISC
-----	--	---	--	---------	---------	-----	--------------	-----	------

>D>		@		30MG/ML	A077201	001	Oct 14, 2005	Apr	DISC
-----	--	---	--	---------	---------	-----	--------------	-----	------

>A>		@		30MG/ML	A075626	001	Jul 24, 2001	Apr	DISC
-----	--	---	--	---------	---------	-----	--------------	-----	------

>A>		@		30MG/ML	A077201	001	Oct 14, 2005	Apr	DISC
-----	--	---	--	---------	---------	-----	--------------	-----	------

>A>		@		30MG/ML	A075631	001	Jun 29, 2001	Apr	DISC
-----	--	---	--	---------	---------	-----	--------------	-----	------

>D>	AP		CLARIS LIFESCIENCES	15MG/ML	A075631	002	Jun 29, 2001	Apr	DISC
-----	----	--	---------------------	---------	---------	-----	--------------	-----	------

>D>	AP			30MG/ML	A075631	001	Jun 29, 2001	Apr	DISC
-----	----	--	--	---------	---------	-----	--------------	-----	------

LABETALOL HYDROCHLORIDEINJECTABLE; INJECTIONLABETALOL HYDROCHLORIDE

>A>		@	APOTEX INC	5MG/ML	A076051	001	Jul 05, 2002	Apr	DISC
-----	--	---	------------	--------	---------	-----	--------------	-----	------

>D>	AP		CLARIS LIFESCIENCES	5MG/ML	A076051	001	Jul 05, 2002	Apr	DISC
-----	----	--	---------------------	--------	---------	-----	--------------	-----	------

TABLET; ORALLABETALOL HYDROCHLORIDE

AB	+		SANDOZ	200MG	A075113	002	Aug 04, 1998	Jan	CRLD
----	---	--	--------	-------	---------	-----	--------------	-----	------

TRANDATE

		@	PROMETHEUS LABS	100MG	N018716	001	May 24, 1985	Jan	DISC
--	--	---	-----------------	-------	---------	-----	--------------	-----	------

		@		200MG	N018716	002	Aug 01, 1984	Jan	DISC
--	--	---	--	-------	---------	-----	--------------	-----	------

LACTULOSESOLUTION; ORALLACTULOSE

>A>		@	APOTEX INC	10GM/15ML	A075911	001	Feb 21, 2002	Apr	DISC
-----	--	---	------------	-----------	---------	-----	--------------	-----	------

>D>	AA		NOVEX	10GM/15ML	A075911	001	Feb 21, 2002	Apr	DISC
-----	----	--	-------	-----------	---------	-----	--------------	-----	------

SOLUTION; ORAL, RECTALLACTULOSE

>A>		@	APOTEX INC	10GM/15ML	A076645	001	Jul 28, 2003	Apr	DISC
-----	--	---	------------	-----------	---------	-----	--------------	-----	------

>D>	AA		NOVEX	10GM/15ML	A076645	001	Jul 28, 2003	Apr	DISC
-----	----	--	-------	-----------	---------	-----	--------------	-----	------

LAMOTRIGINETABLET; ORALLAMICTAL

AB	+		GLAXOSMITHKLINE LLC	25MG	N020241	005	Dec 27, 1994	Mar	CAHN
----	---	--	---------------------	------	---------	-----	--------------	-----	------

		@		50MG	N020241	006	Dec 27, 1994	Mar	CAHN
--	--	---	--	------	---------	-----	--------------	-----	------

AB				100MG	N020241	001	Dec 27, 1994	Mar	CAHN
----	--	--	--	-------	---------	-----	--------------	-----	------

TABLET; ORAL

LAMICTAL

AB	GLAXOSMITHKLINE LLC	150MG	N020241 002	Dec 27, 1994	Mar	CAHN
AB		200MG	N020241 003	Dec 27, 1994	Mar	CAHN
	@	250MG	N020241 004	Dec 27, 1994	Mar	CAHN

TABLET, CHEWABLE; ORAL

LAMICTAL CD

AB	GLAXOSMITHKLINE LLC	2MG	N020764 004	Sep 08, 2000	Mar	CAHN
AB		5MG	N020764 001	Aug 24, 1998	Mar	CAHN
AB	+	25MG	N020764 002	Aug 24, 1998	Mar	CAHN
	@	100MG	N020764 003	Aug 24, 1998	Mar	CAHN

TABLET, EXTENDED RELEASE; ORAL

LAMICTAL XR

AB	GLAXOSMITHKLINE LLC	25MG	N022115 001	May 29, 2009	Mar	CAHN
AB	+	50MG	N022115 002	May 29, 2009	Mar	CAHN
AB		100MG	N022115 003	May 29, 2009	Mar	CAHN
AB		200MG	N022115 004	May 29, 2009	Mar	CAHN
AB		250MG	N022115 006	Jun 21, 2011	Mar	CAHN
AB		300MG	N022115 005	Apr 14, 2010	Mar	CAHN

LAMOTRIGINE

AB	PAR PHARM	25MG	A201791 001	Jan 18, 2013	Jan	NEWA
AB		50MG	A201791 002	Jan 18, 2013	Jan	NEWA
AB		100MG	A201791 003	Jan 18, 2013	Jan	NEWA
AB		200MG	A201791 004	Jan 18, 2013	Jan	NEWA
AB		250MG	A201791 005	Jan 18, 2013	Jan	NEWA
AB		300MG	A201791 006	Jan 18, 2013	Jan	NEWA

TABLET, ORALLY DISINTEGRATING; ORAL

LAMICTAL ODT

	GLAXOSMITHKLINE LLC	25MG	N022251 001	May 08, 2009	Mar	CAHN
+		50MG	N022251 002	May 08, 2009	Mar	CAHN
		100MG	N022251 003	May 08, 2009	Mar	CAHN
		200MG	N022251 004	May 08, 2009	Mar	CAHN

LATANOPROST

SOLUTION/DROPS; OPHTHALMIC

LATANOPROST

>D>	AT	APOTEX	0.005%	A077697 001	Mar 22, 2011	Apr	DISC
>A>		@ APOTEX INC	0.005%	A077697 001	Mar 22, 2011	Apr	DISC
	AT	DR REDDYS LABS LTD	0.005%	A202077 001	Feb 11, 2013	Jan	NEWA

LETROZOLE

TABLET; ORAL

LETROZOLE

>A>	AB	JIANGSU HENGRUI MED	2.5MG	A202716 001	May 16, 2013	Apr	NEWA
-----	----	---------------------	-------	-------------	--------------	-----	------

LEUCOVORIN CALCIUM

INJECTABLE; INJECTION

LEUCOVORIN CALCIUM

AP	TEVA PHARMS USA	EQ 100MG BASE/VIAL	A081277 001	Sep 28, 1993	Mar	CAHN
AP		EQ 350MG BASE/VIAL	A040174 001	Jun 12, 1997	Mar	CAHN

LEUPROLIDE ACETATE

INJECTABLE; INJECTION

LEUPROLIDE ACETATE

AP	TEVA PHARMS USA	1MG/0.2ML	A075471 001	Oct 25, 2000	Mar	CAHN
----	-----------------	-----------	-------------	--------------	-----	------

INJECTABLE; INJECTION

LUPRON DEPOT

>D>	+	ABBOTT ENDOCRINE	3.75MG/VIAL	N020011	001	Oct 22, 1990	Apr	CAHN
>A>	+	ABBVIE ENDOCRINE INC	3.75MG/VIAL	N020011	001	Oct 22, 1990	Apr	CAHN

LEVALBUTEROL HYDROCHLORIDE

SOLUTION; INHALATION

LEVALBUTEROL HYDROCHLORIDE

AN	DEY	EQ 0.0103% BASE	A077800	001	Mar 15, 2013	Mar	NEWA	
AN		EQ 0.021% BASE	A077800	002	Mar 15, 2013	Mar	NEWA	
AN		EQ 0.042% BASE	A077800	003	Mar 15, 2013	Mar	NEWA	
>A>	AN	TEVA PHARMS USA	EQ 0.0103% BASE	A090297	001	Apr 26, 2013	Apr	NEWA
>A>	AN		EQ 0.021% BASE	A090297	002	Apr 26, 2013	Apr	NEWA
>A>	AN		EQ 0.042% BASE	A090297	003	Apr 26, 2013	Apr	NEWA

LEVETIRACETAM

SOLUTION; ORAL

LEVETIRACETAM

>D>	AA	APOTEX	100MG/ML	A090187	001	Aug 05, 2011	Apr	DISC
>A>		@ APOTEX INC	100MG/ML	A090187	001	Aug 05, 2011	Apr	DISC
>D>	AA	HETERO DRUGS LTD	100MG/ML	A203052	001	Feb 28, 2013	Apr	CAHN
	AA		100MG/ML	A203052	001	Feb 28, 2013	Feb	NEWA
>A>	AA	HETERO LABS LTD III	100MG/ML	A203052	001	Feb 28, 2013	Apr	CAHN
>A>	AA	ORIT LABS LLC	100MG/ML	A203067	001	May 09, 2013	Apr	NEWA

TABLET; ORAL

LEVETIRACETAM

>D>	AB	HETERO DRUGS LTD	250MG	A090515	001	Oct 08, 2010	Apr	CAHN
>D>	AB		500MG	A090515	002	Oct 08, 2010	Apr	CAHN
>D>	AB		750MG	A090515	003	Oct 08, 2010	Apr	CAHN
>D>	AB		1GM	A090515	004	Oct 08, 2010	Apr	CAHN
>A>	AB	HETERO LABS LTD III	250MG	A090515	001	Oct 08, 2010	Apr	CAHN
>A>	AB		500MG	A090515	002	Oct 08, 2010	Apr	CAHN
>A>	AB		750MG	A090515	003	Oct 08, 2010	Apr	CAHN
>A>	AB		1GM	A090515	004	Oct 08, 2010	Apr	CAHN
>A>	AB	PRINSTON INC	250MG	A078106	001	Feb 10, 2009	Apr	CAHN
>A>	AB		500MG	A078106	002	Feb 10, 2009	Apr	CAHN
>A>	AB		750MG	A078106	003	Feb 10, 2009	Apr	CAHN
>A>	AB		1GM	A078106	004	Feb 10, 2009	Apr	CAHN
>D>	AB	SOLCO HLTHCARE	250MG	A078106	001	Feb 10, 2009	Apr	CAHN
>D>	AB		500MG	A078106	002	Feb 10, 2009	Apr	CAHN
>D>	AB		750MG	A078106	003	Feb 10, 2009	Apr	CAHN
>D>	AB		1GM	A078106	004	Feb 10, 2009	Apr	CAHN

TABLET, EXTENDED RELEASE; ORAL

LEVETIRACETAM

		@ SANDOZ	500MG	A091668	001	Nov 01, 2012	Mar	DISC
		@	750MG	A091668	002	Nov 01, 2012	Mar	DISC
AB		VINTAGE PHARMS LLC	500MG	A202533	001	Jul 20, 2012	Jan	NEWA
AB			750MG	A202533	002	Jul 20, 2012	Jan	NEWA

LEVOBUNOLOL HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

LEVOBUNOLOL HYDROCHLORIDE

>A>		@ APOTEX INC	0.25%	A075473	001	Aug 03, 2000	Apr	DISC
>A>		@	0.5%	A075475	001	Aug 03, 2000	Apr	DISC
>D>	AT	NOVEX	0.25%	A075473	001	Aug 03, 2000	Apr	DISC
>D>	AT		0.5%	A075475	001	Aug 03, 2000	Apr	DISC

LEVOCETIRIZINE DIHYDROCHLORIDE

TABLET; ORAL

LEVOCETIRIZINE DIHYDROCHLORIDE

AB	SANDOZ	5MG	A090486	001	Mar 26, 2013	Mar	NEWA
AB	SUN PHARMA GLOBAL	5MG	A090362	001	Jan 31, 2013	Jan	NEWA

LEVOFLOXACIN

INJECTABLE; INJECTION

LEVOFLOXACIN

AP	AUROBINDO PHARMA LTD	EQ 500MG/20ML (EQ 25MG/ML)	A202328	001	Jan 24, 2013	Jan	NEWA
AP		EQ 750MG/30ML (EQ 25MG/ML)	A202328	002	Jan 24, 2013	Jan	NEWA
AP	EMCURE PHARMS LTD	EQ 500MG/20ML (EQ 25MG/ML)	A202590	001	Jan 24, 2013	Jan	NEWA
AP		EQ 750MG/30ML (EQ 25MG/ML)	A202590	002	Jan 24, 2013	Jan	NEWA

SOLUTION/DROPS; OPHTHALMIC

LEVOFLOXACIN

>D>	AT	APOTEX	0.5%	A078282	001	Dec 20, 2010	Apr	DISC
>A>		@ APOTEX INC	0.5%	A078282	001	Dec 20, 2010	Apr	DISC

LEVONORGESTREL

INTRAUTERINE DEVICE; INTRAUTERINE

SKYLA

+	BAYER HLTHCARE	13.5MG	N203159	001	Jan 09, 2013	Jan	NEWA
---	----------------	--------	---------	-----	--------------	-----	------

TABLET; ORAL

LEVONORGESTREL

AB	LUPIN LTD	0.75MG	A091328	001	Jan 23, 2013	Jan	NEWA	
AB	NOVEL LABS INC	1.5MG	A202508	001	Feb 22, 2013	Feb	NEWA	
PLAN B ONE-STEP								
>D>	AB	+ DURAMED	1.5MG	N021998	001	Jul 10, 2009	Apr	CAHN
>A>	AB	+ TEVA BRANDED PHARM	1.5MG	N021998	001	Jul 10, 2009	Apr	CAHN

LEVOTHYROXINE SODIUM**

**Refer to Annual Edition Preface Section 1.8 Levothyroxine Sodium for amplifying information

TABLET; ORAL

LEVOXYL

AB1,	KING PHARMS R AND D	0.025MG	N021301	001	May 25, 2001	Mar	CAHN
AB3							
AB1,		0.05MG	N021301	002	May 25, 2001	Mar	CAHN
AB3							
AB1,		0.075MG	N021301	003	May 25, 2001	Mar	CAHN
AB3							
AB1,		0.088MG	N021301	004	May 25, 2001	Mar	CAHN
AB3							
AB1,		0.1MG	N021301	005	May 25, 2001	Mar	CAHN
AB3							
AB1,		0.112MG	N021301	006	May 25, 2001	Mar	CAHN
AB3							
AB1,		0.125MG	N021301	007	May 25, 2001	Mar	CAHN
AB3							
AB1,		0.137MG	N021301	008	May 25, 2001	Mar	CAHN
AB3							
AB1,		0.15MG	N021301	009	May 25, 2001	Mar	CAHN
AB3							
AB1,		0.175MG	N021301	010	May 25, 2001	Mar	CAHN
AB3							
AB1, +		0.2MG	N021301	011	May 25, 2001	Mar	CAHN
AB3							
	@	0.3MG	N021301	012	May 25, 2001	Mar	CAHN

LIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

LIDOCAINE HYDROCHLORIDE

	@ LUITPOLD	2%	A083198 001		Mar	DISC
	LIDOCAINE HYDROCHLORIDE	PRESERVATIVE FREE				
AP	AUROBINDO PHARMA LTD	1%	A203040 001	Mar 14, 2013	Mar	NEWA
AP		1%	A203082 001	Mar 14, 2013	Mar	NEWA
AP		2%	A203082 002	Mar 14, 2013	Mar	NEWA
AP		2%	A203040 002	Mar 14, 2013	Mar	NEWA

LIOTHYRONINE SODIUM

TABLET; ORAL

CYTOMEL

AB	KING PHARMS R AND D	EQ 0.005MG BASE	N010379 001		Mar	CAHN
AB		EQ 0.025MG BASE	N010379 002		Mar	CAHN
AB	+	EQ 0.05MG BASE	N010379 003		Mar	CAHN

LISINOPRIL

TABLET; ORAL

LISINOPRIL

	@ SANDOZ	2.5MG	A075999 001	Jul 01, 2002	Jan	CAHN
	@	5MG	A075999 002	Jul 01, 2002	Jan	CAHN
	@	10MG	A075999 003	Jul 01, 2002	Jan	CAHN
	@	20MG	A075999 004	Jul 01, 2002	Jan	CAHN
	@	30MG	A075999 005	Jul 01, 2002	Jan	CAHN
	@	40MG	A075999 006	Jul 01, 2002	Jan	CAHN

LITHIUM CARBONATE

CAPSULE; ORAL

LITHIUM CARBONATE

	@ APOTEX INC	300MG	A076795 001	Nov 22, 2004	Feb	DISC	
>D>	AB	HETERO DRUGS LTD	150MG	A090702 001	Sep 25, 2009	Apr	CAHN
>D>	AB		300MG	A090702 002	Sep 25, 2009	Apr	CAHN
>D>	AB		600MG	A090702 003	Sep 25, 2009	Apr	CAHN
>A>	AB	HETERO LABS LTD III	150MG	A090702 001	Sep 25, 2009	Apr	CAHN
>A>	AB		300MG	A090702 002	Sep 25, 2009	Apr	CAHN
>A>	AB		600MG	A090702 003	Sep 25, 2009	Apr	CAHN

LOMUSTINE

CAPSULE; ORAL

CEENU

>D>		BRISTOL MYERS SQUIBB	10MG	N017588 001		Apr	CAHN
>D>			40MG	N017588 002		Apr	CAHN
>D>	+		100MG	N017588 003		Apr	CAHN
>A>		CORDEN PHARMA	10MG	N017588 001		Apr	CAHN
>A>			40MG	N017588 002		Apr	CAHN
>A>	+		100MG	N017588 003		Apr	CAHN

LORAZEPAM

CONCENTRATE; ORAL

LORAZEPAM

AA	LUPIN LTD	2MG/ML	A091407 001	Feb 19, 2013	Feb	NEWA
----	-----------	--------	-------------	--------------	-----	------

TABLET; ORALLORAZEPAM

>D>	AB	SANDOZ	0.5MG	A071193 001	Apr 15, 1988	Apr	DISC
>A>		@	0.5MG	A071193 001	Apr 15, 1988	Apr	DISC
>D>	AB		1MG	A071194 001	Apr 15, 1988	Apr	DISC
>A>		@	1MG	A071194 001	Apr 15, 1988	Apr	DISC
>D>	AB		2MG	A071195 001	Apr 15, 1988	Apr	DISC
>A>		@	2MG	A071195 001	Apr 15, 1988	Apr	DISC

LOSARTAN POTASSIUMTABLET; ORALLOSARTAN POTASSIUM

AB		ACTAVIS GRP PTC	25MG	A090382 001	Oct 06, 2010	Mar	CAHN
AB			50MG	A090382 002	Oct 06, 2010	Mar	CAHN
AB			100MG	A090382 003	Oct 06, 2010	Mar	CAHN

LOVASTATINTABLET; ORALLOVASTATIN

AB	+	CARLSBAD	40MG	A075991 003	Jun 05, 2002	Feb	CRLD
		MEVACOR					
		@ MERCK	20MG	N019643 003	Aug 31, 1987	Feb	DISC
		@	40MG	N019643 004	Dec 14, 1988	Feb	DISC

MAFENIDE ACETATEFOR SOLUTION; TOPICALMAFENIDE ACETATE

AB		PAR FORM	5%	A201511 001	Feb 12, 2013	Jan	NEWA
		SULFAMYLLON					
AB	+	MYLAN LLC	5%	N019832 003	Jun 05, 1998	Jan	CFTG

MAGNESIUM SULFATE, POTASSIUM SULFATE, SODIUM SULFATE; POLYETHYLENE GLYCOL 3350, POTASSIUM CHLORIDE, SODIUM BICARBONATE, SODIUM CHLORIDESOLUTION, FOR SOLUTION; ORAL, ORALSUCLEAR

+	BRAINTREE LABS	1.6GM/BOT, 3.13GM/BOT, 17.5GM/BOT, N/A, N/A, N/A, N/A, N/A, N/A, 210GM, 0.74GM, 2.86GM, 5.6GM	N203595 001	Jan 18, 2013	Jan	NEWA
---	----------------	---	-------------	--------------	-----	------

MANNITOLINJECTABLE; INJECTIONMANNITOL 20%

@	B BRAUN	20GM/100ML	N014738 001		Jan	DISC
---	---------	------------	-------------	--	-----	------

MECAMYLAMINE HYDROCHLORIDETABLET; ORALMECAMYLAMINE HYDROCHLORIDE

	NEXGEN PHARMA	2.5MG	A204054 001	Mar 19, 2013	Mar	NEWA
--	---------------	-------	-------------	--------------	-----	------

MEFENAMIC ACIDCAPSULE; ORALMEFENAMIC ACID

AB		CYPRESS PHARM	250MG	A090359 001	Feb 05, 2013	Jan	NEWA
----	--	---------------	-------	-------------	--------------	-----	------

MEGESTROL ACETATE

SUSPENSION; ORAL

MEGESTROL ACETATE

>D>	AB	APOTEX INC	40MG/ML	A077404 001	Feb 16, 2006	Apr	DISC
>A>		@	40MG/ML	A077404 001	Feb 16, 2006	Apr	DISC

MELOXICAM

TABLET; ORAL

MELOXICAM

		@ COREPHARMA	7.5MG	A077930 001	Jul 19, 2006	Feb	DISC
		@	15MG	A077930 002	Jul 19, 2006	Feb	DISC
>D>	AB	CR DOUBLE CRANE	7.5MG	A078039 001	Dec 14, 2006	Apr	DISC
>A>		@	7.5MG	A078039 001	Dec 14, 2006	Apr	DISC
	AB		7.5MG	A078039 001	Dec 14, 2006	Mar	CAHN
>D>	AB		15MG	A078039 002	Dec 14, 2006	Apr	DISC
>A>		@	15MG	A078039 002	Dec 14, 2006	Apr	DISC
	AB		15MG	A078039 002	Dec 14, 2006	Mar	CAHN

MEPROBAMATE

TABLET; ORAL

MEPROBAMATE

	@ TARO	200MG	A200998 001	May 23, 2011	Jan	DISC
	@	400MG	A200998 002	May 23, 2011	Jan	DISC

MESALAMINE

CAPSULE, DELAYED RELEASE; ORAL

DELZICOL

+	WARNER CHILCOTT LLC	400MG	N204412 001	Feb 01, 2013	Feb	NEWA
---	---------------------	-------	-------------	--------------	-----	------

SUPPOSITORY; RECTAL

CANASA

+	APTALIS PHARMA US	1GM	N021252 002	Nov 05, 2004	Feb	CRLD
---	-------------------	-----	-------------	--------------	-----	------

METAPROTERENOL SULFATE

SOLUTION; INHALATION

METAPROTERENOL SULFATE

>A>		@ APOTEX INC	0.4%	A075402 001	Feb 28, 2001	Apr	DISC
>A>		@	0.6%	A075403 001	Feb 28, 2001	Apr	DISC
>D>	AN	NOVEX	0.4%	A075402 001	Feb 28, 2001	Apr	DISC
>D>	AN		0.6%	A075403 001	Feb 28, 2001	Apr	DISC

SYRUP; ORAL

METAPROTERENOL SULFATE

>A>		@ APOTEX INC	10MG/5ML	A075235 001	Jan 27, 2000	Apr	DISC
>D>		@ NOVEX	10MG/5ML	A075235 001	Jan 27, 2000	Apr	DISC
		@	10MG/5ML	A075235 001	Jan 27, 2000	Feb	DISC
+	SILARX		10MG/5ML	A073632 001	Jul 22, 1992	Feb	CTEC

TABLET; ORAL

METAPROTERENOL SULFATE

	PAR PHARM	10MG	A072024 001	Jun 28, 1988	Mar	CTEC
+		20MG	A072025 001	Jun 28, 1988	Mar	CTEC
	@ WATSON LABS	10MG	A073013 001	Jan 31, 1991	Mar	DISC
	@	20MG	A072795 001	Jan 31, 1991	Mar	DISC

METFORMIN HYDROCHLORIDE

TABLET; ORAL

METFORMIN HYDROCHLORIDE

@ SANDOZ	500MG	A075965 001	Jan 25, 2002	Mar	DISC
@	850MG	A075965 002	Jan 25, 2002	Mar	DISC
@	1GM	A075965 003	Jan 25, 2002	Mar	DISC

TABLET, EXTENDED RELEASE; ORAL

METFORMIN HYDROCHLORIDE

@ WATSON LABS INC	500MG	A076818 001	Dec 14, 2004	Mar	DISC
-------------------	-------	-------------	--------------	-----	------

METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE

TABLET; ORAL

PIOGLITAZONE HYDROCHLORIDE AND METFORMIN HYDROCHLORIDE

AB	AUROBINDO PHARMA LTD	500MG;EQ 15MG BASE	A200823 001	Feb 13, 2013	Jan	NEWA
AB		850MG;EQ 15MG BASE	A200823 002	Feb 13, 2013	Jan	NEWA
>A>	AB	SANDOZ	500MG;EQ 15MG BASE	A091273 001	Apr 16, 2013	Apr
>A>	AB		850MG;EQ 15MG BASE	A091273 002	Apr 16, 2013	Apr
AB	TORRENT PHARMS LTD	500MG;EQ 15MG BASE	A202001 001	Feb 13, 2013	Jan	NEWA
AB		850MG;EQ 15MG BASE	A202001 002	Feb 13, 2013	Jan	NEWA

METHADONE HYDROCHLORIDE

TABLET, FOR SUSPENSION; ORAL

METHADONE HYDROCHLORIDE

AA	MALLINCKRODT INC	40MG	A077142 001	Jul 12, 2005	Mar	CDFR
AA	+ ROXANE	40MG	N017058 001		Mar	CDFR
AA	SANDOZ	40MG	A075082 001	Mar 25, 1998	Mar	CDFR
	METHADOSE					
AA	MALLINCKRODT	40MG	A074184 001	Apr 29, 1993	Mar	CDFR

METHOCARBAMOL

TABLET; ORAL

METHOCARBAMOL

	@ AUSTARPHARMA LLC	500MG	A200958 001	Oct 21, 2011	Jan	DISC
	@	750MG	A200958 002	Oct 21, 2011	Jan	DISC
>D>	AA	HETERO DRUGS	500MG	A090200 001	Nov 06, 2009	Apr
>D>	AA		750MG	A090200 002	Nov 06, 2009	Apr
>A>	AA	HETERO LABS LTD III	500MG	A090200 001	Nov 06, 2009	Apr
>A>	AA		750MG	A090200 002	Nov 06, 2009	Apr
AA	PRINSTON INC	500MG	A086989 001		Feb	CMFD
AA		750MG	A086988 001		Feb	CAHN
	@ SOLCO HLTHCARE	500MG	A086989 001		Jan	DISC

METHOXSALEN

CAPSULE; ORAL

OXSORALEN-ULTRA

>A>	+	DOW PHARM	10MG	N019600 001	Oct 30, 1986	Apr	CAHN
>D>	+	VALEANT PHARM INTL	10MG	N019600 001	Oct 30, 1986	Apr	CAHN

METHYCLOTHIAZIDE

TABLET; ORAL

METHYCLOTHIAZIDE

+	MYLAN PHARMS INC	5MG	A087672 001	Aug 17, 1982	Jan	CTEC
	@ WATSON LABS	5MG	A088724 001	Sep 06, 1984	Jan	DISC

METHYLDOPA

TABLET; ORAL

METHYLDOPA

>D>		@ ACCORD HLTH	125MG	A070070	003	Oct 15, 1985	Apr	CAHN
>D>	AB		250MG	A070084	001	Oct 15, 1985	Apr	CAHN
>D>	AB		500MG	A070085	001	Oct 15, 1985	Apr	CAHN
>A>		@ ACCORD HLTHCARE	125MG	A070070	003	Oct 15, 1985	Apr	CAHN
>A>	AB		250MG	A070084	001	Oct 15, 1985	Apr	CAHN
>A>	AB		500MG	A070085	001	Oct 15, 1985	Apr	CAHN

METHYLPHENIDATE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

METHYLPHENIDATE HYDROCHLORIDE

>D>	AB1	ACTAVIS	20MG	A078458	001	Dec 01, 2011	Apr	CAHN
>D>	AB1		30MG	A078458	002	Dec 01, 2011	Apr	CAHN
>D>	AB1		40MG	A078458	003	Dec 01, 2011	Apr	CAHN
>A>	AB1	WATSON LABS INC	20MG	A078458	001	Dec 01, 2011	Apr	CAHN
>A>	AB1		30MG	A078458	002	Dec 01, 2011	Apr	CAHN
>A>	AB1		40MG	A078458	003	Dec 01, 2011	Apr	CAHN

TABLET, EXTENDED RELEASE; ORAL

METHYLIN ER

MALLINCKRODT INC

10MG

A075629 001 May 09, 2000 Feb CTEC

METOCLOPRAMIDE HYDROCHLORIDE

INJECTABLE; INJECTION

METOCLOPRAMIDE HYDROCHLORIDE

>A>	AP	BD RX	EQ 5MG BASE/ML	A091392	001	Apr 19, 2013	Apr	NEWA
		@ TEVA PARENTERAL	EQ 5MG BASE/ML	A073135	001	Nov 27, 1991	Feb	DISC

METOLAZONE

TABLET; ORAL

METOLAZONE

@ TEVA

2.5MG

A076600 001 Jan 06, 2004 Mar DISC

METOPROLOL SUCCINATE

TABLET, EXTENDED RELEASE; ORAL

METOPROLOL SUCCINATE

@ NESHER PHARMS

EQ 25MG TARTRATE

A077779 001 Mar 20, 2008 Feb DISC

METOPROLOL TARTRATE

INJECTABLE; INJECTION

METOPROLOL TARTRATE

>A>	AP	CLARIS LIFESCIENCES	1MG/ML	A078950	001	Apr 29, 2013	Apr	NEWA
		@ WATSON LABS	1MG/ML	A074032	001	Dec 21, 1993	Mar	DISC

TABLET; ORAL

METOPROLOL TARTRATE

@ PRINSTON INC

50MG

A074453 001 Apr 27, 1995 Mar CAHN

@

100MG

A074453 002 Apr 27, 1995 Mar CAHN

METRONIDAZOLE

TABLET; ORAL

METRONIDAZOLE

AB		TEVA PHARMS USA	250MG
----	--	-----------------	-------

A070027 001 Nov 06, 1984 Mar CAHN

MIDAZOLAM HYDROCHLORIDE

INJECTABLE; INJECTION

MIDAZOLAM HYDROCHLORIDE

>A>	@	APOTEX INC	EQ 1MG BASE/ML	A075637	001	Oct 31, 2000	Apr	DISC
>A>	@		EQ 5MG BASE/ML	A075637	002	Oct 31, 2000	Apr	DISC
>D>	@	CLARIS LIFESCIENCES	EQ 1MG BASE/ML	A075637	001	Oct 31, 2000	Apr	DISC
	@		EQ 1MG BASE/ML	A075637	001	Oct 31, 2000	Jan	DISC
>D>	@		EQ 5MG BASE/ML	A075637	002	Oct 31, 2000	Apr	DISC
	@		EQ 5MG BASE/ML	A075637	002	Oct 31, 2000	Jan	DISC

SYRUP; ORAL

MIDAZOLAM HYDROCHLORIDE

>D>	AA	APOTEX INC	EQ 2MG BASE/ML	A077115	001	Sep 09, 2005	Apr	DISC
>A>	@		EQ 2MG BASE/ML	A077115	001	Sep 09, 2005	Apr	DISC

MILRINONE LACTATE

INJECTABLE; INJECTION

MILRINONE LACTATE

>A>	@	APOTEX INC	EQ 1MG BASE/ML	A076427	001	Sep 21, 2004	Apr	DISC
>D>	AP	CLARIS LIFESCIENCES	EQ 1MG BASE/ML	A076427	001	Sep 21, 2004	Apr	DISC
		MILRINONE LACTATE IN DEXTROSE 5% IN PLASTIC CONTAINER						
>A>	@	APOTEX INC	EQ 20MG BASE/100ML (EQ 0.2MG BASE/ML)	A077151	001	Jul 20, 2005	Apr	DISC
>D>	AP	CLARIS LIFESCIENCES	EQ 20MG BASE/100ML (EQ 0.2MG BASE/ML)	A077151	001	Jul 20, 2005	Apr	DISC

MINOCYCLINE HYDROCHLORIDE

CAPSULE; ORAL

MINOCYCLINE HYDROCHLORIDE

>A>	AB	CARACO	EQ 50MG BASE	A090867	001	May 13, 2013	Apr	NEWA
>A>	AB		EQ 75MG BASE	A090867	002	May 13, 2013	Apr	NEWA
>A>	AB		EQ 100MG BASE	A090867	003	May 13, 2013	Apr	NEWA

TABLET, EXTENDED RELEASE; ORAL

>D>		SOLODYN						
>D>	AB	MEDICIS	EQ 45MG BASE	N050808	001	May 08, 2006	Apr	DISC
>A>	@		EQ 45MG BASE	N050808	001	May 08, 2006	Apr	DISC
>D>			EQ 55MG BASE	N050808	008	Aug 27, 2010	Apr	CRLD
>A>	+		EQ 55MG BASE	N050808	008	Aug 27, 2010	Apr	CRLD
>D>			EQ 80MG BASE	N050808	007	Aug 27, 2010	Apr	CRLD
>A>	+		EQ 80MG BASE	N050808	007	Aug 27, 2010	Apr	CRLD
>D>	AB	+	EQ 135MG BASE	N050808	003	May 08, 2006	Apr	DISC
>A>	@		EQ 135MG BASE	N050808	003	May 08, 2006	Apr	DISC

MIPOMERSEN SODIUM

SOLUTION; SUBCUTANEOUS

KYNAMRO

+	GENZYME CORP	200MG/ML (200MG/ML)	N203568	001	Jan 29, 2013	Jan	NEWA
---	--------------	---------------------	---------	-----	--------------	-----	------

MITOXANTRONE HYDROCHLORIDE

INJECTABLE; INJECTION

MITOXANTRONE HYDROCHLORIDE

AP		ONCO THERAPIES LTD	EQ 20MG BASE/10ML (EQ 2MG BASE/ML)	A201014	001	Dec 11, 2012	Mar	CAIN
----	--	--------------------	------------------------------------	---------	-----	--------------	-----	------

MOMETASONE FUROATE

CREAM; TOPICAL

ELOCON

>A>	AB	MERCK SHARP DOHME	0.1%	N019625	002	Apr 19, 2013	Apr	NEWA
-----	----	-------------------	------	---------	-----	--------------	-----	------

MORPHINE SULFATE

CAPSULE, EXTENDED RELEASE; ORAL

KADIAN

>D>	+	ACTAVIS ELIZABETH	10MG	N020616	008	Apr 20, 2007	Apr	CAHN
>D>	AB1		20MG	N020616	001	Jul 03, 1996	Apr	CAHN
>D>	AB1		30MG	N020616	004	Mar 09, 2001	Apr	CAHN
>D>			40MG	N020616	009	Jul 09, 2012	Apr	CAHN
>D>	AB1		50MG	N020616	002	Jul 03, 1996	Apr	CAHN
>D>	AB1		60MG	N020616	005	Mar 09, 2001	Apr	CAHN
>D>			70MG	N020616	010	Jul 09, 2012	Apr	CAHN
>D>	AB1		80MG	N020616	006	Oct 27, 2006	Apr	CAHN
>D>	AB1	+	100MG	N020616	003	Jul 03, 1996	Apr	CAHN
>D>			130MG	N020616	011	Jul 09, 2012	Apr	CAHN
>D>			150MG	N020616	012	Jul 09, 2012	Apr	CAHN
>D>	+		200MG	N020616	007	Feb 27, 2007	Apr	CAHN
>A>	+	WATSON LABS INC	10MG	N020616	008	Apr 20, 2007	Apr	CAHN
>A>	AB1		20MG	N020616	001	Jul 03, 1996	Apr	CAHN
>A>	AB1		30MG	N020616	004	Mar 09, 2001	Apr	CAHN
>A>			40MG	N020616	009	Jul 09, 2012	Apr	CAHN
>A>	AB1		50MG	N020616	002	Jul 03, 1996	Apr	CAHN
>A>	AB1		60MG	N020616	005	Mar 09, 2001	Apr	CAHN
>A>			70MG	N020616	010	Jul 09, 2012	Apr	CAHN
>A>	AB1		80MG	N020616	006	Oct 27, 2006	Apr	CAHN
>A>	AB1	+	100MG	N020616	003	Jul 03, 1996	Apr	CAHN
>A>			130MG	N020616	011	Jul 09, 2012	Apr	CAHN
>A>			150MG	N020616	012	Jul 09, 2012	Apr	CAHN
>A>	+		200MG	N020616	007	Feb 27, 2007	Apr	CAHN

MORPHINE SULFATE

>D>	AB	PAR PHARM INC	20MG	A200812	001	Nov 10, 2011	Apr	CTEC
>A>	AB1		20MG	A200812	001	Nov 10, 2011	Apr	CTEC
>D>	AB		30MG	A200812	002	Nov 10, 2011	Apr	CTEC
>A>	AB1		30MG	A200812	002	Nov 10, 2011	Apr	CTEC
>D>	AB		50MG	A200812	003	Nov 10, 2011	Apr	CTEC
>A>	AB1		50MG	A200812	003	Nov 10, 2011	Apr	CTEC
>D>	AB		60MG	A200812	004	Nov 10, 2011	Apr	CTEC
>A>	AB1		60MG	A200812	004	Nov 10, 2011	Apr	CTEC
>D>	AB		80MG	A200812	005	Nov 10, 2011	Apr	CTEC
>A>	AB1		80MG	A200812	005	Nov 10, 2011	Apr	CTEC
>D>	AB		100MG	A200812	006	Nov 10, 2011	Apr	CTEC
>A>	AB1		100MG	A200812	006	Nov 10, 2011	Apr	CTEC

MUPIROCIN CALCIUM

CREAM; TOPICAL

BACTROBAN

AB	+	GLAXOSMITHKLINE	EQ 2% BASE	N050746	001	Dec 11, 1997	Jan	CFTG
----	---	-----------------	------------	---------	-----	--------------	-----	------

MUPIROCIN

AB		GLENMARK GENERICS	EQ 2% BASE	A201587	001	Jan 24, 2013	Jan	NEWA
----	--	-------------------	------------	---------	-----	--------------	-----	------

MYCOPHENOLATE MOFETIL

CAPSULE; ORAL

MYCOPHENOLATE MOFETIL

>A>	AB	ACCORD HLTHCARE	250MG	A090253	001	May 04, 2009	Apr	CAHN
>D>	AB	ACCORD HLTHCARE INC	250MG	A090253	001	May 04, 2009	Apr	CAHN

NABUMETONE

TABLET; ORAL

NABUMETONE

>D>	AB	DR REDDYS LABS LTD	500MG	A078420	001	Sep 24, 2008	Apr	DISC
>A>		@	500MG	A078420	001	Sep 24, 2008	Apr	DISC
>D>	AB		750MG	A078420	002	Sep 24, 2008	Apr	DISC
>A>		@	750MG	A078420	002	Sep 24, 2008	Apr	DISC
		@ PROSAM LABS	500MG	A079093	001	Feb 27, 2009	Mar	DISC
		@	750MG	A079093	002	Feb 27, 2009	Mar	DISC

NALTREXONE HYDROCHLORIDE

TABLET; ORAL

NALTREXONE HYDROCHLORIDE

>D>	AB	SANDOZ	50MG	A075434	001	Mar 08, 2000	Apr	DISC
>A>		@	50MG	A075434	001	Mar 08, 2000	Apr	DISC

NAPROXEN

TABLET; ORAL

NAPROXEN

>A>	AB	WEST WARD PHARM CORP	250MG	A076494	001	Jan 14, 2004	Apr	CAHN
>A>	AB		375MG	A076494	002	Jan 14, 2004	Apr	CAHN
>A>	AB		500MG	A076494	003	Jan 14, 2004	Apr	CAHN
>D>	AB	WESTWARD	250MG	A076494	001	Jan 14, 2004	Apr	CAHN
>D>	AB		375MG	A076494	002	Jan 14, 2004	Apr	CAHN
>D>	AB		500MG	A076494	003	Jan 14, 2004	Apr	CAHN

NARATRIPTAN HYDROCHLORIDE

TABLET; ORAL

AMERGE

AB		GLAXOSMITHKLINE LLC	EQ 1MG BASE	N020763	002	Feb 10, 1998	Mar	CAHN
AB	+		EQ 2.5MG BASE	N020763	001	Feb 10, 1998	Mar	CAHN

NEOMYCIN SULFATE

POWDER; FOR RX COMPOUNDING

NEO-RX

@ X GEN PHARMS	100%	A061579	001			Mar	DISC
----------------	------	---------	-----	--	--	-----	------

NIFEDIPINE

CAPSULE; ORAL

NIFEDIPINE

>D>		ACTAVIS ELIZABETH	20MG	A072556	001	Sep 20, 1990	Apr	CTEC
>A>	AB		20MG	A072556	001	Sep 20, 1990	Apr	CTEC
>D>	AB	CATALENT	10MG	A073250	001	Oct 08, 1991	Apr	DISC
>A>		@	10MG	A073250	001	Oct 08, 1991	Apr	DISC
>A>	AB	EMCURE PHARMS USA	10MG	A202644	001	Apr 25, 2013	Apr	NEWA
>A>	AB		20MG	A202644	002	Apr 25, 2013	Apr	NEWA

NILUTAMIDE

TABLET; ORAL

NILANDRON

>A>	@ COVIS PHARMA SARL	50MG	N020169 001	Sep 19, 1996	Apr	CAHN
>A>	+	150MG	N020169 002	Apr 30, 1999	Apr	CAHN
>D>	@ SANOFI AVENTIS US	50MG	N020169 001	Sep 19, 1996	Apr	CAHN
>D>	+	150MG	N020169 002	Apr 30, 1999	Apr	CAHN

NITROFURANTOIN, MACROCRYSTALLINE

CAPSULE; ORAL

MACRODANTIN

	ALVOGEN INC	25MG	N016620 003		Mar	CTEC
AB		25MG	N016620 003		Feb	CAHN
AB		50MG	N016620 001		Feb	CAHN
AB	+	100MG	N016620 002		Feb	CAHN
	NITROFURANTOIN					
	@ WATSON LABS	25MG	A073696 001	Dec 31, 1992	Mar	DISC
	@	50MG	A073696 002	Dec 31, 1992	Mar	DISC
	@	100MG	A073696 003	Dec 31, 1992	Mar	DISC

NITROFURANTOIN; NITROFURANTOIN, MACROCRYSTALLINE

CAPSULE; ORAL

MACROBID

AB	+	ALVOGEN INC	75MG;25MG	N020064 001	Dec 24, 1991	Mar	CAHN
----	---	-------------	-----------	-------------	--------------	-----	------

NITROGLYCERIN

FILM, EXTENDED RELEASE; TRANSDERMAL

NITRO-DUR

AB1	+	MERCK SHARP DOHME	0.1MG/HR	N020145 001	Apr 04, 1995	Mar	CAHN
AB1	+		0.2MG/HR	N020145 002	Apr 04, 1995	Mar	CAHN
	+		0.3MG/HR	N020145 003	Apr 04, 1995	Mar	CAHN
AB1	+		0.4MG/HR	N020145 004	Apr 04, 1995	Mar	CAHN
AB1	+		0.6MG/HR	N020145 005	Apr 04, 1995	Mar	CAHN
	+		0.8MG/HR	N020145 006	Apr 04, 1995	Mar	CAHN

NIZATIDINE

CAPSULE; ORAL

NIZATIDINE

	@ APOTEX INC	150MG	A076383 001	Jan 23, 2003	Feb	DISC
	@	300MG	A076383 002	Jan 23, 2003	Feb	DISC

NORETHINDRONE

TABLET; ORAL-28

JENCYCLA

>D>	AB	LUPIN LTD	0.35MG	A091323 001	Mar 28, 2013	Apr	CTEC
>A>	AB2		0.35MG	A091323 001	Mar 28, 2013	Apr	CTEC
	AB		0.35MG	A091323 001	Mar 28, 2013	Mar	NEWA

NYSTATIN

SUSPENSION; ORAL

NILSTAT

	@ GLENMARK GENERICS	100,000 UNITS/ML	N050299 001		Feb	DISC
--	---------------------	------------------	-------------	--	-----	------

OFLOXACIN

SOLUTION/DROPS; OPHTHALMIC

OFLOXACIN

>A>	AT	ALTAIRE PHARMS INC	0.3%	A202692	001	Apr 29, 2013	Apr	NEWA
>A>		@ APOTEX INC	0.3%	A076513	001	May 14, 2004	Apr	DISC
>D>	AT	NOVEX	0.3%	A076513	001	May 14, 2004	Apr	DISC

OMEPRAZOLE; SODIUM BICARBONATE

FOR SUSPENSION; ORAL

>A>		OMEPRAZOLE AND SODIUM BICARBONATE						
>A>	AB	PAR PHARM	20MG/PACKET;1.68GM/PACKET	A079182	001	Apr 19, 2013	Apr	NEWA
>A>	AB		40MG/PACKET;1.68GM/PACKET	A079182	002	Apr 19, 2013	Apr	NEWA
		ZEGERID						
>D>		SANTARUS	20MG/PACKET;1.68GM/PACKET	N021636	001	Jun 15, 2004	Apr	CFTG
>A>	AB		20MG/PACKET;1.68GM/PACKET	N021636	001	Jun 15, 2004	Apr	CFTG
>D>	+		40MG/PACKET;1.68GM/PACKET	N021636	002	Dec 21, 2004	Apr	CFTG
>A>	AB	+	40MG/PACKET;1.68GM/PACKET	N021636	002	Dec 21, 2004	Apr	CFTG

ONDANSETRON HYDROCHLORIDE

INJECTABLE; INJECTION

ONDANSETRON HYDROCHLORIDE

>D>	AP	APOTEX	EQ 2MG BASE/ML	A077368	001	Dec 26, 2006	Apr	DISC
>A>		@ APOTEX INC	EQ 2MG BASE/ML	A077368	001	Dec 26, 2006	Apr	DISC
	AP	CLARIS LIFESCIENCES	2MG/ML	A078288	001	Feb 22, 2013	Feb	NEWA
		@ LUITPOLD	EQ 2MG BASE/ML	A077582	001	Dec 26, 2006	Mar	DISC
		@ PLIVA HRVATSKA DOO	EQ 2MG BASE/ML	A077544	001	Dec 26, 2006	Feb	DISC
		ONDANSETRON HYDROCHLORIDE AND DEXTROSE IN PLASTIC CONTAINER						
		@ CLARIS LIFESCIENCES	EQ 0.64MG BASE/ML	A078308	001	Mar 17, 2008	Jan	DISC
		@ HOSPIRA	EQ 0.64MG BASE/ML	A077348	001	Feb 01, 2007	Jan	DISC
		ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE						
>D>	AP	APOTEX INC	EQ 2MG BASE/ML	A077343	001	Dec 26, 2006	Apr	DISC
>A>		@	EQ 2MG BASE/ML	A077343	001	Dec 26, 2006	Apr	DISC
	AP	CLARIS LIFESCIENCES	2MG/ML	A078287	001	Feb 22, 2013	Feb	NEWA
		@ LUITPOLD	EQ 2MG BASE/ML	A077387	001	Dec 26, 2006	Mar	DISC

OSPEMIFENE

TABLET; ORAL

OSPHENA

+	SHIONOGI INC	60MG	N203505	001	Feb 26, 2013	Feb	NEWA
---	--------------	------	---------	-----	--------------	-----	------

OXACILLIN SODIUM

INJECTABLE; INJECTION

OXACILLIN SODIUM

AP	AUROBINDO PHARMA LTD	EQ 1GM BASE/VIAL	A201539	001	Jan 18, 2013	Jan	NEWA
AP		EQ 2GM BASE/VIAL	A201539	002	Jan 18, 2013	Jan	NEWA
AP		EQ 10GM BASE/VIAL	A201538	001	Jan 18, 2013	Jan	NEWA

OXAPROZIN

TABLET; ORAL

OXAPROZIN

@	CARACO	600MG	A075844	001	Jan 03, 2002	Jan	DISC
---	--------	-------	---------	-----	--------------	-----	------

OXCARBAZEPINE

TABLET; ORAL

OXCARBAZEPINE

@	TEVA PHARMS USA	150MG	A078005 001	Dec 11, 2007	Mar	DISC
@		300MG	A078005 002	Dec 11, 2007	Mar	DISC
@		600MG	A078005 003	Dec 11, 2007	Mar	DISC

OXYBUTYNIN CHLORIDE

SYRUP; ORAL

OXYBUTYNIN CHLORIDE

>A>	@	APOTEX INC	5MG/5ML	A074997 001	Oct 15, 1997	Apr	DISC
>D>	AA	NOVEX	5MG/5ML	A074997 001	Oct 15, 1997	Apr	DISC

TABLET; ORAL

OXYBUTYNIN CHLORIDE

AB		TEVA PHARMS USA	5MG	A071655 001	Nov 14, 1988	Mar	CAHN
----	--	-----------------	-----	-------------	--------------	-----	------

OXYCODONE HYDROCHLORIDE

TABLET; ORAL

OXYCODONE HYDROCHLORIDE

@	NESHER PHARMS	5MG	A077290 001	Dec 08, 2005	Mar	DISC
@		10MG	A077290 002	Dec 08, 2005	Mar	DISC
@		15MG	A077290 003	Dec 08, 2005	Mar	DISC
@		20MG	A077290 004	Dec 08, 2005	Mar	DISC
@		30MG	A077290 005	Dec 08, 2005	Mar	DISC

OXYMORPHONE HYDROCHLORIDE

TABLET; ORAL

OXYMORPHONE HYDROCHLORIDE

AB		AVANTHI INC	5MG	A203601 001	Jan 30, 2013	Jan	NEWA
AB			10MG	A203601 002	Jan 30, 2013	Jan	NEWA
>A>	AB	MALLINCKRODT INC	5MG	A202321 001	Apr 25, 2013	Apr	NEWA
>A>	AB		10MG	A202321 002	Apr 25, 2013	Apr	NEWA

TABLET, EXTENDED RELEASE; ORAL

OXYMORPHONE HYDROCHLORIDE

>D>	AB	ACTAVIS	7.5MG	A079046 001	Dec 13, 2010	Apr	CAHN
>D>	AB		15MG	A079046 002	Dec 13, 2010	Apr	CAHN
>A>	AB	ACTAVIS ELIZABETH	7.5MG	A079046 001	Dec 13, 2010	Apr	CAHN
>A>	AB		15MG	A079046 002	Dec 13, 2010	Apr	CAHN

OXYTOCIN

INJECTABLE; INJECTION

OXYTOCIN

AP		HIKMA FARMACEUTICA	10USP UNITS/ML (10USP UNITS/ML)	A200219 001	Feb 13, 2013	Jan	NEWA
----	--	--------------------	---------------------------------	-------------	--------------	-----	------

PACLITAXEL

INJECTABLE; INJECTION

PACLITAXEL

>A>	@	ACCORD HLTHCARE	6MG/ML	A075436 001	Nov 12, 2004	Apr	DISC
>D>	AP	ACCORD HLTHCARE INC	6MG/ML	A075436 001	Nov 12, 2004	Apr	DISC

TAXOL

>D>	@	HQ SPCLT PHARMA	6MG/ML	N020262 001	Dec 29, 1992	Apr	CMFD
>A>	AP		6MG/ML	N020262 001	Dec 29, 1992	Apr	CMFD
	@		6MG/ML	N020262 001	Dec 29, 1992	Jan	CAHN

PAMIDRONATE DISODIUM

INJECTABLE; INJECTION

PAMIDRONATE DISODIUM

AP	TEVA PHARMS USA	30MG/10ML (3MG/ML)	A076153 001	Mar 27, 2002	Mar	CAHN
AP		90MG/10ML (9MG/ML)	A076153 002	Mar 27, 2002	Mar	CAHN

PANCRELIPASE (AMYLASE;LIPASE;PROTEASE)

CAPSULE, DELAYED RELEASE; ORAL

CREON

ABBVIE	180,000USP UNITS;36,000USP UNITS;114,000USP UNITS	N020725 005	Mar 14, 2013	Mar	NEWA
--------	---	-------------	--------------	-----	------

PANCURONIUM BROMIDE

INJECTABLE; INJECTION

PANCURONIUM BROMIDE

AP	+	TEVA PHARMS USA	2MG/ML	A072760 001	Jul 31, 1990	Mar	CAHN
----	---	-----------------	--------	-------------	--------------	-----	------

PAROXETINE HYDROCHLORIDE

SUSPENSION; ORAL

PAROXETINE HYDROCHLORIDE

>D>	AB	APOTEX INC	EQ 10MG BASE/5ML	A077395 001	Dec 05, 2006	Apr	DISC
>A>		@	EQ 10MG BASE/5ML	A077395 001	Dec 05, 2006	Apr	DISC

PEGINESATIDE ACETATE

SOLUTION; INTRAVENOUS, SUBCUTANEOUS

OMONTYS

>D>	+	AFFYMAX	EQ 10MG BASE/ML (EQ 10MG BASE/ML)	N202799 007	Mar 27, 2012	Apr	CAHN
>D>	+		EQ 20MG BASE/2ML (EQ 10MG BASE/ML)	N202799 008	Mar 27, 2012	Apr	CAHN
>A>	+	TAKEDA PHARMS USA	EQ 10MG BASE/ML (EQ 10MG BASE/ML)	N202799 007	Mar 27, 2012	Apr	CAHN
>A>	+		EQ 20MG BASE/2ML (EQ 10MG BASE/ML)	N202799 008	Mar 27, 2012	Apr	CAHN

OMONTYS PRESERVATIVE FREE

>D>	+	AFFYMAX	EQ 1MG BASE/0.5ML (EQ 1MG BASE/0.5ML)	N202799 001	Mar 27, 2012	Apr	CAHN
>D>	+		EQ 2MG BASE/0.5ML (EQ 2MG BASE/0.5ML)	N202799 002	Mar 27, 2012	Apr	CAHN
>D>	+		EQ 3MG BASE/0.5ML (EQ 3MG BASE/0.5ML)	N202799 003	Mar 27, 2012	Apr	CAHN
>D>	+		EQ 4MG BASE/0.5ML (EQ 4MG BASE/0.5ML)	N202799 004	Mar 27, 2012	Apr	CAHN
>D>	+		EQ 5MG BASE/0.5ML (EQ 5MG BASE/0.5ML)	N202799 005	Mar 27, 2012	Apr	CAHN
>D>	+		EQ 6MG BASE/0.5ML (EQ 6MG BASE/0.5ML)	N202799 006	Mar 27, 2012	Apr	CAHN
>A>	+	TAKEDA PHARMS USA	EQ 1MG BASE/0.5ML (EQ 1MG BASE/0.5ML)	N202799 001	Mar 27, 2012	Apr	CAHN
>A>	+		EQ 2MG BASE/0.5ML (EQ 2MG BASE/0.5ML)	N202799 002	Mar 27, 2012	Apr	CAHN
>A>	+		EQ 3MG BASE/0.5ML (EQ 3MG BASE/0.5ML)	N202799 003	Mar 27, 2012	Apr	CAHN
>A>	+		EQ 4MG BASE/0.5ML (EQ 4MG BASE/0.5ML)	N202799 004	Mar 27, 2012	Apr	CAHN
>A>	+		EQ 5MG BASE/0.5ML (EQ 5MG BASE/0.5ML)	N202799 005	Mar 27, 2012	Apr	CAHN
>A>	+		EQ 6MG BASE/0.5ML (EQ 6MG BASE/0.5ML)	N202799 006	Mar 27, 2012	Apr	CAHN

PHENYLEPHRINE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

PHENYLEPHRINE HYDROCHLORIDE

PARAGON BIOTECK	2.5%	N203510 001	Mar 21, 2013	Mar	NEWA
+	10%	N203510 002	Mar 21, 2013	Mar	NEWA

PHENYTOIN SODIUM

INJECTABLE; INJECTION

PHENYTOIN SODIUM

@ HOSPIRA	50MG/ML	A089744 001	Dec 18, 1987	Mar	DISC
-----------	---------	-------------	--------------	-----	------

PIOGLITAZONE HYDROCHLORIDE

TABLET; ORAL

PIOGLITAZONE HYDROCHLORIDE

AB	ACCORD HLTHCARE	EQ 15MG BASE	A200044 001	Feb 13, 2013	Jan	NEWA
AB		EQ 30MG BASE	A200044 002	Feb 13, 2013	Jan	NEWA
AB		EQ 45MG BASE	A200044 003	Feb 13, 2013	Jan	NEWA
AB	AUROBINDO PHARMA LTD	EQ 15MG BASE	A200268 001	Feb 13, 2013	Jan	NEWA
AB		EQ 30MG BASE	A200268 002	Feb 13, 2013	Jan	NEWA
AB		EQ 45MG BASE	A200268 003	Feb 13, 2013	Jan	NEWA
AB	DR REDDYS LABS LTD	EQ 15MG BASE	A078383 001	Mar 12, 2013	Mar	NEWA
AB		EQ 30MG BASE	A078383 002	Mar 12, 2013	Mar	NEWA
AB		EQ 45MG BASE	A078383 003	Mar 12, 2013	Mar	NEWA
AB	MACLEODS PHARMS LTD	EQ 15MG BASE	A202467 001	Feb 06, 2013	Jan	NEWA
AB		EQ 30MG BASE	A202467 002	Feb 06, 2013	Jan	NEWA
AB		EQ 45MG BASE	A202467 003	Feb 06, 2013	Jan	NEWA
AB	SANDOZ	EQ 15MG BASE	A078670 001	Feb 13, 2013	Jan	NEWA
AB		EQ 30MG BASE	A078670 002	Feb 13, 2013	Jan	NEWA
AB		EQ 45MG BASE	A078670 003	Feb 13, 2013	Jan	NEWA
AB	SYNTHON PHARMS	EQ 15MG BASE	A078472 001	Feb 13, 2013	Jan	NEWA
AB		EQ 30MG BASE	A078472 002	Feb 13, 2013	Jan	NEWA
AB		EQ 45MG BASE	A078472 003	Feb 13, 2013	Jan	NEWA
AB	TORRENT PHARMS LTD	EQ 15MG BASE	A091298 001	Feb 13, 2013	Jan	NEWA
AB		EQ 30MG BASE	A091298 002	Feb 13, 2013	Jan	NEWA
AB		EQ 45MG BASE	A091298 003	Feb 13, 2013	Jan	NEWA
AB	ZYDUS PHARMS USA INC	EQ 15MG BASE	A202456 001	Feb 13, 2013	Jan	NEWA
AB		EQ 30MG BASE	A202456 002	Feb 13, 2013	Jan	NEWA
AB		EQ 45MG BASE	A202456 003	Feb 13, 2013	Jan	NEWA

POLYMYXIN B SULFATE

POWDER; FOR RX COMPOUNDING

POLY-RX

@ X GEN PHARMS	100,000,000 UNITS/BOT	A061578 001		Mar	DISC
----------------	-----------------------	-------------	--	-----	------

POMALIDOMIDE

CAPSULE; ORAL

POMALYST

CELGENE	1MG	N204026 001	Feb 08, 2013	Feb	NEWA
	2MG	N204026 002	Feb 08, 2013	Feb	NEWA
	3MG	N204026 003	Feb 08, 2013	Feb	NEWA
+	4MG	N204026 004	Feb 08, 2013	Feb	NEWA

POTASSIUM CHLORIDECAPSULE, EXTENDED RELEASE; ORAL
POTASSIUM CHLORIDE

AB	AMNEAL PHARMS	10MEQ	A202128	001	Feb 22, 2013	Feb	NEWA
----	---------------	-------	---------	-----	--------------	-----	------

PRAMIPEXOLE DIHYDROCHLORIDE

TABLET; ORAL

PRAMIPEXOLE DIHYDROCHLORIDE

AB	ACTAVIS GRP PTC	0.125MG	A091254	001	Nov 30, 2010	Mar	CAHN
AB		0.25MG	A091254	002	Nov 30, 2010	Mar	CAHN
AB		0.5MG	A091254	003	Nov 30, 2010	Mar	CAHN
AB		0.75MG	A091254	004	Nov 30, 2010	Mar	CAHN
AB		1MG	A091254	005	Nov 30, 2010	Mar	CAHN
AB		1.5MG	A091254	006	Nov 30, 2010	Mar	CAHN
AB	SUN PHARM INDS INC	0.125MG	A091683	001	Mar 27, 2013	Mar	NEWA
AB		0.25MG	A091683	002	Mar 27, 2013	Mar	NEWA
AB		0.5MG	A091683	003	Mar 27, 2013	Mar	NEWA
AB		0.75MG	A091683	004	Mar 27, 2013	Mar	NEWA
AB		1MG	A091683	005	Mar 27, 2013	Mar	NEWA
AB		1.5MG	A091683	006	Mar 27, 2013	Mar	NEWA

PRAMLINTIDE ACETATE

INJECTABLE; SUBCUTANEOUS

SYMLIN

	AMYLIN PHARMS	EQ 1.5MG BASE/1.5ML (EQ 1MG BASE/ML)	N021332	002	Sep 25, 2007	Jan	CAHN
		EQ 2.7MG BASE/2.7ML (EQ 1MG BASE/ML)	N021332	003	Sep 25, 2007	Jan	CAHN
+		EQ 3MG BASE/5ML (EQ 600MCG BASE/ML)	N021332	001	Mar 16, 2005	Jan	CAHN

PREDNISOLONE

SYRUP; ORAL

PREDNISOLONE

>D>	AA	APOTEX INC	5MG/5ML	A040570	001	Aug 25, 2005	Apr	DISC
>A>		@	5MG/5ML	A040570	001	Aug 25, 2005	Apr	DISC
>D>	AA		15MG/5ML	A040571	001	Aug 25, 2005	Apr	DISC
>A>		@	15MG/5ML	A040571	001	Aug 25, 2005	Apr	DISC

PREDNISOLONE SODIUM PHOSPHATE

SOLUTION; ORAL

PREDNISOLONE SODIUM PHOSPHATE

@	PHARM ASSOC	EQ 5MG BASE/5ML	A076123	001	Dec 23, 2002	Mar	DISC
@	WE PHARMS	EQ 15MG BASE/5ML	A075250	001	Jul 12, 2002	Mar	DISC

TABLET, ORALLY DISINTEGRATING; ORAL

ORAPRED ODT

AB	SHIONOGI INC	EQ 10MG BASE	N021959	001	Jun 01, 2006	Mar	CFTG
AB		EQ 15MG BASE	N021959	002	Jun 01, 2006	Mar	CFTG
AB	+	EQ 30MG BASE	N021959	003	Jun 01, 2006	Mar	CFTG
		PREDNISOLONE SODIUM PHOSPHATE					
AB	MYLAN PHARMS INC	EQ 10MG BASE	A202179	001	Apr 10, 2013	Mar	NEWA
AB		EQ 15MG BASE	A202179	002	Apr 10, 2013	Mar	NEWA
AB		EQ 30MG BASE	A202179	003	Apr 10, 2013	Mar	NEWA

PRIMIDONE

TABLET; ORAL

PRIMIDONE

>D>	AB	DR REDDYS LABS LTD	50MG	A040862 001	Oct 03, 2008	Apr	DISC
>A>		@	50MG	A040862 001	Oct 03, 2008	Apr	DISC
>D>	AB		250MG	A040862 002	Oct 03, 2008	Apr	DISC
>A>		@	250MG	A040862 002	Oct 03, 2008	Apr	DISC

PROMETHAZINE HYDROCHLORIDE

INJECTABLE; INJECTION

PROMETHAZINE HYDROCHLORIDE

AP	+	TEVA PHARMS USA	25MG/ML	A040454 001	Aug 22, 2002	Mar	CAHN
AP	+		50MG/ML	A040454 002	Aug 22, 2002	Mar	CAHN

PROPOFOL

INJECTABLE; INJECTION

PROPOFOL

AB		TEVA PHARMS USA	10MG/ML	A075102 001	Jan 04, 1999	Mar	CAHN
----	--	-----------------	---------	-------------	--------------	-----	------

PROPRANOLOL HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

PROPRANOLOL HYDROCHLORIDE

AB		GLATT AIR	60MG	A078065 001	Jan 26, 2007	Feb	CAHN
AB			80MG	A078065 002	Jan 26, 2007	Feb	CAHN
AB			120MG	A078065 003	Jan 26, 2007	Feb	CAHN
AB			160MG	A078065 004	Jan 26, 2007	Feb	CAHN

PROTRIPTYLINE HYDROCHLORIDE

TABLET; ORAL

VIVACTIL

@ TEVA WOMENS

@

5MG

10MG

N016012 001

Mar CAHN

N016012 002

Mar CAHN

PYRIMETHAMINE

TABLET; ORAL

DARAPRIM

>A>	+	AMEDRA PHARMS	25MG	N008578 001		Apr	CAHN
>D>	+	COREPHARMA	25MG	N008578 001		Apr	CAHN

QUETIAPINE FUMARATE

TABLET; ORAL

QUETIAPINE FUMARATE

>A>	AB	ACCORD HLTHCARE	EQ 25MG BASE	A202152 001	Mar 27, 2012	Apr	CAHN
>A>	AB		EQ 50MG BASE	A202152 002	Mar 27, 2012	Apr	CAHN
>A>	AB		EQ 100MG BASE	A202152 003	Mar 27, 2012	Apr	CAHN
>A>	AB		EQ 200MG BASE	A202152 004	Mar 27, 2012	Apr	CAHN
>A>	AB		EQ 300MG BASE	A202152 005	Mar 27, 2012	Apr	CAHN
>A>	AB		EQ 400MG BASE	A202152 006	Mar 27, 2012	Apr	CAHN
>D>	AB	ACCORD HLTHCARE INC	EQ 25MG BASE	A202152 001	Mar 27, 2012	Apr	CAHN
>D>	AB		EQ 50MG BASE	A202152 002	Mar 27, 2012	Apr	CAHN
>D>	AB		EQ 100MG BASE	A202152 003	Mar 27, 2012	Apr	CAHN
>D>	AB		EQ 200MG BASE	A202152 004	Mar 27, 2012	Apr	CAHN
>D>	AB		EQ 300MG BASE	A202152 005	Mar 27, 2012	Apr	CAHN
>D>	AB		EQ 400MG BASE	A202152 006	Mar 27, 2012	Apr	CAHN

TABLET; ORAL

QUETIAPINE FUMARATE

AB	ACTAVIS PHARMA	EQ 25MG BASE	A201762 001	Feb 27, 2013	Feb	NEWA
AB		EQ 50MG BASE	A201762 002	Feb 27, 2013	Feb	NEWA
AB		EQ 100MG BASE	A201762 003	Feb 27, 2013	Feb	NEWA
AB		EQ 150MG BASE	A201762 004	Feb 27, 2013	Feb	NEWA
AB		EQ 200MG BASE	A201762 005	Feb 27, 2013	Feb	NEWA
AB		EQ 300MG BASE	A201762 006	Feb 27, 2013	Feb	NEWA
AB		EQ 400MG BASE	A201762 007	Feb 27, 2013	Feb	NEWA
AB	ALKEM LABS LTD	EQ 25MG BASE	A201504 001	Feb 12, 2013	Jan	NEWA
AB		EQ 50MG BASE	A201504 002	Feb 12, 2013	Jan	NEWA
AB		EQ 100MG BASE	A201504 003	Feb 12, 2013	Jan	NEWA
AB		EQ 150MG BASE	A201504 004	Feb 12, 2013	Jan	NEWA
AB		EQ 200MG BASE	A201504 005	Feb 12, 2013	Jan	NEWA
AB		EQ 300MG BASE	A201504 006	Feb 12, 2013	Jan	NEWA
AB		EQ 400MG BASE	A201504 007	Feb 12, 2013	Jan	NEWA

QUINAPRIL HYDROCHLORIDE

TABLET; ORAL

QUINAPRIL HYDROCHLORIDE

	@ APOTEX INC	EQ 5MG BASE	A076240 001	Jan 26, 2006	Mar	DISC
	@	EQ 10MG BASE	A076240 002	Jan 26, 2006	Mar	DISC
	@	EQ 20MG BASE	A076240 003	Jan 26, 2006	Mar	DISC
	@	EQ 40MG BASE	A076240 004	Jan 26, 2006	Mar	DISC
>A>	AB AUROBINDO PHARMA LTD	EQ 5MG BASE	A202725 001	Apr 29, 2013	Apr	NEWA
>A>	AB	EQ 10MG BASE	A202725 002	Apr 29, 2013	Apr	NEWA
>A>	AB	EQ 20MG BASE	A202725 003	Apr 29, 2013	Apr	NEWA
>A>	AB	EQ 40MG BASE	A202725 004	Apr 29, 2013	Apr	NEWA

RABEPRAZOLE SODIUM

CAPSULE, DELAYED RELEASE; ORAL

ACIPHEX SPRINKLE

	EISAI INC	5MG	N204736 001	Mar 26, 2013	Mar	NEWA
	+	10MG	N204736 002	Mar 26, 2013	Mar	NEWA

RANITIDINE HYDROCHLORIDE

INJECTABLE; INJECTION

RANITIDINE HYDROCHLORIDE

AP	ZYDUS PHARMS USA INC	25MG/ML	A091534 001	Feb 22, 2013	Feb	NEWA
----	----------------------	---------	-------------	--------------	-----	------

SYRUP; ORAL

RANITIDINE HYDROCHLORIDE

>D>	AA APOTEX	EQ 15MG BASE/ML	A077602 001	Sep 17, 2007	Apr	DISC
>A>	@ APOTEX INC	EQ 15MG BASE/ML	A077602 001	Sep 17, 2007	Apr	DISC
>A>	AA BIO PHARM INC	EQ 15MG BASE/ML	A090102 001	May 26, 2009	Apr	CAHN
>A>	AA CARACO	EQ 15MG BASE/ML	A091091 001	Sep 20, 2011	Apr	CAHN
>D>	AA DR REDDYS LABS LTD	EQ 15MG BASE/ML	A090102 001	May 26, 2009	Apr	CAHN
>D>	AA SUN PHARM INDS INC	EQ 15MG BASE/ML	A091091 001	Sep 20, 2011	Apr	CAHN

TABLET; ORAL

RANITIDINE HYDROCHLORIDE

	@ WATSON LABS	EQ 150MG BASE	A074864 001	Oct 20, 1997	Jan	DISC
	@	EQ 300MG BASE	A074864 002	Oct 20, 1997	Jan	DISC
	@ WATSON LABS INC	EQ 150MG BASE	A077426 001	Dec 19, 2005	Mar	DISC
	@	EQ 300MG BASE	A077426 002	Dec 19, 2005	Mar	DISC

RILUZOLE

TABLET; ORAL

RILUTEK

>A>	AB	+	COVIS PHARMA SARL	50MG	N020599	001	Dec 12, 1995	Apr	CAHN
>D>	AB	+	SANOFI AVENTIS US	50MG	N020599	001	Dec 12, 1995	Apr	CAHN

RIMANTADINE HYDROCHLORIDE

TABLET; ORAL

RIMANTADINE HYDROCHLORIDE

@ COREPHARMA

100MG

A075916 001 Nov 02, 2001 Feb DISC

RISPERIDONE

TABLET, ORALLY DISINTEGRATING; ORAL

RISPERIDONE

AB	MYLAN PHARMS INC	0.25MG	A091537	006	Feb 12, 2013	Feb	NEWA
AB	PAR PHARM	0.25MG	A077494	001	Apr 30, 2009	Feb	CTEC
AB	SUN PHARM INDS LTD	0.5MG	A078464	001	Apr 08, 2013	Mar	NEWA
AB		1MG	A078464	002	Apr 08, 2013	Mar	NEWA
AB		2MG	A078464	003	Apr 08, 2013	Mar	NEWA
AB		3MG	A078464	004	Apr 08, 2013	Mar	NEWA
AB		4MG	A078464	005	Apr 08, 2013	Mar	NEWA

RIVASTIGMINE TARTRATE

CAPSULE; ORAL

RIVASTIGMINE TARTRATE

>A>	AB	APOTEX INC	EQ 1.5MG BASE	A091072	001	May 16, 2013	Apr	NEWA
>A>	AB		EQ 3MG BASE	A091072	002	May 16, 2013	Apr	NEWA
>A>	AB		EQ 4.5MG BASE	A091072	003	May 16, 2013	Apr	NEWA
>A>	AB		EQ 6MG BASE	A091072	004	May 16, 2013	Apr	NEWA

RIZATRIPTAN BENZOATE

TABLET; ORAL

RIZATRIPTAN BENZOATE

AB	CIPLA LTD	EQ 5MG BASE	A077526	001	Mar 26, 2013	Mar	NEWA
AB		EQ 10MG BASE	A077526	002	Mar 26, 2013	Mar	NEWA

ROCURONIUM BROMIDE

INJECTABLE; INJECTION

ZEMURON

@ ORGANON USA INC

10MG/ML (10MG/ML)

N020214 002 Mar 17, 1994 Jan CAHN

AP	+		50MG/5ML (10MG/ML)	N020214	001	Mar 17, 1994	Jan	CAHN
----	---	--	--------------------	---------	-----	--------------	-----	------

AP	+		100MG/10ML (10MG/ML)	N020214	003	Mar 17, 1994	Jan	CAHN
----	---	--	----------------------	---------	-----	--------------	-----	------

ROPINIROLE HYDROCHLORIDE

TABLET; ORAL

REQUIP

AB	+	GLAXOSMITHKLINE LLC	EQ 0.25MG BASE	N020658	001	Sep 19, 1997	Mar	CAHN
AB			EQ 0.5MG BASE	N020658	002	Sep 19, 1997	Mar	CAHN
AB			EQ 1MG BASE	N020658	003	Sep 19, 1997	Mar	CAHN
AB			EQ 2MG BASE	N020658	004	Sep 19, 1997	Mar	CAHN
AB			EQ 3MG BASE	N020658	006	Jan 27, 1999	Mar	CAHN
AB			EQ 4MG BASE	N020658	007	Jan 27, 1999	Mar	CAHN
AB			EQ 5MG BASE	N020658	005	Sep 19, 1997	Mar	CAHN

TABLET, EXTENDED RELEASE; ORAL

REQUIP XL

AB	+	GLAXOSMITHKLINE LLC	EQ 2MG BASE	N022008 001	Jun 13, 2008	Mar	CAHN
		@	EQ 3MG BASE	N022008 002	Jun 13, 2008	Mar	CAHN
AB			EQ 4MG BASE	N022008 003	Jun 13, 2008	Mar	CAHN
AB			EQ 6MG BASE	N022008 006	Apr 10, 2009	Mar	CAHN
AB			EQ 8MG BASE	N022008 004	Jun 13, 2008	Mar	CAHN
AB			EQ 12MG BASE	N022008 005	Oct 31, 2008	Mar	CAHN

ROPINIROLE HYDROCHLORIDE

>D>	AB	ACTAVIS	EQ 2MG BASE	A090869 001	May 17, 2012	Apr	CAHN
>D>	AB		EQ 4MG BASE	A090869 002	May 17, 2012	Apr	CAHN
>D>	AB		EQ 6MG BASE	A090869 003	May 17, 2012	Apr	CAHN
>D>	AB		EQ 8MG BASE	A090869 004	May 17, 2012	Apr	CAHN
>D>	AB		EQ 12MG BASE	A090869 005	May 17, 2012	Apr	CAHN
>A>	AB	ACTAVIS ELIZABETH	EQ 2MG BASE	A090869 001	May 17, 2012	Apr	CAHN
>A>	AB		EQ 4MG BASE	A090869 002	May 17, 2012	Apr	CAHN
>A>	AB		EQ 6MG BASE	A090869 003	May 17, 2012	Apr	CAHN
>A>	AB		EQ 8MG BASE	A090869 004	May 17, 2012	Apr	CAHN
>A>	AB		EQ 12MG BASE	A090869 005	May 17, 2012	Apr	CAHN
>A>	AB	ALEMBIC LTD	EQ 2MG BASE	A202786 001	Apr 22, 2013	Apr	NEWA
>A>	AB		EQ 4MG BASE	A202786 002	Apr 22, 2013	Apr	NEWA
>A>	AB		EQ 6MG BASE	A202786 003	Apr 22, 2013	Apr	NEWA
>A>	AB		EQ 8MG BASE	A202786 004	Apr 22, 2013	Apr	NEWA
>A>	AB		EQ 12MG BASE	A202786 005	Apr 22, 2013	Apr	NEWA

ROSIGLITAZONE MALEATE

TABLET; ORAL

AVANDIA

AB		SB PHARMCO	EQ 2MG BASE	N021071 002	May 25, 1999	Jan	CFTG
AB			EQ 4MG BASE	N021071 003	May 25, 1999	Jan	CFTG
AB	+		EQ 8MG BASE	N021071 004	May 25, 1999	Jan	CFTG

ROSIGLITAZONE MALEATE

AB		TEVA	EQ 2MG BASE	A076747 001	Jan 25, 2013	Jan	NEWA
AB			EQ 4MG BASE	A076747 002	Jan 25, 2013	Jan	NEWA
AB			EQ 8MG BASE	A076747 003	Jan 25, 2013	Jan	NEWA

SAQUINAVIR MESYLATE

TABLET; ORAL

INVIRASE

+	HOFFMAN LA ROCHE	EQ 500MG BASE	N021785 001	Dec 17, 2004	Feb	CAHN
---	------------------	---------------	-------------	--------------	-----	------

SELEGILINE HYDROCHLORIDE

TABLET; ORAL

SELEGILINE HYDROCHLORIDE

@	DAVA PHARMS INC	5MG	A074641 001	Aug 02, 1996	Jan	DISC
---	-----------------	-----	-------------	--------------	-----	------

SERTRALINE HYDROCHLORIDE

TABLET; ORAL

SERTRALINE HYDROCHLORIDE

>D>	AB	DR REDDYS LABS LTD	EQ 25MG BASE	A076442 001	Apr 30, 2007	Apr	DISC
>A>		@	EQ 25MG BASE	A076442 001	Apr 30, 2007	Apr	DISC
>D>	AB		EQ 50MG BASE	A076442 002	Apr 30, 2007	Apr	DISC
>A>		@	EQ 50MG BASE	A076442 002	Apr 30, 2007	Apr	DISC
>D>	AB		EQ 100MG BASE	A076442 003	Apr 30, 2007	Apr	DISC
>A>		@	EQ 100MG BASE	A076442 003	Apr 30, 2007	Apr	DISC

SILDENAFIL CITRATE

TABLET; ORAL

SILDENAFIL CITRATE

>A>	AB	ACTAVIS GRP PTC	EQ 20MG BASE	A200149	001	Feb 25, 2013	Apr	CAHN
>D>	AB	ACTAVIS PHARMA	EQ 20MG BASE	A200149	001	Feb 25, 2013	Apr	CAHN
	AB		EQ 20MG BASE	A200149	001	Feb 25, 2013	Feb	NEWA
	AB	AMNEAL PHARMS	EQ 20MG BASE	A202025	001	Feb 28, 2013	Feb	NEWA

SODIUM CHLORIDE

INJECTABLE; INJECTION

SODIUM CHLORIDE 0.9%

MEDEFIL INC

18MG/2ML (9MG/ML)

N202832 002 Jan 06, 2012 Mar NEWA

22.5MG/2.5ML (9MG/ML)

N202832 003 Jan 06, 2012 Mar NEWA

27MG/3ML (9MG/ML)

N202832 004 Jan 06, 2012 Mar NEWA

45MG/5ML (9MG/ML)

N202832 005 Jan 06, 2012 Mar NEWA

90MG/10ML (9MG/ML)

N202832 006 Jan 06, 2012 Mar NEWA

SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

MEDEFIL INC

9MG/ML (9MG/ML)

N202832 001 Jan 06, 2012 Mar CPOT

SOLUTION; IRRIGATION

SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

@ BAXTER HLTHCARE

450MG/100ML

N017864 001 Jan DISC

SODIUM PHENYLBUTYRATE

POWDER; ORAL

BUPHENYL

AB	+	MEDICIS	3GM/TEASPOONFUL	N020573	001	Apr 30, 1996	Mar	CFTG
----	---	---------	-----------------	---------	-----	--------------	-----	------

SODIUM PHENYLBUTYRATE

AB		SIGMAPHARM LABS LLC	3GM/TEASPOONFUL	A202819	001	Mar 22, 2013	Mar	NEWA
----	--	---------------------	-----------------	---------	-----	--------------	-----	------

SODIUM POLYSTYRENE SULFONATE

POWDER; ORAL, RECTAL

KAYEXALATE

>A>	AA	+	COVIS PHARMA SARL	453.6GM/BOT	N011287	001	Apr	CAHN
-----	----	---	-------------------	-------------	---------	-----	-----	------

>D>	AA	+	SANOFI AVENTIS US	453.6GM/BOT	N011287	001	Apr	CAHN
-----	----	---	-------------------	-------------	---------	-----	-----	------

SUSPENSION; ORAL, RECTAL

SODIUM POLYSTYRENE SULFONATE

@ ROXANE

15GM/60ML

A089049 001 Nov 17, 1986 Mar DISC

STAVUDINE

CAPSULE; ORAL

STAVUDINE

>D>	AB	HETERO DRUGS	15MG	A078957	001	Dec 29, 2008	Apr	CAHN
>D>	AB		20MG	A078957	002	Dec 29, 2008	Apr	CAHN
>D>	AB		30MG	A078957	003	Dec 29, 2008	Apr	CAHN
>D>	AB		40MG	A078957	004	Dec 29, 2008	Apr	CAHN
>A>	AB	HETERO LABS LTD III	15MG	A078957	001	Dec 29, 2008	Apr	CAHN
>A>	AB		20MG	A078957	002	Dec 29, 2008	Apr	CAHN
>A>	AB		30MG	A078957	003	Dec 29, 2008	Apr	CAHN
>A>	AB		40MG	A078957	004	Dec 29, 2008	Apr	CAHN

STREPTOZOCIN

INJECTABLE; INJECTION

ZANOSAR

>D>	+	TEVA PARENTERAL	1GM/VIAL	N050577	001	May 07, 1982	Apr	CAHN
-----	---	-----------------	----------	---------	-----	--------------	-----	------

INJECTABLE; INJECTION

ZANOSAR

>A>	+	TEVA PHARMS USA	1GM/VIAL	N050577	001	May 07, 1982	Apr	CAHN
-----	---	-----------------	----------	---------	-----	--------------	-----	------

SULFACETAMIDE SODIUM

LOTION; TOPICAL

KLARON

AB	+	VALEANT BERMUDA	10%	N019931	001	Dec 23, 1996	Feb	CAHN
----	---	-----------------	-----	---------	-----	--------------	-----	------

SULFAMETHOXAZOLE; TRIMETHOPRIM

INJECTABLE; INJECTION

SULFAMETHOXAZOLE AND TRIMETHOPRIM

+	TEVA PHARMS USA	80MG/ML;16MG/ML	A073303	001	Oct 31, 1991	Mar	CAHN
---	-----------------	-----------------	---------	-----	--------------	-----	------

TABLET; ORAL

SULFAMETHOPRIM

@	NOVEL LABS INC	400MG;80MG	A070022	001	Feb 15, 1985	Mar	DISC
---	----------------	------------	---------	-----	--------------	-----	------

SULFAMETHOPRIM-DS

@	NOVEL LABS INC	800MG;160MG	A070032	001	Feb 15, 1985	Mar	DISC
---	----------------	-------------	---------	-----	--------------	-----	------

SULINDAC

TABLET; ORAL

SULINDAC

>D>	@	HERITAGE PHARMS INC	150MG	A073262	002	Sep 06, 1991	Apr	CMFD
-----	---	---------------------	-------	---------	-----	--------------	-----	------

>A>	AB		150MG	A073262	002	Sep 06, 1991	Apr	CMFD
-----	----	--	-------	---------	-----	--------------	-----	------

>D>	@		200MG	A073262	001	Sep 06, 1991	Apr	CMFD
-----	---	--	-------	---------	-----	--------------	-----	------

>A>	AB		200MG	A073262	001	Sep 06, 1991	Apr	CMFD
-----	----	--	-------	---------	-----	--------------	-----	------

SUMATRIPTAN SUCCINATE

INJECTABLE; SUBCUTANEOUS

SUMATRIPTAN SUCCINATE

>A>	AP	AUROBINDO PHARMA LTD	EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	A202758	001	Apr 23, 2013	Apr	NEWA
-----	----	----------------------	-------------------------------------	---------	-----	--------------	-----	------

AP	SAGENT AGILA	EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	A090641	001	Jul 28, 2010	Feb	CAHN
----	--------------	-------------------------------------	---------	-----	--------------	-----	------

AP	TEVA PHARMS USA	EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	A077907	001	Feb 06, 2009	Mar	CAHN
----	-----------------	-------------------------------------	---------	-----	--------------	-----	------

SYSTEM; IONTOPHORESIS

ZECUITY

+	NUPATHE	EQ 6.5MG BASE/4HR	N202278	001	Jan 17, 2013	Jan	NEWA
---	---------	-------------------	---------	-----	--------------	-----	------

TAMSULOSIN HYDROCHLORIDE

CAPSULE; ORAL

TAMSULOSIN HYDROCHLORIDE

>A>	AB	AUROBINDO PHARMA LTD	0.4MG	A202433	001	Apr 30, 2013	Apr	NEWA
-----	----	----------------------	-------	---------	-----	--------------	-----	------

TECHNETIUM TC-99M TILMANOCEPT

INJECTABLE; INJECTION

LYMPHOSEEK KIT

+	NAVIDEA BIOPHARMS	N/A	N202207	001	Mar 13, 2013	Mar	NEWA
---	-------------------	-----	---------	-----	--------------	-----	------

TENIPOSIDE

INJECTABLE; INJECTION

VUMON

>D>	+	BRISTOL MYERS SQUIBB	10MG/ML	N020119	001	Jul 14, 1992	Apr	CAHN
-----	---	----------------------	---------	---------	-----	--------------	-----	------

>A>	+	CORDEN PHARMA	10MG/ML	N020119	001	Jul 14, 1992	Apr	CAHN
-----	---	---------------	---------	---------	-----	--------------	-----	------

TERBUTALINE SULFATE

INJECTABLE; INJECTION

TERBUTALINE SULFATE

@ TEVA PHARMS USA

1MG/ML

A076853 001 Jul 20, 2004 Mar CAHN

TESTOSTERONE

GEL; TRANSDERMAL

TESTOSTERONE

PERRIGO ISRAEL

25MG/2.5GM PACKET

N203098 002 Jan 31, 2013 Jan NEWA

50MG/5GM PACKET

N203098 003 Jan 31, 2013 Jan NEWA

GEL, METERED; TRANSDERMAL

TESTOSTERONE

PERRIGO ISRAEL

12.5MG/1.25GM ACTUATION

N203098 001 Jan 31, 2013 Jan NEWA

TESTOSTERONE ENANTHATE

INJECTABLE; INJECTION

DELATESTRYL

AO + ENDO PHARMS

200MG/ML

N009165 003

Jan CAHN

@

200MG/ML

N009165 001

Jan CAHN

THEOPHYLLINE

TABLET, EXTENDED RELEASE; ORAL

THEOPHYLLINE

AB + TEVA PHARMS

450MG

A081236 001 Nov 09, 1992 Mar CAHN

THIOGUANINE

TABLET; ORAL

THIOGUANINE

+ ASPEN GLOBAL INC

40MG

N012429 001

Mar CAHN

TIMOLOL MALEATE

SOLUTION/DROPS; OPHTHALMIC

TIMOLOL MALEATE

>D> AT APOTEX INC

EQ 0.25% BASE

A075411 001 Sep 08, 2000 Apr DISC

>A> @

EQ 0.25% BASE

A075411 001 Sep 08, 2000 Apr DISC

>D> AT

EQ 0.5% BASE

A075412 001 Sep 08, 2000 Apr DISC

>A> @

EQ 0.5% BASE

A075412 001 Sep 08, 2000 Apr DISC

SOLUTION, GEL FORMING/DROPS; OPHTHALMIC

TIMOPTIC-XE

AB + VALEANT PHARMS LLC

EQ 0.25% BASE

N020330 001 Nov 04, 1993 Jan CAHN

AB +

EQ 0.5% BASE

N020330 002 Nov 04, 1993 Jan CAHN

TIZANIDINE HYDROCHLORIDE

TABLET; ORAL

TIZANIDINE HYDROCHLORIDE

@ MYLAN PHARMS INC

EQ 2MG BASE

A076282 001 Dec 16, 2003 Feb DISC

@

EQ 4MG BASE

A076282 002 Dec 16, 2003 Feb DISC

TOBRAMYCIN

POWDER; INHALATION

TOBI PODHALER

+ NOVARTIS

28MG

N201688 001 Mar 22, 2013 Mar NEWA

SOLUTION/DROPS; OPHTHALMIC

TOBRAMYCIN

>A>	@ APOTEX INC	0.3%	A065087	001	Feb 25, 2002	Apr	DISC
>D>	AT NOVEX	0.3%	A065087	001	Feb 25, 2002	Apr	DISC

TOLAZAMIDE

TABLET; ORAL

TOLAZAMIDE

	MYLAN PHARMS INC	250MG	A070259	001	Jan 02, 1986	Mar	CTEC
+		500MG	A070259	003	Mar 17, 1986	Mar	CTEC
	@ WATSON LABS	250MG	A070514	001	Jan 09, 1986	Mar	DISC
	@	500MG	A070515	001	Jan 09, 1986	Mar	DISC

TOPIRAMATE

TABLET; ORAL

TOPAMAX

>D>	AB + JANSSEN PHARMS	25MG	N020505	004	Dec 24, 1996	Apr	CRLD
>A>	AB	25MG	N020505	004	Dec 24, 1996	Apr	CRLD
>D>	AB	100MG	N020505	001	Dec 24, 1996	Apr	CRLD
>A>	AB +	100MG	N020505	001	Dec 24, 1996	Apr	CRLD

TOPIRAMATE

AB	ACTIVIS TOTOWA LLC	25MG	A078637	001	Feb 27, 2013	Feb	NEWA
AB		50MG	A078637	002	Feb 27, 2013	Feb	NEWA
AB		100MG	A078637	003	Feb 27, 2013	Feb	NEWA
AB		200MG	A078637	004	Feb 27, 2013	Feb	NEWA
AB	UNICHEM LABS LTD	200MG	A090162	004	Feb 19, 2013	Feb	NEWA

TORSEMIDE

TABLET; ORAL

TORSEMIDE

>D>	AB HETERO DRUGS	5MG	A079234	001	Jan 27, 2009	Apr	CAHN
>D>	AB	10MG	A079234	002	Jan 27, 2009	Apr	CAHN
>D>	AB	20MG	A079234	003	Jan 27, 2009	Apr	CAHN
>D>	AB	100MG	A079234	004	Jan 27, 2009	Apr	CAHN
>A>	AB HETERO LABS LTD III	5MG	A079234	001	Jan 27, 2009	Apr	CAHN
>A>	AB	10MG	A079234	002	Jan 27, 2009	Apr	CAHN
>A>	AB	20MG	A079234	003	Jan 27, 2009	Apr	CAHN
>A>	AB	100MG	A079234	004	Jan 27, 2009	Apr	CAHN

TRAMADOL HYDROCHLORIDE

TABLET; ORAL

TRAMADOL HYDROCHLORIDE

>A>	AB ACCORD HLTHCARE INC	50MG	A202390	001	May 16, 2013	Apr	NEWA
	AB CSPC OUYI PHARM CO	50MG	A091498	001	Mar 29, 2013	Mar	NEWA

TABLET, EXTENDED RELEASE; ORAL

RYZOLT

	@ PURDUE PHARMA	100MG	N021745	001	Dec 30, 2008	Jan	DISC
	@	200MG	N021745	002	Dec 30, 2008	Jan	DISC
	@	300MG	N021745	003	Dec 30, 2008	Jan	DISC

TRAMADOL HYDROCHLORIDE

>D>	AB2 ACTAVIS	100MG	A091609	001	Jun 27, 2012	Apr	CAHN
>D>	AB2	200MG	A091609	002	Jun 27, 2012	Apr	CAHN
>D>	AB2	300MG	A091609	003	Jun 27, 2012	Apr	CAHN
>A>	AB2 ACTAVIS ELIZABETH	100MG	A091609	001	Jun 27, 2012	Apr	CAHN
>A>	AB2	200MG	A091609	002	Jun 27, 2012	Apr	CAHN
>A>	AB2	300MG	A091609	003	Jun 27, 2012	Apr	CAHN

TABLET, EXTENDED RELEASE; ORAL

TRAMADOL HYDROCHLORIDE

AB1	PAR PHARM INC	100MG	A078783	001	Nov 13, 2009	Feb	CRLD
AB2	+ SUN PHARMA GLOBAL	100MG	A091607	001	Dec 30, 2011	Feb	CRLD

TRANDOLAPRIL

TABLET; ORAL

TRANDOLAPRIL

>D>	AB	DR REDDYS LABS LTD	1MG	A078493	001	Aug 25, 2008	Apr	DISC
>A>		@	1MG	A078493	001	Aug 25, 2008	Apr	DISC
>D>	AB		2MG	A078493	002	Aug 25, 2008	Apr	DISC
>A>		@	2MG	A078493	002	Aug 25, 2008	Apr	DISC
>D>	AB		4MG	A078493	003	Aug 25, 2008	Apr	DISC
>A>		@	4MG	A078493	003	Aug 25, 2008	Apr	DISC

TRAVOPROST

SOLUTION/DROPS; OPHTHALMIC

TRAVOPROST

PAR PHARM	0.004%	A091340	001	Mar 01, 2013	Feb	NEWA
-----------	--------	---------	-----	--------------	-----	------

TRAZODONE HYDROCHLORIDE

TABLET; ORAL

TRAZODONE HYDROCHLORIDE

AB	TEVA PHARMS USA	50MG	A071523	001	Dec 11, 1987	Mar	CAHN
AB		100MG	A071524	001	Dec 11, 1987	Mar	CAHN

TRETINOIN

GEL; TOPICAL

ATRALIN

>A>	+	DOW PHARM	0.05%	N022070	001	Jul 26, 2007	Apr	CAHN
>D>	+	DOW PHARM SCIENCES	0.05%	N022070	001	Jul 26, 2007	Apr	CAHN

TRIAMCINOLONE ACETONIDE

CREAM; TOPICAL

KENALOG

>D>	AT	+	APOTHECON	0.025%	N011601	003		Apr	DISC
>A>			@	0.025%	N011601	003		Apr	DISC
>D>	AT	+		0.1%	N011601	006		Apr	DISC
>A>			@	0.1%	N011601	006		Apr	DISC

TRACET

>D>	AT	TEVA	0.025%	A084908	001		Apr	DISC
>A>		@	0.025%	A084908	001		Apr	DISC
>D>	AT		0.5%	A084908	003		Apr	DISC
>A>		@	0.5%	A084908	003		Apr	DISC

TRIAMCINOLONE ACETONIDE

>D>	AT	FOUGERA PHARMS	0.025%	A085692	001		Apr	CRLD
>A>	AT	+	0.025%	A085692	001		Apr	CRLD
>D>	AT		0.1%	A085692	003		Apr	CRLD
>A>	AT	+	0.1%	A085692	003		Apr	CRLD
>D>	AT	TARO	0.025%	A086277	001		Apr	DISC
>A>		@	0.025%	A086277	001		Apr	DISC
>D>	AT		0.1%	A086276	001		Apr	DISC
>A>		@	0.1%	A086276	001		Apr	DISC
>D>	AT		0.5%	A086275	001		Apr	DISC
>A>		@	0.5%	A086275	001		Apr	DISC

LOTION; TOPICAL

TRIAMCINOLONE ACETONIDE

>D>	AT	+	MORTON GROVE	0.025%	A088450	001	Apr 01, 1985	Apr	CAHN
>A>	AT		VERSAPHARM INC	0.025%	A202374	001	May 08, 2013	Apr	NEWA
>A>	AT			0.1%	A202374	002	May 08, 2013	Apr	NEWA
>A>	AT	+	WOCKHARDT EU OPERATN	0.025%	A088450	001	Apr 01, 1985	Apr	CAHN

OINTMENT; TOPICAL

KENALOG

>D>	AT		APOTHECON	0.025%	N011600	003		Apr	DISC
>A>		@		0.025%	N011600	003		Apr	DISC
>D>	AT			0.1%	N011600	001		Apr	DISC
>A>		@		0.1%	N011600	001		Apr	DISC

URSODIOL

TABLET; ORAL

URSODIOL

	AB		PAR PHARM	250MG	A202540	001	Feb 14, 2013	Feb	NEWA
	AB			500MG	A202540	002	Feb 14, 2013	Feb	NEWA
>D>	AB		TEVA PHARMS	250MG	A079184	001	May 13, 2009	Apr	DISC
>D>	AB			500MG	A079184	002	May 13, 2009	Apr	DISC
>A>		@	TEVA PHARMS USA	250MG	A079184	001	May 13, 2009	Apr	DISC
>A>		@		500MG	A079184	002	May 13, 2009	Apr	DISC

VALACYCLOVIR HYDROCHLORIDE

TABLET; ORAL

VALACYCLOVIR HYDROCHLORIDE

	AB		ACTAVIS GRP PTC	EQ 500MG BASE	A090370	001	Mar 16, 2011	Mar	CAHN
	AB			EQ 1GM BASE	A090370	002	Mar 16, 2011	Mar	CAHN

VALPROIC ACID

CAPSULE; ORAL

VALPROIC ACID

	AB		SUN PHARM INDS LTD	250MG	A091037	001	Feb 22, 2013	Feb	NEWA
--	----	--	--------------------	-------	---------	-----	--------------	-----	------

VECURONIUM BROMIDE

INJECTABLE; INJECTION

VECURONIUM BROMIDE

>D>	AP		TEVA PARENTERAL	10MG/VIAL	A074688	001	Aug 25, 1999	Apr	CAHN
>D>	AP			20MG/VIAL	A074688	002	Aug 25, 1999	Apr	CAHN
>A>	AP		TEVA PHARMS USA	10MG/VIAL	A074688	001	Aug 25, 1999	Apr	CAHN
>A>	AP			20MG/VIAL	A074688	002	Aug 25, 1999	Apr	CAHN

VERAPAMIL HYDROCHLORIDE

INJECTABLE; INJECTION

VERAPAMIL HYDROCHLORIDE

	@	INTL MEDICATION	2.5MG/ML	A070451	001	Dec 16, 1985	Mar	DISC
--	---	-----------------	----------	---------	-----	--------------	-----	------

VERTEPORFIN

INJECTABLE; INJECTION

VISUDYNE

	+	VALEANT PHARMS INC	15MG/VIAL	N021119	001	Apr 12, 2000	Jan	CAHN
--	---	--------------------	-----------	---------	-----	--------------	-----	------

VINCRIStINE SULFATE

INJECTABLE; INJECTION

VINCRIStINE SULFATE PFS

>D>	AP	TEVA PARENTERAL	1MG/ML	A075493	001	Sep 01, 1999	Apr	CAHN
>A>	AP	TEVA PHARMS USA	1MG/ML	A075493	001	Sep 01, 1999	Apr	CAHN

VINORELBINE TARTRATE

INJECTABLE; INJECTION

VINORELBINE TARTRATE

>D>	AP	TEVA PARENTERAL	EQ 10MG BASE/ML	A076028	001	Feb 03, 2003	Apr	CAHN
>A>	AP	TEVA PHARMS USA	EQ 10MG BASE/ML	A076028	001	Feb 03, 2003	Apr	CAHN

WARFARIN SODIUM

TABLET; ORAL

WARFARIN SODIUM

AB		AMNEAL PHARMS	1MG	A202202	001	Mar 04, 2013	Feb	NEWA
AB			2MG	A202202	002	Mar 04, 2013	Feb	NEWA
AB			2.5MG	A202202	003	Mar 04, 2013	Feb	NEWA
AB			3MG	A202202	004	Mar 04, 2013	Feb	NEWA
AB			4MG	A202202	005	Mar 04, 2013	Feb	NEWA
AB			5MG	A202202	006	Mar 04, 2013	Feb	NEWA
AB			6MG	A202202	007	Mar 04, 2013	Feb	NEWA
AB			7.5MG	A202202	008	Mar 04, 2013	Feb	NEWA
AB			10MG	A202202	009	Mar 04, 2013	Feb	NEWA

ZALEPLON

CAPSULE; ORAL

SONATA

>D>	AB	KING PHARMS	5MG	N020859	001	Aug 13, 1999	Apr	CAHN
>D>	AB	+	10MG	N020859	002	Aug 13, 1999	Apr	CAHN
>A>	AB	PFIZER	5MG	N020859	001	Aug 13, 1999	Apr	CAHN
>A>	AB	+	10MG	N020859	002	Aug 13, 1999	Apr	CAHN

ZIDOVUDINE

TABLET; ORAL

RETROVIR

>D>	AB	+	VIIV HLTHCARE	300MG	N020518	002	Oct 04, 1996	Apr	DISC
>A>		@		300MG	N020518	002	Oct 04, 1996	Apr	DISC

ZIDOVUDINE

	AB	HEC PHARM USA INC	300MG	A202058	001	Oct 07, 2011	Feb	CMFD	
		@	300MG	A202058	001	Oct 07, 2011	Jan	DISC	
>D>	AB	HETERO DRUGS LTD	300MG	A090092	001	Apr 25, 2008	Apr	CRLD	
>A>	AB	+	HETERO LABS LTD III	300MG	A090092	001	Apr 25, 2008	Apr	CRLD

ZOLEDRONIC ACID

INJECTABLE; INJECTION

ZOLEDRONIC ACID

AP		DR REDDYS LABS LTD	EQ 5MG BASE/100ML	A091363	001	Mar 29, 2013	Mar	NEWA
AP		EMCURE PHARMS LTD	EQ 5MG BASE/100ML	A201801	001	Mar 29, 2013	Mar	NEWA

INJECTABLE; IV (INFUSION)

RECLAST

AP	+	NOVARTIS	EQ 5MG BASE/100ML	N021817	001	Apr 16, 2007	Mar	CTEC
----	---	----------	-------------------	---------	-----	--------------	-----	------

ZOLEDRONIC ACID

AP		ACTAVIS INC	EQ 4MG BASE/5ML	A202472	001	Mar 04, 2013	Feb	NEWA
----	--	-------------	-----------------	---------	-----	--------------	-----	------

INJECTABLE; IV (INFUSION)

ZOLEDRONIC ACID

AP	AGILA SPECLTS	EQ 4MG BASE/5ML	A202650	001	Mar 04, 2013	Feb	NEWA
AP	DR REDDYS LABS LTD	EQ 4MG BASE/5ML	A091186	001	Mar 04, 2013	Feb	NEWA
AP	EMCURE PHARMS LTD	EQ 4MG BASE/5ML	A201783	001	Mar 12, 2013	Mar	NEWA
AP	HOSPIRA INC	EQ 5MG BASE/100ML	A202837	001	Apr 05, 2013	Mar	NEWA
AP	PHARMACEUTICS	EQ 4MG BASE/5ML	A091170	001	Mar 04, 2013	Feb	NEWA
>A>	AP	PHARMS	A202571	001	May 07, 2013	Apr	NEWA
	+	SUN PHARMA GLOBAL	A090018	001	Mar 04, 2013	Feb	NEWA
AP		EQ 4MG BASE/5ML	A202746	001	Mar 04, 2013	Feb	NEWA
ZOMETA							
AP	+	NOVARTIS	N021223	002	Mar 07, 2003	Feb	CFTG

ZOLMITRIPTAN

TABLET; ORAL

>A>	ZOLMITRIPTAN							
>A>	AB	APOTEX INC	2.5MG	A202078	001	May 14, 2013	Apr	NEWA
>A>	AB		5MG	A202078	002	May 14, 2013	Apr	NEWA
>A>	AB	GLENMARK GENERICS	2.5MG	A201779	001	May 14, 2013	Apr	NEWA
>A>	AB		5MG	A201779	002	May 14, 2013	Apr	NEWA
>A>	AB	MYLAN PHARMS INC	2.5MG	A203186	001	May 14, 2013	Apr	NEWA
>A>	AB		5MG	A203186	002	May 14, 2013	Apr	NEWA
ZOMIG								
>D>		IPR	2.5MG	N020768	001	Nov 25, 1997	Apr	CFTG
>A>	AB		2.5MG	N020768	001	Nov 25, 1997	Apr	CFTG
>D>	+		5MG	N020768	002	Nov 25, 1997	Apr	CFTG
>A>	AB	+	5MG	N020768	002	Nov 25, 1997	Apr	CFTG
TABLET, ORALLY DISINTEGRATING; ORAL								
>A>	ZOLMITRIPTAN							
>A>	AB	APOTEX INC	2.5MG	A202476	001	May 14, 2013	Apr	NEWA
>A>	AB		5MG	A202476	002	May 14, 2013	Apr	NEWA
>A>	AB	GLENMARK GENERICS	2.5MG	A202560	001	May 14, 2013	Apr	NEWA
>A>	AB		5MG	A202560	002	May 14, 2013	Apr	NEWA
>A>	AB	ZYDUS PHARMS USA INC	2.5MG	A202890	001	May 15, 2013	Apr	NEWA
>A>	AB		5MG	A202890	002	May 15, 2013	Apr	NEWA
ZOMIG-ZMT								
>D>		ASTRAZENECA	2.5MG	N021231	001	Feb 13, 2001	Apr	CFTG
>A>	AB		2.5MG	N021231	001	Feb 13, 2001	Apr	CFTG
>D>	+		5MG	N021231	002	Sep 17, 2001	Apr	CFTG
>A>	AB	+	5MG	N021231	002	Sep 17, 2001	Apr	CFTG

ZOLPIDEM TARTRATE

TABLET; ORAL

ZOLPIDEM TARTRATE

>D>	AB	DR REDDYS LABS LTD	5MG	A077985	001	Apr 23, 2007	Apr	DISC
>A>		@	5MG	A077985	001	Apr 23, 2007	Apr	DISC
>D>	AB		10MG	A077985	002	Apr 23, 2007	Apr	DISC
>A>		@	10MG	A077985	002	Apr 23, 2007	Apr	DISC

TABLET, EXTENDED RELEASE; ORAL

ZOLPIDEM TARTRATE

>A>	AB	ACTAVIS ELIZABETH	6.25MG	A078179	002	Oct 13, 2010	Apr	CAHN
>A>	AB		12.5MG	A078179	001	Jun 06, 2011	Apr	CAHN
>D>	AB	ACTAVIS S ATLANTIC	6.25MG	A078179	002	Oct 13, 2010	Apr	CAHN
>D>	AB		12.5MG	A078179	001	Jun 06, 2011	Apr	CAHN
	AB	WATSON LABS INC FL	6.25MG	A090153	001	Mar 25, 2013	Mar	NEWA
	AB		12.5MG	A090153	002	Mar 25, 2013	Mar	NEWA

ZONISAMIDE

CAPSULE; ORAL

ZONISAMIDE

@ COREPHARMA	25MG	A077876 001	Feb 21, 2007	Feb	DISC
@	50MG	A077876 002	Feb 21, 2007	Feb	DISC
@	100MG	A077876 003	Feb 21, 2007	Feb	DISC
@ DR REDDYS LABS LTD	25MG	A077645 002	Sep 29, 2006	Mar	DISC
@	50MG	A077645 003	Sep 29, 2006	Mar	DISC
@	100MG	A077645 001	Dec 22, 2005	Mar	DISC

OTC DRUG PRODUCT LIST - 33RD EDITION

OTC DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 4 - April 2013

2-1

ASPIRIN

CAPSULE; ORAL

ASPIRIN

+	PLX PHARMA	325MG	N203697	001	Jan 14, 2013	Jan	NEWA
---	------------	-------	---------	-----	--------------	-----	------

CETIRIZINE HYDROCHLORIDE

SYRUP; ORAL

CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY

>D>	APOTEX	5MG/5ML	A090188	002	Apr 22, 2008	Apr	DISC
-----	--------	---------	---------	-----	--------------	-----	------

>A>	@ APOTEX INC	5MG/5ML	A090188	002	Apr 22, 2008	Apr	DISC
-----	--------------	---------	---------	-----	--------------	-----	------

CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF

>D>	APOTEX	5MG/5ML	A090188	001	Apr 22, 2008	Apr	DISC
-----	--------	---------	---------	-----	--------------	-----	------

>A>	@ APOTEX INC	5MG/5ML	A090188	001	Apr 22, 2008	Apr	DISC
-----	--------------	---------	---------	-----	--------------	-----	------

TABLET, CHEWABLE; ORAL

CETIRIZINE HYDROCHLORIDE ALLERGY

>D>	SANDOZ	10MG	A078692	002	Feb 14, 2008	Apr	CRLD
-----	--------	------	---------	-----	--------------	-----	------

>A>	+	10MG	A078692	002	Feb 14, 2008	Apr	CRLD
-----	---	------	---------	-----	--------------	-----	------

CHILDREN'S ZYRTEC ALLERGY

>D>	+	5MG	N021621	003	Nov 16, 2007	Apr	DISC
-----	---	-----	---------	-----	--------------	-----	------

>A>	@	5MG	N021621	003	Nov 16, 2007	Apr	DISC
-----	---	-----	---------	-----	--------------	-----	------

+

	@	10MG	N021621	004	Nov 16, 2007	Feb	DISC
--	---	------	---------	-----	--------------	-----	------

CHILDREN'S ZYRTEC HIVES RELIEF

>D>	+	5MG	N021621	005	Nov 16, 2007	Apr	DISC
-----	---	-----	---------	-----	--------------	-----	------

>A>	@	5MG	N021621	005	Nov 16, 2007	Apr	DISC
-----	---	-----	---------	-----	--------------	-----	------

+

	@	10MG	N021621	006	Nov 16, 2007	Feb	DISC
--	---	------	---------	-----	--------------	-----	------

CHLORHEXIDINE GLUCONATE

SOLUTION; TOPICAL

DYNA-HEX

>A>	BAJAJ MEDICAL LLC	0.75%	N020111	001	Sep 11, 1997	Apr	CAHN
-----	-------------------	-------	---------	-----	--------------	-----	------

>D>	XTTRIUM	0.75%	N020111	001	Sep 11, 1997	Apr	CAHN
-----	---------	-------	---------	-----	--------------	-----	------

CHLORHEXIDINE GLUCONATE; ISOPROPYL ALCOHOL

SWAB; TOPICAL

PREVANTICS MAXI SWABSTICK

+	PROF DSPLS	3.15%;70% (5.1ML)	N021524	003	Jun 03, 2005	Mar	CTNA
---	------------	-------------------	---------	-----	--------------	-----	------

PREVANTICS SWAB

+	PROF DSPLS	3.15%;70% (1ML)	N021524	001	Jun 03, 2005	Mar	CTNA
---	------------	-----------------	---------	-----	--------------	-----	------

PREVANTICS SWABSTICK

+	PROF DSPLS	3.15%;70% (1.6ML)	N021524	002	Jun 03, 2005	Mar	CTNA
---	------------	-------------------	---------	-----	--------------	-----	------

DEXBROMPHENIRAMINE MALEATE; PSEUDOEPHEDRINE SULFATE

TABLET, EXTENDED RELEASE; ORAL

DEXBROMPHENIRAMINE MALEATE AND PSEUDOEPHEDRINE SULFATE

	AVANTHI INC	6MG;120MG	A078648	001	Feb 27, 2013	Feb	NEWA
--	-------------	-----------	---------	-----	--------------	-----	------

FEXOFENADINE HYDROCHLORIDE

TABLET, ORALLY DISINTEGRATING; ORAL

CHILDREN'S FEXOFENADINE HYDROCHLORIDE ALLERGY

	DR REDDYS LABS LTD	30MG	A202978	001	Jan 18, 2013	Jan	NEWA
--	--------------------	------	---------	-----	--------------	-----	------

TABLET, ORALLY DISINTEGRATING; ORAL
 CHILDREN'S FEXOFENADINE HYDROCHLORIDE HIVES
 DR REDDYS LABS LTD 30MG

A202978 002 Jan 18, 2013 Jan NEWA

KETOTIFEN FUMARATE

SOLUTION/DROPS; OPHTHALMIC
 KETOTIFEN FUMARATE

>D>	APOTEX INC	EQ 0.025% BASE	A077354 001	May 09, 2006	Apr	DISC
>A>	@	EQ 0.025% BASE	A077354 001	May 09, 2006	Apr	DISC

LEVONORGESTREL

TABLET; ORAL
 LEVONORGESTREL

	LUPIN LTD	0.75MG	A091328 001	Jan 23, 2013	Jan	NEWA
AB	NOVEL LABS INC	1.5MG	A202508 001	Feb 22, 2013	Feb	NEWA
	PLAN B ONE-STEP					
>D>	+ DURAMED	1.5MG	N021998 001	Jul 10, 2009	Apr	CAHN
>A>	+ TEVA BRANDED PHARM	1.5MG	N021998 001	Jul 10, 2009	Apr	CAHN

LORATADINE

SYRUP; ORAL
 LORATADINE

>D>	APOTEX INC	1MG/ML	A075565 001	Oct 05, 2004	Apr	DISC
>A>	@	1MG/ML	A075565 001	Oct 05, 2004	Apr	DISC

LORATADINE; PSEUDOEPHEDRINE SULFATE

TABLET, EXTENDED RELEASE; ORAL
 LORATADINE AND PSEUDOEPHEDRINE SULFATE
 @ WATSON LABS INC FL 5MG;120MG

A076208 001 Jan 28, 2004 Feb DISC

MICONAZOLE NITRATE

CREAM; VAGINAL
 MICONAZOLE NITRATE
 APHENA PHARMA MD 2%

A074366 001 Feb 22, 1996 Jan CAHN

MINOXIDIL

SOLUTION; TOPICAL
 MINOXIDIL (FOR MEN)

>D>	NOVEX	2%	A074924 001	Apr 29, 1998	Apr	DISC
>A>	@	2%	A074924 001	Apr 29, 1998	Apr	DISC

MINOXIDIL (FOR WOMEN)

>A>	@ APOTEX INC	2%	A074924 002	Apr 29, 1998	Apr	DISC
>D>	NOVEX	2%	A074924 002	Apr 29, 1998	Apr	DISC

MINOXIDIL EXTRA STRENGTH (FOR MEN)

>A>	@ APOTEX INC	5%	A075839 001	Oct 01, 2001	Apr	DISC
>D>	NOVEX	5%	A075839 001	Oct 01, 2001	Apr	DISC

NAPHAZOLINE HYDROCHLORIDE; PHENIRAMINE MALEATE

SOLUTION/DROPS; OPHTHALMIC
 NAPHAZOLINE HYDROCHLORIDE AND PHENIRAMINE MALEATE
 AKORN INC 0.025%;0.3%

A202795 001 Jan 24, 2013 Jan NEWA

OXYBUTYNIN

FILM, EXTENDED RELEASE; TRANSDERMAL
OXYTROL FOR WOMEN

+ MSD CONSUMER 3.9MG/24HR N202211 001 Jan 25, 2013 Jan NEWA

POLYETHYLENE GLYCOL 3350

FOR SOLUTION; ORAL
POLYETHYLENE GLYCOL 3350

PAR PHARM 17GM/SCOOPFUL A079214 001 Jan 31, 2013 Jan NEWA

RANITIDINE HYDROCHLORIDE

TABLET; ORAL
RANITIDINE HYDROCHLORIDE

@ WATSON LABS EQ 75MG BASE A075212 001 Jan 14, 2000 Mar DISC

**DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT
ADMINISTERED BY THE CENTER FOR BIOLOGICS EVALUATION AND RESEARCH LIST**

CUMULATIVE SUPPLEMENT NUMBER 04 APRIL 2013

NO APRIL 2013 APPROVALS

ORPHAN PRODUCT DESIGNATIONS AND APPROVALS LIST

The list of List of Orphan Designations and Approvals is available at:

<http://www.fda.gov/orphan/designat/list.htm>

**DRUG PRODUCTS WHICH MUST DEMONSTRATE *IN VIVO* BIOAVAILABILITY
ONLY IF PRODUCT FAILS TO ACHIEVE ADEQUATE DISSOLUTION**

NO APRIL 2013 ADDITIONS

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 4 - April 2013

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ACETYLCYSTEINE - ACETADOTE</u>						
N021539 001	8399445	Aug 24, 2025	U-1373			
<u>ACYCLOVIR - SITAVIG</u>						
N203791 001					>A> NP	Apr 12, 2016
<u>ADAPALENE; BENZOYL PEROXIDE - EPIDUO</u>						
N022320 001					NPP	Feb 01, 2016
<u>ALOGLIPTIN BENZOATE - NESINA</u>						
N022271 001	6150383	Jun 19, 2016	U-1330		NCE	Jan 25, 2018
	6211205	Jun 19, 2016	U-1331			
	6303640	Aug 09, 2016	U-1332			
	6303661	Apr 24, 2017	U-1333			
	6329404	Jun 19, 2016	DP U-1334			
	6890898	Feb 02, 2019	U-1335			
	7078381	Feb 02, 2019	U-1335			
	7459428	Feb 02, 2019	U-1336			
	7807689	Jun 27, 2028	DS DP U-1337			
	8173663	Mar 15, 2025	U-1338			
	8288539	Mar 15, 2025	DS			
<u>ALOGLIPTIN BENZOATE - NESINA</u>						
N022271 002	6150383	Jun 19, 2016	U-1330		NCE	Jan 25, 2018
	6211205	Jun 19, 2016	U-1331			
	6303640	Aug 09, 2016	U-1332			
	6303661	Apr 24, 2017	U-1333			
	6329404	Jun 19, 2016	DP U-1334			
	6890898	Feb 02, 2019	U-1335			
	7078381	Feb 02, 2019	U-1335			
	7459428	Feb 02, 2019	U-1336			
	7807689	Jun 27, 2028	DS DP U-1337			
	8173663	Mar 15, 2025	U-1338			
	8288539	Mar 15, 2025	DS			
<u>ALOGLIPTIN BENZOATE - NESINA</u>						
N022271 003	6150383	Jun 19, 2016	U-1330		NCE	Jan 25, 2018
	6211205	Jun 19, 2016	U-1331			
	6303640	Aug 09, 2016	U-1332			
	6303661	Apr 24, 2017	U-1333			
	6329404	Jun 19, 2016	DP U-1334			
	6890898	Feb 02, 2019	U-1335			
	7078381	Feb 02, 2019	U-1335			
	7459428	Feb 02, 2019	U-1336			
	7807689	Jun 27, 2028	DS DP U-1337			
	8173663	Mar 15, 2025	U-1338			
	8288539	Mar 15, 2025	DS			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 4 - April 2013

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ALOGLIPTIN BENZOATE; METFORMIN HYDROCHLORIDE - KAZANO</u>						
N203414 001	5965584	Jun 19, 2016	U-1339		NCE	Jan 25, 2018
	6150383	Jun 19, 2016	U-1330		NC	Jan 25, 2016
	6150384	Jun 19, 2016	U-1340			
	6166042	Jun 19, 2016	U-1341			
	6166043	Jun 19, 2016	U-1342			
	6172090	Jun 19, 2016	U-1343			
	6211205	Jun 19, 2016	U-1331			
	6303640	Aug 09, 2016	U-1332			
	6303661	Apr 24, 2017	U-1333			
	6329404	Jun 19, 2016	U-1334			
	6890898	Feb 02, 2019	U-1335			
	7078381	Feb 02, 2019	U-1335			
	7459428	Feb 02, 2019	U-1336			
	7807689	Jun 27, 2028	DS DP U-1337			
	8173663	Mar 15, 2025	U-1338			
	8288539	Mar 15, 2025	DS			
<u>ALOGLIPTIN BENZOATE; METFORMIN HYDROCHLORIDE - KAZANO</u>						
N203414 002	5965584	Jun 19, 2016	U-1339		NCE	Jan 25, 2018
	6150383	Jun 19, 2016	U-1330		NC	Jan 25, 2016
	6150384	Jun 19, 2016	U-1340			
	6166042	Jun 19, 2016	U-1341			
	6166043	Jun 19, 2016	U-1342			
	6172090	Jun 19, 2016	U-1343			
	6211205	Jun 19, 2016	U-1331			
	6303640	Aug 09, 2016	U-1332			
	6303661	Apr 24, 2017	U-1333			
	6329404	Jun 19, 2016	U-1334			
	6890898	Feb 02, 2019	U-1335			
	7078381	Feb 02, 2019	U-1335			
	7459428	Feb 02, 2019	U-1336			
	7807689	Jun 27, 2028	DS DP U-1337			
	8173663	Mar 15, 2025	U-1338			
	8288539	Mar 15, 2025	DS			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 4 - April 2013

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE - OSENI</u>						
N022426 001	5965584	Jun 19, 2016	DP U-1339		NCE	Jan 25, 2018
	6150383	Jun 19, 2016	U-1330		NC	Jan 25, 2016
	6150384	Jun 19, 2016	U-1340			
	6166042	Jun 19, 2016	U-1341			
	6166043	Jun 19, 2016	U-1342			
	6172090	Jun 19, 2016	U-1343			
	6211205	Jun 19, 2016	U-1331			
	6271243	Jun 19, 2016	U-1344			
	6303640	Aug 09, 2016	U-1332			
	6303661	Apr 24, 2017	U-1333			
	6329404	Jun 19, 2016	DP U-1334			
	6890898	Feb 02, 2019	U-1335			
	7078381	Feb 02, 2019	U-1335			
	7459428	Feb 02, 2019	U-1336			
	7807689	Jun 27, 2028	DS DP U-1337			
	8173663	Mar 15, 2025	U-1338			
	8288539	Mar 15, 2025	DS			
<u>ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE - OSENI</u>						
N022426 002	5965584	Jun 19, 2016	DP U-1339		NCE	Jan 25, 2018
	6150383	Jun 19, 2016	U-1330		NC	Jan 25, 2016
	6150384	Jun 19, 2016	U-1340			
	6166042	Jun 19, 2016	U-1341			
	6166043	Jun 19, 2016	U-1342			
	6172090	Jun 19, 2016	U-1343			
	6211205	Jun 19, 2016	U-1331			
	6271243	Jun 19, 2016	U-1344			
	6303640	Aug 09, 2016	U-1332			
	6303661	Apr 24, 2017	U-1333			
	6329404	Jun 19, 2016	DP U-1334			
	6890898	Feb 02, 2019	U-1335			
	7078381	Feb 02, 2019	U-1335			
	7459428	Feb 02, 2019	U-1336			
	7807689	Jun 27, 2028	DS DP U-1337			
	8173663	Mar 15, 2025	U-1338			
	8288539	Mar 15, 2025	DS			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 4 - April 2013

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE - OSENI</u>						
N022426 003	5965584	Jun 19, 2016	DP U-1339		NCE	Jan 25, 2018
	6150383	Jun 19, 2016	U-1330		NC	Jan 25, 2016
	6150384	Jun 19, 2016	U-1340			
	6166042	Jun 19, 2016	U-1341			
	6166043	Jun 19, 2016	U-1342			
	6172090	Jun 19, 2016	U-1343			
	6211205	Jun 19, 2016	U-1331			
	6271243	Jun 19, 2016	U-1344			
	6303640	Aug 09, 2016	U-1332			
	6303661	Apr 24, 2017	U-1333			
	6329404	Jun 19, 2016	DP U-1334			
	6890898	Feb 02, 2019	U-1335			
	7078381	Feb 02, 2019	U-1335			
	7459428	Feb 02, 2019	U-1336			
	7807689	Jun 27, 2028	DS DP U-1337			
	8173663	Mar 15, 2025	U-1338			
	8288539	Mar 15, 2025	DS			
<u>ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE - OSENI</u>						
N022426 004	5965584	Jun 19, 2016	DP U-1339		NCE	Jan 25, 2018
	6150383	Jun 19, 2016	U-1330		NC	Jan 25, 2016
	6150384	Jun 19, 2016	U-1340			
	6166042	Jun 19, 2016	U-1341			
	6166043	Jun 19, 2016	U-1342			
	6172090	Jun 19, 2016	U-1343			
	6211205	Jun 19, 2016	U-1331			
	6271243	Jun 19, 2016	U-1344			
	6303640	Aug 09, 2016	U-1332			
	6303661	Apr 24, 2017	U-1333			
	6329404	Jun 19, 2016	DP U-1334			
	6890898	Feb 02, 2019	U-1335			
	7078381	Feb 02, 2019	U-1335			
	7459428	Feb 02, 2019	U-1336			
	7807689	Jun 27, 2028	DS DP U-1337			
	8173663	Mar 15, 2025	U-1338			
	8288539	Mar 15, 2025	DS			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 4 - April 2013

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE - OSENI</u>						
N022426 005	5965584	Jun 19, 2016	DP U-1339		NCE	Jan 25, 2018
	6150383	Jun 19, 2016	U-1330		NC	Jan 25, 2016
	6150384	Jun 19, 2016	U-1340			
	6166042	Jun 19, 2016	U-1341			
	6166043	Jun 19, 2016	U-1342			
	6172090	Jun 19, 2016	U-1343			
	6211205	Jun 19, 2016	U-1331			
	6271243	Jun 19, 2016	U-1344			
	6303640	Aug 09, 2016	U-1332			
	6303661	Apr 24, 2017	U-1333			
	6329404	Jun 19, 2016	DP U-1334			
	6890898	Feb 02, 2019	U-1335			
	7078381	Feb 02, 2019	U-1335			
	7459428	Feb 02, 2019	U-1336			
	7807689	Jun 27, 2028	DS DP U-1337			
	8173663	Mar 15, 2025	U-1338			
	8288539	Mar 15, 2025	DS			
<u>ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE - OSENI</u>						
N022426 006	5965584	Jun 19, 2016	DP U-1339		NCE	Jan 25, 2018
	6150383	Jun 19, 2016	U-1330		NC	Jan 25, 2016
	6150384	Jun 19, 2016	U-1340			
	6166042	Jun 19, 2016	U-1341			
	6166043	Jun 19, 2016	U-1342			
	6172090	Jun 19, 2016	U-1343			
	6211205	Jun 19, 2016	U-1331			
	6271243	Jun 19, 2016	U-1344			
	6303640	Aug 09, 2016	U-1332			
	6303661	Apr 24, 2017	U-1333			
	6329404	Jun 19, 2016	DP U-1334			
	6890898	Feb 02, 2019	U-1335			
	7078381	Feb 02, 2019	U-1335			
	7459428	Feb 02, 2019	U-1336			
	7807689	Jun 27, 2028	DS DP U-1337			
	8173663	Mar 15, 2025	U-1338			
	8288539	Mar 15, 2025	DS			
<u>AMBRISANTAN - LETAIRIS</u>						
N022081 001	>A> 8349843	Oct 07, 2015	DS DP			
<u>AMBRISANTAN - LETAIRIS</u>						
N022081 002	>A> 8349843	Oct 07, 2015	DS DP			
<u>AMOXICILLIN - MOXATAG</u>						
N050813 001	8357394	Dec 08, 2026	DP			
<u>APIXABAN - ELIQUIS</u>						
N202155 001	6413980	Dec 22, 2019	DS DP U-1200			
	6967208	Feb 03, 2023	DS DP U-1323			
	6967208	Feb 03, 2023	DS DP U-1200			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 4 - April 2013

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>APIXABAN - ELIQUIS</u>						
N202155 002	6413980	Dec 22, 2019	DS DP U-1200			
	6967208	Feb 03, 2023	DS DP U-1323			
	6967208	Feb 03, 2023	DS DP U-1200			
<u>ARIPIPRAZOLE - ABILIFY MAINTENA KIT</u>						
N202971 001	>A> 5006528	Apr 20, 2015	DS DP U-543		NDF	Feb 28, 2016
	>A> 7807680	Oct 19, 2024	DP			
	>A> 8030313	Oct 19, 2024	U-543			
	>A> 8338427	Mar 15, 2025	DP U-543			
	>A> 8338428	Aug 06, 2023	DP U-543			
	>A> 8399469	Dec 29, 2023	DS			
<u>ARIPIPRAZOLE - ABILIFY MAINTENA KIT</u>						
N202971 002	>A> 5006528	Apr 20, 2015	DS DP U-543		NDF	Feb 28, 2016
	>A> 7807680	Oct 19, 2024	DP			
	>A> 8030313	Oct 19, 2024	U-543			
	>A> 8338427	Mar 15, 2025	DP U-543			
	>A> 8338428	Aug 06, 2023	DP U-543			
	>A> 8399469	Dec 29, 2023	DS			
<u>AZTREONAM - CAYSTON</u>						
N050814 001	>A> 8399496	Dec 20, 2021	DP U-1377			
<u>BEDAQUILINE FUMARATE - SIRTURO</u>						
N204384 001	7498343	Oct 02, 2024	DS DP U-1321		ODE	Dec 28, 2019
<u>BEPOTASTINE BESILATE - BEPREVE</u>						
N022288 001	>A> 6780877	Sep 09, 2019	DS DP			
<u>BESIFLOXACIN HYDROCHLORIDE - BESIVANCE</u>						
N022308 001	>A> 8415342	Nov 07, 2030	U-80			
<u>BOCEPREVIR - VICTRELIS</u>						
N202258 001					M-126 NPP	Feb 27, 2016 Feb 13, 2016
<u>BRIMONIDINE TARTRATE; BRINZOLAMIDE - SIMBRINZA</u>						
N204251 001					>A> NC	Apr 19, 2016
<u>BRIMONIDINE TARTRATE; TIMOLOL MALEATE - COMBIGAN</u>						
N021398 001	8354409	Apr 19, 2022	DP U-1371			
<u>BROMFENAC SODIUM - PROLENSA</u>						
N203168 001	>A> 8129431	Sep 11, 2025	DS DP		>A> NP	Apr 05, 2016
<u>BROMOCRIPTINE MESYLATE - CYCLOSET</u>						
N020866 001	>A> 7888310	Jul 25, 2023	U-976			
	>A> 7888310	Jul 25, 2023	U-1379			
	>A> 8137992	Jul 25, 2023	U-1380			
	>A> 8137993	Jul 25, 2023	U-1379			
	>A> 8137994	Jul 25, 2023	U-1379			
	>A> 8431155	Apr 30, 2032	DP U-1379			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 4 - April 2013

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>BUDESONIDE - UCERIS</u>						
N203634 001	7410651	Jun 09, 2020	DP U-1325		NDF	Jan 14, 2016
	7431943	Jun 09, 2020	DP			
	8293273	Jun 09, 2020	DP			
	RE43799	Jun 09, 2020	DP U-1325			
<u>BUDESONIDE; FORMOTEROL FUMARATE DIHYDRATE - SYMBICORT</u>						
N021929 001	8387615	Nov 10, 2024	DP			
<u>BUDESONIDE; FORMOTEROL FUMARATE DIHYDRATE - SYMBICORT</u>						
N021929 002	8387615	Nov 10, 2024	DP			
<u>CABOZANTINIB S-MALATE - COMETRIQ</u>						
N203756 001					ODE	Nov 29, 2019
<u>CABOZANTINIB S-MALATE - COMETRIQ</u>						
N203756 002					ODE	Nov 29, 2019
<u>CALCITONIN SALMON RECOMBINANT - FORTICAL</u>						
N021406 001	>A> RE43580	Feb 02, 2021	DP U-227			
<u>CANAGLIFLOZIN - INVOKANA</u>						
N204042 001	>A> 7943582	Feb 26, 2029	DS DP U-493		NCE	Mar 29, 2018
	>A> 7943788	Jul 14, 2027	DS DP			
	>A> 8222219	Jul 30, 2024	U-493			
<u>CANAGLIFLOZIN - INVOKANA</u>						
N204042 002	>A> 7943582	Feb 26, 2029	DS DP U-493		NCE	Mar 29, 2018
	>A> 7943788	Jul 14, 2027	DS DP			
	>A> 8222219	Jul 30, 2024	U-493			
<u>CANDESARTAN CILEXETIL; HYDROCHLOROTHIAZIDE - CANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE</u>						
A090704 003					PC	Jun 02, 2013
<u>CARBINOXAMINE MALEATE - KARBINAL ER</u>						
N022556 001	>A> 8062667	Mar 29, 2029	DP			
<u>CELECOXIB - CELEBREX</u>						
N020998 001	RE44048	Jun 02, 2015	U-247			
	RE44048	Jun 02, 2015	U-1352			
	RE44048	Jun 02, 2015	U-1351			
	RE44048	Jun 02, 2015	U-1350			
	RE44048	Jun 02, 2015	U-1349			
	RE44048	Jun 02, 2015	U-1348			
	RE44048*PED	Dec 02, 2015				
<u>CELECOXIB - CELEBREX</u>						
N020998 002	RE44048	Jun 02, 2015	U-247			
	RE44048	Jun 02, 2015	U-1352			
	RE44048	Jun 02, 2015	U-1351			
	RE44048	Jun 02, 2015	U-1350			
	RE44048	Jun 02, 2015	U-1349			
	RE44048	Jun 02, 2015	U-1348			
	RE44048*PED	Dec 02, 2015				

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 4 - April 2013

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>CELECOXIB - CELEBREX</u>						
N020998 003	RE44048	Jun 02, 2015	U-247			
	RE44048	Jun 02, 2015	U-1352			
	RE44048	Jun 02, 2015	U-1351			
	RE44048	Jun 02, 2015	U-1350			
	RE44048	Jun 02, 2015	U-1349			
	RE44048	Jun 02, 2015	U-1348			
	RE44048*PED	Dec 02, 2015				
<u>CELECOXIB - CELEBREX</u>						
N020998 004	RE44048	Jun 02, 2015	U-247			
	RE44048	Jun 02, 2015	U-1352			
	RE44048	Jun 02, 2015	U-1351			
	RE44048	Jun 02, 2015	U-1350			
	RE44048	Jun 02, 2015	U-1349			
	RE44048	Jun 02, 2015	U-1348			
	RE44048*PED	Dec 02, 2015				
<u>CICLESONIDE - ALVESCO</u>						
N021658 002	8371292	Aug 25, 2027	U-1355		M-125	Dec 17, 2015
<u>CICLESONIDE - ALVESCO</u>						
N021658 003	8371292	Aug 25, 2027	U-1355		M-125	Dec 17, 2015
<u>CICLESONIDE - OMNARIS</u>						
N022004 001	8371292	Aug 25, 2027	U-1356			
	8383611	Oct 20, 2020	DP			
<u>CICLESONIDE - ZETONNA</u>						
N202129 001	8371292	Aug 25, 2027	U-1357			
<u>CLOBAZAM - ONFI</u>						
N203993 001					ODE	Oct 21, 2018
<u>CLOBETASOL PROPIONATE - CLOBETASOL PROPIONATE</u>						
A201402 001					PC	Jul 31, 2013
<u>COBICISTAT; ELVITEGRAVIR; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - STRIBILD</u>						
N203100 001	7635704	Oct 26, 2026	DS DP U-257			
<u>COLCHICINE - COLCRYS</u>						
N022352 001	>A> 8415395	Oct 06, 2028	U-1007			
	>A> 8415396	Oct 06, 2028	U-1007			
<u>CYSTEAMINE BITARTRATE - PROCYSBI</u>						
N203389 001					>A> NDF	Apr 30, 2016
<u>CYSTEAMINE BITARTRATE - PROCYSBI</u>						
N203389 002					>A> NDF	Apr 30, 2016
<u>DALFAMPRIDINE - AMPYRA</u>						
N022250 001	>A> 8354437	Dec 22, 2026	U-1030			
<u>DARUNAVIR ETHANOLATE - PREZISTA</u>						
N021976 001					D-135 PED	Feb 01, 2016 Aug 01, 2016
<u>DARUNAVIR ETHANOLATE - PREZISTA</u>						
N021976 002					D-135 PED	Feb 01, 2016 Aug 01, 2016

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 4 - April 2013

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DARUNAVIR ETHANOLATE - PREZISTA</u>						
N021976	003				D-135 PED	Feb 01, 2016 Aug 01, 2016
<u>DARUNAVIR ETHANOLATE - PREZISTA</u>						
N021976	004				D-135 PED	Feb 01, 2016 Aug 01, 2016
<u>DARUNAVIR ETHANOLATE - PREZISTA</u>						
N021976	005				D-135 PED	Feb 01, 2016 Aug 01, 2016
<u>DARUNAVIR ETHANOLATE - PREZISTA</u>						
N021976	006				D-135 PED	Feb 01, 2016 Aug 01, 2016
<u>DARUNAVIR ETHANOLATE - PREZISTA</u>						
N202895	001				D-135 PED	Feb 01, 2016 Aug 01, 2016
<u>DEFERASIROX - EXJADE</u>						
N021882	001				I-665	Jan 23, 2016
<u>DEFERASIROX - EXJADE</u>						
N021882	002				I-665	Jan 23, 2016
<u>DEFERASIROX - EXJADE</u>						
N021882	003				I-665	Jan 23, 2016
<u>DESOXIMETASONE - TOPICORT</u>						
N204141	001				>A> NDF	Apr 11, 2016
<u>DESVENLAFAXINE SUCCINATE - PRISTIQ</u>						
N021992	001	6673838	Feb 11, 2022	DS DP U-860		
		6673838	Feb 11, 2022	DS DP U-1364		
<u>DESVENLAFAXINE SUCCINATE - PRISTIQ</u>						
N021992	002	6673838	Feb 11, 2022	DS DP U-860		
		6673838	Feb 11, 2022	DS DP U-1364		
<u>DEXMEDETOMIDINE HYDROCHLORIDE - PRECEDEX</u>						
N021038	001	4910214	Jul 15, 2013	DS DP U-421		
		4910214*PED	Jan 15, 2014			
		6716867	Mar 31, 2019	U-572		
		6716867*PED	Oct 01, 2019			
<u>DIFLUPREDNATE - DUREZOL</u>						
N022212	001	6114319	May 18, 2019	DP	I-653 M-127 ODE PED PED	Jun 13, 2015 Mar 22, 2016 Jun 13, 2019 Dec 13, 2019 Sep 22, 2016
		6114319*PED	Nov 18, 2019		PED	Dec 13, 2015
<u>DIMETHYL FUMARATE - TECFIDERA</u>						
N204063	001	>A> 6509376	Oct 29, 2019	DP	NCE	Mar 27, 2018
		>A> 7320999	May 18, 2020	U-1384		
		>A> 7619001	Apr 01, 2018	U-1384		
		>A> 7803840	Apr 01, 2018	U-1385		
		>A> 8399514	Feb 07, 2028	U-1384		

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 4 - April 2013

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DIMETHYL FUMARATE - TECFIDERA</u>						
N204063 002	>A> 6509376	Oct 29, 2019	DP		NCE	Mar 27, 2018
	>A> 7320999	May 18, 2020	U-1384			
	>A> 7619001	Apr 01, 2018	U-1384			
	>A> 7803840	Apr 01, 2018	U-1385			
	>A> 8399514	Feb 07, 2028	U-1384			
<u>DOXYCYCLINE - ORACEA</u>						
N050805 001	>A> 8394405	Dec 24, 2025	DP U-925			
	8394406	Dec 24, 2025	DP U-925			
<u>DOXYCYCLINE HYCLATE - DORYX</u>						
N050795 005					>A> D-136	Apr 11, 2016
					>A> NS	Apr 11, 2016
<u>DOXYLAMINE SUCCINATE; PYRIDOXINE HYDROCHLORIDE - DICLEGIS</u>						
N021876 001	>A> 6340695	Jun 21, 2021	DP U-1382		>A> NP	Apr 08, 2016
	>A> 7560122	Jan 25, 2019	DP			
<u>DRONEDARONE HYDROCHLORIDE - MULTAQ</u>						
N022425 001	>A> 8410167	Apr 16, 2029	U-1388			
	>A> 8410167	Apr 16, 2029	U-1387			
<u>DROSPIRENONE; ETHINYL ESTRADIOL - YAZ</u>						
N021676 001	RE43916	Jun 30, 2014	U-1326			
<u>DROSPIRENONE; ETHINYL ESTRADIOL; LEVOMEFOLATE CALCIUM - BEYAZ</u>						
N022532 001	RE43916	Jun 30, 2014	U-1326			
<u>DULOXETINE HYDROCHLORIDE - CYMBALTA</u>						
N021427 001					M-61 PED	Oct 18, 2015 Apr 18, 2016
<u>DULOXETINE HYDROCHLORIDE - CYMBALTA</u>						
N021427 002					M-61 PED	Oct 18, 2015 Apr 18, 2016
<u>DULOXETINE HYDROCHLORIDE - CYMBALTA</u>						
N021427 004					M-61 PED	Oct 18, 2015 Apr 18, 2016
<u>EFAVIRENZ - SUSTIVA</u>						
N020972 001	5519021	May 21, 2013	DS DP			
	5519021*PED	Nov 21, 2013				
	5663169	Sep 02, 2014	U-257			
	5663169*PED	Mar 02, 2015				
	6238695	Apr 06, 2019	DP			
	6238695*PED	Oct 06, 2019				
	6555133	Apr 06, 2019	U-248			
	6555133*PED	Oct 06, 2019				
	6639071	Feb 14, 2018	DS			
	6639071*PED	Aug 14, 2018				
	6939964	Jan 20, 2018	DS			
	6939964*PED	Jul 20, 2018				

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 4 - April 2013

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>EFAVIRENZ - SUSTIVA</u>						
N020972 002	5519021	May 21, 2013	DS DP			
	5519021*PED	Nov 21, 2013				
	5663169	Sep 02, 2014			U-257	
	5663169*PED	Mar 02, 2015				
	6238695	Apr 06, 2019	DP			
	6238695*PED	Oct 06, 2019				
	6555133	Apr 06, 2019			U-248	
	6555133*PED	Oct 06, 2019				
	6639071	Feb 14, 2018	DS			
	6639071*PED	Aug 14, 2018				
	6939964	Jan 20, 2018	DS			
	6939964*PED	Jul 20, 2018				
<u>EFAVIRENZ - SUSTIVA</u>						
N020972 003	5519021	May 21, 2013	DS DP			
	5519021*PED	Nov 21, 2013				
	5663169	Sep 02, 2014			U-257	
	5663169*PED	Mar 02, 2015				
	6238695	Apr 06, 2019	DP			
	6238695*PED	Oct 06, 2019				
	6555133	Apr 06, 2019			U-248	
	6555133*PED	Oct 06, 2019				
	6639071	Feb 14, 2018	DS			
	6639071*PED	Aug 14, 2018				
	6939964	Jan 20, 2018	DS			
	6939964*PED	Jul 20, 2018				
<u>EFAVIRENZ - SUSTIVA</u>						
N021360 001	5519021	May 21, 2013				
	5519021*PED	Nov 21, 2013				
	5663169	Sep 02, 2014				
	5663169*PED	Mar 02, 2015				
	6639071	Feb 14, 2018	DS			
	6639071*PED	Aug 14, 2018				
	6939964	Jan 20, 2018	DS			
	6939964*PED	Jul 20, 2018				
<u>EFAVIRENZ - SUSTIVA</u>						
N021360 002	5519021	May 21, 2013	DS DP			
	5519021*PED	Nov 21, 2013				
	5663169	Sep 02, 2014			U-248	
	5663169*PED	Mar 02, 2015				
	6639071	Feb 14, 2018	DS			
	6639071*PED	Aug 14, 2018				
	6939964	Jan 20, 2018	DS			
	6939964*PED	Jul 20, 2018				

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 4 - April 2013

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>EFAVIRENZ; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - ATRIPLA</u>						
N021937 001	5519021	May 21, 2013	DS DP			
	5519021*PED	Nov 21, 2013				
	5663169	Sep 02, 2014		U-750		
	5663169	Sep 02, 2014		U-1170		
	5663169*PED	Mar 02, 2015				
	6639071	Feb 14, 2018	DS			
	6639071*PED	Aug 14, 2018				
	6939964	Jan 20, 2018	DS			
	6939964*PED	Jul 20, 2018				
<u>EPINEPHRINE - AUVI-Q</u>						
N201739 001	7731686	Jun 01, 2026	DP			
	7731690	Jan 15, 2025	DP			
	7749194	Oct 30, 2028	DP			
	7918823	Nov 23, 2024	DP			
	7947017	Mar 12, 2028	DP			
	8016788	Mar 21, 2025	DP			
	8206360	Feb 27, 2027	DP			
	8361029	Nov 23, 2024	DP			
<u>EPINEPHRINE - AUVI-Q</u>						
N201739 002	7731686	Jun 01, 2026	DP			
	7731690	Jan 15, 2025	DP			
	7749194	Oct 30, 2028	DP			
	7918823	Nov 23, 2024	DP			
	7947017	Mar 12, 2028	DP			
	8016788	Mar 21, 2025	DP			
	8206360	Feb 27, 2027	DP			
	8361029	Nov 23, 2024	DP			
<u>EPOPROSTENOL SODIUM - VELETRI</u>						
N022260 001	8318802	Mar 15, 2027	DP			
<u>EPOPROSTENOL SODIUM - VELETRI</u>						
N022260 002	8318802	Mar 15, 2027	DP			
<u>ESTRADIOL - MINIVELLE</u>						
N203752 001	5646286	Aug 12, 2014	DS DP			
	6024976	Jan 07, 2014	DS DP			
	8231906	May 24, 2030	DS DP			
<u>ESTRADIOL - MINIVELLE</u>						
N203752 002	5646286	Aug 12, 2014	DS DP			
	6024976	Jan 07, 2014	DS DP			
	8231906	May 24, 2030	DS DP			
<u>ESTRADIOL - MINIVELLE</u>						
N203752 003	5646286	Aug 12, 2014	DS DP			
	6024976	Jan 07, 2014	DS DP			
	8231906	May 24, 2030	DS DP			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 4 - April 2013

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ESTRADIOL - MINIVELLE</u>						
N203752 004	5646286	Aug 12, 2014	DS DP			
	6024976	Jan 07, 2014	DS DP			
	8231906	May 24, 2030	DS DP			
<u>ESZOPICLONE - LUNESTA</u>						
N021476 001					M-61 PED	Oct 10, 2015 Apr 10, 2016
<u>ESZOPICLONE - LUNESTA</u>						
N021476 002					M-61 PED	Oct 10, 2015 Apr 10, 2016
<u>ESZOPICLONE - LUNESTA</u>						
N021476 003					M-61 PED	Oct 10, 2015 Apr 10, 2016
<u>ETHINYL ESTRADIOL; LEVONORGESTREL - QUARTETTE</u>						
N204061 001	>A> 8415332	Mar 11, 2029	DP		NP	Mar 28, 2016
<u>ETHINYL ESTRADIOL; NORETHINDRONE ACETATE - MINASTRIN 24 FE</u>						
N204426 001	>A> 5552394	Jul 22, 2014	U-1			
	>A> 6652880	Mar 29, 2020	DP			
<u>EVEROLIMUS - AFINITOR</u>						
N022334 001	8410131	May 22, 2025	DS DP U-1368			
	8410131*PED	Nov 22, 2025				
<u>EVEROLIMUS - AFINITOR</u>						
N022334 002	8410131	May 22, 2025	DS DP U-1368			
	8410131*PED	Nov 22, 2025				
<u>EVEROLIMUS - AFINITOR</u>						
N022334 003	8410131	May 22, 2025	DS DP U-1368			
	8410131*PED	Nov 22, 2025				
<u>EVEROLIMUS - AFINITOR</u>						
N022334 004	8410131	May 22, 2025	DS DP U-1368			
	8410131*PED	Nov 22, 2025				
<u>EVEROLIMUS - ZORTRESS</u>						
N021560 001	5665772	Sep 09, 2019	DS DP U-1365		I-668	Feb 15, 2016
	5665772	Sep 09, 2019	DS DP U-1049			
	5665772*PED	Mar 09, 2020				
	6004973	Jul 12, 2016	DP U-1365			
	6004973	Jul 12, 2016	DP U-1049			
	6004973*PED	Jan 12, 2017				
	6440990	Sep 24, 2013	DP U-1365			
	6440990	Sep 24, 2013	DP U-1049			
	6440990*PED	Mar 24, 2014				
	6455518	Jul 29, 2017	U-1365			
	6455518	Jul 29, 2017	U-1049			
	6455518*PED	Jan 29, 2018				

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 4 - April 2013

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>EVEROLIMUS - ZORTRESS</u>						
N021560 002	5665772	Sep 09, 2019	DS DP U-1365		I-668	Feb 15, 2016
	5665772	Sep 09, 2019	DS DP U-1049			
	5665772*PED	Mar 09, 2020				
	6004973	Jul 12, 2016	DP U-1365			
	6004973	Jul 12, 2016	DP U-1049			
	6004973*PED	Jan 12, 2017				
	6440990	Sep 24, 2013	DP U-1365			
	6440990	Sep 24, 2013	DP U-1049			
	6440990*PED	Mar 24, 2014				
	6455518	Jul 29, 2017	U-1365			
	6455518	Jul 29, 2017	U-1049			
	6455518*PED	Jan 29, 2018				
<u>EVEROLIMUS - ZORTRESS</u>						
N021560 003	5665772	Sep 09, 2019	DS DP U-1365		I-668	Feb 15, 2016
	5665772	Sep 09, 2019	DS DP U-1049			
	5665772*PED	Mar 09, 2020				
	6004973	Jul 12, 2016	DP U-1365			
	6004973	Jul 12, 2016	DP U-1049			
	6004973*PED	Jan 12, 2017				
	6440990	Sep 24, 2013	DP U-1365			
	6440990	Sep 24, 2013	DP U-1049			
	6440990*PED	Mar 24, 2014				
	6455518	Jul 29, 2017	U-1365			
	6455518	Jul 29, 2017	U-1049			
	6455518*PED	Jan 29, 2018				
<u>FEBUXOSTAT - ULORIC</u>						
N021856 001	8372872	Sep 08, 2031	U-1346			
<u>FEBUXOSTAT - ULORIC</u>						
N021856 002	8372872	Sep 08, 2031	U-1346			
<u>FESOTERODINE FUMARATE - TOVIAZ</u>						
N022030 001	8338478	May 11, 2019	DS DP U-913			
<u>FESOTERODINE FUMARATE - TOVIAZ</u>						
N022030 002	8338478	May 11, 2019	DS DP U-913			
<u>FLUTICASONE FUROATE - VERAMYST</u>						
N022051 001	8347879	Apr 01, 2027	DP			
<u>FOLLITROPIN ALFA/BETA - FOLLISTIM AQ</u>						
N021211 001	5929028	Jan 14, 2018	DP U-567			
	5929028	Jan 14, 2018	DP U-1366			
	7563763	Aug 23, 2019	U-993			
	7563763	Aug 23, 2019	U-1367			
	7563763	Aug 23, 2019	U-1183			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 4 - April 2013

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>FOLLITROPIN ALFA/BETA - FOLLISTIM AQ</u>						
N021211 002	5929028	Jan 14, 2018	DP U-567			
	5929028	Jan 14, 2018	DP U-1366			
	7563763	Aug 23, 2019	U-993			
	7563763	Aug 23, 2019	U-1367			
	7563763	Aug 23, 2019	U-1183			
<u>FOLLITROPIN ALFA/BETA - FOLLISTIM AQ</u>						
N021211 003	5929028	Jan 14, 2018	DP U-567			
	5929028	Jan 14, 2018	DP U-1366			
	7563763	Aug 23, 2019	U-993			
	7563763	Aug 23, 2019	U-1367			
	7563763	Aug 23, 2019	U-1183			
<u>FOLLITROPIN ALFA/BETA - FOLLISTIM AQ</u>						
N021211 004	5929028	Jan 14, 2018	DP U-567			
	5929028	Jan 14, 2018	DP U-1366			
	7563763	Aug 23, 2019	U-993			
	7563763	Aug 23, 2019	U-1367			
	7563763	Aug 23, 2019	U-1183			
<u>FOLLITROPIN ALFA/BETA - FOLLISTIM AQ</u>						
N021273 001	5767251	Jun 16, 2015	DS			
	5929028	Jan 14, 2018	DP U-1366			
<u>FOLLITROPIN ALFA/BETA - FOLLISTIM AQ</u>						
N021273 002	5767251	Jun 16, 2015	DS			
	5929028	Jan 14, 2018	DP U-1366			
<u>GABAPENTIN - GRALISE</u>						
N022544 001	8333992	Oct 25, 2022	DP U-1114			
<u>GABAPENTIN - GRALISE</u>						
N022544 002	8333992	Oct 25, 2022	DP U-1114			
<u>GADOFOSVESET TRISODIUM - ABLAVAR</u>						
N021711 001	>A> 8394356	Feb 01, 2015	U-1112			
<u>GADOFOSVESET TRISODIUM - ABLAVAR</u>						
N021711 002	>A> 8394356	Feb 01, 2015	U-1112			
<u>GADOTERATE MEGLUMINE - DOTAREM</u>						
N204781 001					NCE	Mar 20, 2018
<u>GADOTERATE MEGLUMINE - DOTAREM</u>						
N204781 002					NCE	Mar 20, 2018
<u>GADOTERATE MEGLUMINE - DOTAREM</u>						
N204781 003					NCE	Mar 20, 2018
<u>GADOTERATE MEGLUMINE - DOTAREM</u>						
N204781 004					NCE	Mar 20, 2018
<u>GADOXETATE DISODIUM - EOVI</u>						
N022090 002					NCE	Jul 03, 2013
<u>GANIRELIX ACETATE - GANIRELIX ACETATE INJECTION</u>						
N021057 001	6653286	Jun 16, 2018	U-1354			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 4 - April 2013

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>GLATIRAMER ACETATE - COPAXONE</u>						
N020622 002	8367605	May 24, 2014	DS			
<u>GLYCEROL PHENYLBUTYRATE - RAVICTI</u>						
N203284 001	>A> 5968979	Feb 07, 2015	DS DP U-1378		NE	Feb 01, 2016
	>A> 8404215	Mar 09, 2032	U-1383		>A> ODE	Feb 01, 2020
<u>GLYCOPYRROLATE - ROBINUL</u>						
N012827 001	>A> 7091236	Apr 24, 2024	U-877	Y		
<u>GLYCOPYRROLATE - ROBINUL FORTE</u>						
N012827 002	>A> 7091236	Apr 24, 2024	U-877	Y		
<u>IBUPROFEN LYSINE - NEOPROFEN</u>						
N021903 001	>A> 8415337	Mar 02, 2032	DS DP			
<u>ICOSAPENT ETHYL - VASCEPA</u>						
N202057 001	8357677	Feb 09, 2030	U-1287			
	8367652	Feb 09, 2030	U-1287			
	8377920	Feb 09, 2030	U-1287			
	8399446	Feb 09, 2030	U-1287			
	8415335	Feb 09, 2030	U-1287			
	>A> 8426399	Feb 09, 2030	U-1287			
	>A> 8431560	Feb 09, 2030	U-1287			
	>A> 8440650	Feb 09, 2030	U-1287			
<u>IMATINIB MESYLATE - GLEEVEC</u>						
N021588 001	7544799	Jan 16, 2019	DS DP	Y	I-666	Jan 25, 2016
	RE43932	Jan 16, 2019	DS DP		ODE	Jan 25, 2020
	RE43932*PED	Jul 16, 2019				
<u>IMATINIB MESYLATE - GLEEVEC</u>						
N021588 002	7544799	Jan 16, 2019	DS DP	Y	I-666	Jan 25, 2016
	RE43932	Jan 16, 2019	DS DP		ODE	Jan 25, 2020
	RE43932*PED	Jul 16, 2019				
<u>INDACATEROL MALEATE - ARCAPTA NEOHALER</u>						
N022383 001	>A> 8067437	Jun 02, 2020	U-1168			
<u>INGENOL MEBUTATE - PICATO</u>						
N202833 001	8372827	Dec 18, 2026	DS DP			
	8372828	Dec 18, 2026	DS DP			
	8377919	Dec 18, 2026	DS DP			
<u>INGENOL MEBUTATE - PICATO</u>						
N202833 002	8372827	Dec 18, 2026	DS DP			
	8372828	Dec 18, 2026	DS DP			
	8377919	Dec 18, 2026	DS DP			
<u>IOBENGUANE SULFATE I-123 - ADREVIEW</u>						
N022290 001					I-669	Mar 20, 2016
<u>IRON SUCROSE - VENOFER</u>						
N021135 005					NPP	Sep 21, 2015
<u>ISOTRETINOIN - ABSORICA</u>						
N021951 001	8367102	Sep 21, 2021	U-1347			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 4 - April 2013

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ISOTRETINOIN - ABSORICA</u>						
N021951 002	8367102	Sep 21, 2021	U-1347			
<u>ISOTRETINOIN - ABSORICA</u>						
N021951 003	8367102	Sep 21, 2021	U-1347			
<u>ISOTRETINOIN - ABSORICA</u>						
N021951 004	8367102	Sep 21, 2021	U-1347			
<u>IVACAFTOR - KALYDECO</u>						
N203188 001	>A> 8410274	Dec 28, 2026	DP			
<u>KETOROLAC TROMETHAMINE - ACULAR LS</u>						
N021528 001	8377982	May 28, 2024	U-1363			
	8377982*PED	Nov 28, 2024				
<u>LENALIDOMIDE - REVLIMID</u>						
N021880 001	8404717	Apr 11, 2023	U-1215			
<u>LENALIDOMIDE - REVLIMID</u>						
N021880 002	8404717	Apr 11, 2023	U-1215			
<u>LENALIDOMIDE - REVLIMID</u>						
N021880 003	8404717	Apr 11, 2023	U-1215			
<u>LENALIDOMIDE - REVLIMID</u>						
N021880 004	8404717	Apr 11, 2023	U-1215			
<u>LENALIDOMIDE - REVLIMID</u>						
N021880 005	8404717	Apr 11, 2023	U-1215			
<u>LEVALBUTEROL HYDROCHLORIDE - LEVALBUTEROL HYDROCHLORIDE</u>						
A077756 001					PC	Feb 16, 2013
<u>LEVALBUTEROL HYDROCHLORIDE - LEVALBUTEROL HYDROCHLORIDE</u>						
A077756 002					PC	Feb 16, 2013
<u>LEVALBUTEROL HYDROCHLORIDE - LEVALBUTEROL HYDROCHLORIDE</u>						
A077756 003					PC	Feb 16, 2013
<u>LEVOLEUCOVORIN CALCIUM - FUSILEV</u>						
N020140 001	6500829	Mar 07, 2022	DS DP			
<u>LEVOLEUCOVORIN CALCIUM - FUSILEV</u>						
N020140 002	6500829	Mar 07, 2022	DS DP			
<u>LEVOLEUCOVORIN CALCIUM - FUSILEV</u>						
N020140 003	6500829	Mar 07, 2022	DS DP			
<u>LEVONORGESTREL - SKYLA</u>						
N203159 001	5785053	Dec 05, 2015	DP		NP	Jan 09, 2016
	7252839	Nov 13, 2023	DP			
<u>LOMITAPIDE MESYLATE - JUXTAPID</u>						
N203858 001	5712279	Feb 21, 2015	DS	U-1317		
	7932268	Aug 19, 2027		U-1316	ODE	Dec 21, 2019
<u>LOMITAPIDE MESYLATE - JUXTAPID</u>						
N203858 002	5712279	Feb 21, 2015	DS	U-1317		
	7932268	Aug 19, 2027		U-1316	ODE	Dec 21, 2019

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 4 - April 2013

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LOMITAPIDE MESYLATE - JUXTAPID</u>						
N203858 003	5712279	Feb 21, 2015	DS U-1317		ODE	Dec 21, 2019
	7932268	Aug 19, 2027	U-1316			
<u>LOPINAVIR; RITONAVIR - KALETRA</u>						
N021906 001	8025899	Dec 14, 2027	DP			
	8025899*PED	Jun 14, 2028				
	8377952	Oct 22, 2027	U-1372			
	8377952*PED	Apr 22, 2028				
	8399015	Aug 25, 2024	DP			
	8399015*PED	Feb 25, 2025				
<u>LOPINAVIR; RITONAVIR - KALETRA</u>						
N021906 002	8025899	Dec 14, 2027	DP			
	8025899*PED	Jun 14, 2028				
	8377952	Oct 22, 2027	U-1372			
	8377952*PED	Apr 22, 2028				
	8399015	Aug 25, 2024	DP			
	8399015*PED	Feb 25, 2025				
<u>LOTEPREDNOL ETABONATE - LOTEMAX</u>						
N202872 001	5800807	Jan 29, 2017	DP			
<u>LOXAPINE - ADASUVE</u>						
N022549 001	6716416	May 20, 2022	DP			
	7052679	Mar 20, 2022	DP			
	7078020	Oct 26, 2021	DP U-1375			
	7090830	Oct 26, 2021	DP			
	7458374	Aug 18, 2024	DP			
	7537009	Oct 26, 2021	DP			
	7585493	Oct 26, 2021	DP			
	7601337	Oct 26, 2021	DP			
	8074644	Oct 26, 2021	DP			
	8173107	Oct 26, 2021	DP			
	8235037	Oct 26, 2021	DP			
	8387612	Oct 23, 2026	DP			
<u>LUBIPROSTONE - AMITIZA</u>						
N021908 001	>A> 6414016	Sep 05, 2020	U-717		>A> I-670	Apr 19, 2016
	>A> 6414016	Sep 05, 2020	U-1392			
	>A> 6982283	Dec 04, 2022	U-1391			
	>A> 8026393	Oct 25, 2027	DP U-1391			
	>A> 8071613	Sep 05, 2020	U-1393			
	>A> 8071613	Sep 05, 2020	U-1203			
	>A> 8097653	Nov 14, 2022	U-1394			
	>A> 8097653	Nov 14, 2022	U-1214			
	>A> 8389542	Nov 14, 2022	DP U-1395			
	>A> 8389542	Nov 14, 2022	DP U-1345			
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N200603 001	>A> 5532372	Jul 02, 2018	DS			
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N200603 002	>A> 5532372	Jul 02, 2018	DS			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 4 - April 2013

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N200603 003	>A> 5532372	Jul 02, 2018	DS			
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N200603 004	>A> 5532372	Jul 02, 2018	DS			
<u>MAGNESIUM SULFATE; POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; POTASSIUM SULFATE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM SULFATE - SUCLEAR</u>						
N203595 001					NC	Jan 18, 2016
<u>MEMANTINE HYDROCHLORIDE - NAMENDA XR</u>						
N022525 001	>A> 8168209	Nov 22, 2025	DP			
	>A> 8173708	Nov 22, 2025	U-539			
	>A> 8283379	Nov 22, 2025	U-539			
	>A> 8329752	Nov 22, 2025	DP			
	>A> 8362085	Nov 22, 2025	U-539			
<u>MEMANTINE HYDROCHLORIDE - NAMENDA XR</u>						
N022525 002	>A> 8168209	Nov 22, 2025	DP			
	>A> 8173708	Nov 22, 2025	U-539			
	>A> 8283379	Nov 22, 2025	U-539			
	>A> 8329752	Nov 22, 2025	DP			
	>A> 8362085	Nov 22, 2025	U-539			
<u>MEMANTINE HYDROCHLORIDE - NAMENDA XR</u>						
N022525 003	>A> 8168209	Nov 22, 2025	DP			
	>A> 8173708	Nov 22, 2025	U-539			
	>A> 8283379	Nov 22, 2025	U-539			
	>A> 8329752	Nov 22, 2025	DP			
	>A> 8362085	Nov 22, 2025	U-539			
<u>MEMANTINE HYDROCHLORIDE - NAMENDA XR</u>						
N022525 004	>A> 8168209	Nov 22, 2025	DP			
	>A> 8173708	Nov 22, 2025	U-539			
	>A> 8283379	Nov 22, 2025	U-539			
	>A> 8329752	Nov 22, 2025	DP			
	>A> 8362085	Nov 22, 2025	U-539			
<u>MESALAMINE - DELZICOL</u>						
N204412 001	>A> 5541170	Jul 30, 2013	DP U-141			
	>A> 5541171	Jul 30, 2013	DP U-141			
<u>METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE - JANUMET</u>						
N022044 001	>A> 7459428	Feb 02, 2019	U-1036			
	>A> 8414921	Jul 21, 2028	DP U-1036			
<u>METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE - JANUMET</u>						
N022044 002	>A> 7459428	Feb 02, 2019	U-1036			
	>A> 8414921	Jul 21, 2028	DP U-1036			
<u>METHYLNALTREXONE BROMIDE - RELISTOR</u>						
N021964 001	>A> 8420663	Sep 30, 2029	U-1185			
<u>METHYLNALTREXONE BROMIDE - RELISTOR</u>						
N021964 002	>A> 8420663	Sep 30, 2029	U-1185			
<u>METHYLNALTREXONE BROMIDE - RELISTOR</u>						
N021964 003	>A> 8420663	Sep 30, 2029	U-1185			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 4 - April 2013

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>METHYLPHENIDATE HYDROCHLORIDE - QUILLIVANT XR</u>						
N202100 001	8062667	Mar 29, 2029	DP			
	8287903	Feb 15, 2031	DP			
<u>MINOCYCLINE HYDROCHLORIDE - XIMINO</u>						
N201922 001	>A> 5908838	Feb 19, 2018	U-1376			
	>A> 7541347	Apr 02, 2027	U-917			
	>A> 7544373	Apr 02, 2027	DP			
	>A> 7790705	Jun 24, 2025	U-124			
	>A> 7919483	Mar 07, 2027	U-124			
	>A> 8252776	Jun 24, 2025	U-124			
	>A> 8268804	Jun 24, 2025	U-124			
<u>MINOCYCLINE HYDROCHLORIDE - XIMINO</u>						
N201922 003	>A> 5908838	Feb 19, 2018	U-1376			
	>A> 7541347	Apr 02, 2027	U-917			
	>A> 7544373	Apr 02, 2027	DP			
	>A> 7790705	Jun 24, 2025	U-124			
	>A> 7919483	Mar 07, 2027	U-124			
	>A> 8252776	Jun 24, 2025	U-124			
	>A> 8268804	Jun 24, 2025	U-124			
<u>MINOCYCLINE HYDROCHLORIDE - XIMINO</u>						
N201922 005	>A> 5908838	Feb 19, 2018	U-1376			
	>A> 7541347	Apr 02, 2027	U-917			
	>A> 7544373	Apr 02, 2027	DP			
	>A> 7790705	Jun 24, 2025	U-124			
	>A> 7919483	Mar 07, 2027	U-124			
	>A> 8252776	Jun 24, 2025	U-124			
	>A> 8268804	Jun 24, 2025	U-124			
<u>MIPOMERSEN SODIUM - KYNAMRO</u>						
N203568 001	5914396	Jun 22, 2016	DS		NCE	Jan 29, 2018
	6166197	Dec 26, 2017	DS		ODE	Jan 29, 2020
	6222025	Mar 06, 2015	DS			
	6451991	Feb 11, 2017	DS			
	7015315	Mar 21, 2023	DS			
	7101993	Sep 05, 2023	DS			
	7407943	Aug 01, 2021	U-1353			
	7511131	Dec 13, 2025	DS			
<u>MOMETASONE FUROATE - ELOCON</u>						
N019625 002				>A> NP		Apr 19, 2016
<u>MUPIROCIN CALCIUM - BACTROBAN</u>						
N050703 001	5569672	Oct 29, 2013	U-1358			
<u>MUPIROCIN CALCIUM - BACTROBAN</u>						
N050746 001	5569672	Oct 29, 2013	U-1358			
<u>NEPAFENAC - NEPAFENAC</u>						
N203491 001	5475034	Jun 06, 2014	U-100			
	6403609	Jul 17, 2018	DP			
	7947295	Jun 08, 2024	DP			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 4 - April 2013

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>NILOTINIB HYDROCHLORIDE MONOHYDRATE - TASIGNA</u>						
N022068 001	8389537	Jul 18, 2026	DS DP U-1374			
<u>NILOTINIB HYDROCHLORIDE MONOHYDRATE - TASIGNA</u>						
N022068 002	8389537	Jul 18, 2026	DS DP U-1374			
<u>NITRIC OXIDE - INOMAX</u>						
N020845 002	>A> 8431163	Jun 30, 2029	U-1286			
	>A> 8431163*PED	Dec 30, 2029				
<u>NITRIC OXIDE - INOMAX</u>						
N020845 003	>A> 8431163	Jun 30, 2029	U-1286			
	>A> 8431163*PED	Dec 30, 2029				
<u>OLOPATADINE HYDROCHLORIDE - PATANASE</u>						
N021861 001	8399508	Sep 17, 2022	U-726			
	8399508*PED	Mar 17, 2023				
<u>OMEPRAZOLE; SODIUM BICARBONATE - ZEGERID OTC</u>						
N022281 001	>A> 6489346	Jul 15, 2016	DP U-1025	Y		
	>A> 6645988	Jul 15, 2016	DP	Y		
	>A> 6699885	Jul 15, 2016	DP	Y		
<u>OSELTAMIVIR PHOSPHATE - TAMIFLU</u>						
N021087 001					NPP	Dec 21, 2015
<u>OSELTAMIVIR PHOSPHATE - TAMIFLU</u>						
N021087 002					NPP	Dec 21, 2015
<u>OSELTAMIVIR PHOSPHATE - TAMIFLU</u>						
N021087 003					NPP	Dec 21, 2015
<u>OSELTAMIVIR PHOSPHATE - TAMIFLU</u>						
N021246 001					NPP	Dec 21, 2015
<u>OSELTAMIVIR PHOSPHATE - TAMIFLU</u>						
N021246 002					NPP	Dec 21, 2015
<u>OSPEMIFENE - OSPHENA</u>						
N203505 001	6245819	Jul 21, 2020	U-1369		NCE	Feb 26, 2018
	>A> 8236861	Aug 11, 2026	U-1370			
	>A> 8236861	Aug 11, 2026	U-1369			
<u>OXYBUTYNIN - OXYTROL FOR WOMEN</u>						
N202211 001	5601839	Apr 26, 2015	DP U-1329		NP	Jan 25, 2016
	5834010	Apr 26, 2015	DP U-1329			
	6743441	Apr 26, 2020	DP U-1329			
	7081249	Apr 26, 2020	DP U-1329			
	7081250	Apr 26, 2020	DP U-1329			
	7081251	Apr 26, 2020	DP U-1329			
	7081252	Apr 26, 2020	DP U-1329			
	7179483	Apr 26, 2020	U-1329			
<u>OXYCODONE HYDROCHLORIDE - OXECTA</u>						
N202080 001	>A> 8409616	Nov 26, 2023	DP			
<u>OXYCODONE HYDROCHLORIDE - OXECTA</u>						
N202080 002	>A> 8409616	Nov 26, 2023	DP			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 4 - April 2013

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>OXYMORPHONE HYDROCHLORIDE - OXYMORPHONE HYDROCHLORIDE</u>						
A079087	006				>A> PC	Jul 07, 2013
<u>PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - CREON</u>						
N020725	005				M-93 NCE	Jul 29, 2019 Apr 30, 2014
<u>PLERIXAFOR - MOZOBIL</u>						
N022311	001	RE42152	Dec 10, 2018	DP		
<u>POMALIDOMIDE - POMALYST</u>						
N204026	001	5635517	Jul 24, 2016	U-1359	NCE	Feb 08, 2018
		6045501	Aug 28, 2018	U-1361	ODE	Feb 08, 2020
		6315720	Oct 23, 2020	U-1361		
		6316471	Aug 10, 2016	DP U-1360		
		6476052	Jul 24, 2016	DP U-1360		
		6561976	Aug 28, 2018	U-1361		
		6561977	Oct 23, 2020	U-1361		
		6755784	Oct 23, 2020	U-1361		
		6908432	Aug 28, 2018	U-1361		
		8158653	Aug 10, 2016	DP		
		8198262	Oct 19, 2024	U-1360		
		8204763	Aug 28, 2018	U-1361		
		8315886	Oct 23, 2020	U-1361		
<u>POMALIDOMIDE - POMALYST</u>						
N204026	002	5635517	Jul 24, 2016	U-1359	NCE	Feb 08, 2018
		6045501	Aug 28, 2018	U-1361	ODE	Feb 08, 2020
		6315720	Oct 23, 2020	U-1361		
		6316471	Aug 10, 2016	DP U-1360		
		6476052	Jul 24, 2016	DP U-1360		
		6561976	Aug 28, 2018	U-1361		
		6561977	Oct 23, 2020	U-1361		
		6755784	Oct 23, 2020	U-1361		
		6908432	Aug 28, 2018	U-1361		
		8158653	Aug 10, 2016	DP		
		8198262	Oct 19, 2024	U-1360		
		8204763	Aug 28, 2018	U-1361		
		8315886	Oct 23, 2020	U-1361		
<u>POMALIDOMIDE - POMALYST</u>						
N204026	003	5635517	Jul 24, 2016	U-1359	NCE	Feb 08, 2018
		6045501	Aug 28, 2018	U-1361	ODE	Feb 08, 2020
		6315720	Oct 23, 2020	U-1361		
		6316471	Aug 10, 2016	DP U-1360		
		6476052	Jul 24, 2016	DP U-1360		
		6561976	Aug 28, 2018	U-1361		
		6561977	Oct 23, 2020	U-1361		
		6755784	Oct 23, 2020	U-1361		
		6908432	Aug 28, 2018	U-1361		
		8158653	Aug 10, 2016	DP		
		8198262	Oct 19, 2024	U-1360		
		8204763	Aug 28, 2018	U-1361		
		8315886	Oct 23, 2020	U-1361		

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 4 - April 2013

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>POMALIDOMIDE - POMALYST</u>						
N204026 004	5635517	Jul 24, 2016	U-1359		NCE	Feb 08, 2018
	6045501	Aug 28, 2018	U-1361		ODE	Feb 08, 2020
	6315720	Oct 23, 2020	U-1361			
	6316471	Aug 10, 2016	DP U-1360			
	6476052	Jul 24, 2016	DP U-1360			
	6561976	Aug 28, 2018	U-1361			
	6561977	Oct 23, 2020	U-1361			
	6755784	Oct 23, 2020	U-1361			
	6908432	Aug 28, 2018	U-1361			
	8158653	Aug 10, 2016	DP			
	8198262	Oct 19, 2024	U-1360			
	8204763	Aug 28, 2018	U-1361			
	8315886	Oct 23, 2020	U-1361			
<u>PONATINIB HYDROCHLORIDE - ICLUSIG</u>						
N203469 001					ODE	Dec 14, 2019
<u>PONATINIB HYDROCHLORIDE - ICLUSIG</u>						
N203469 002					ODE	Dec 14, 2019
<u>PRALATREXATE - FOLOTYN</u>						
N022468 001	6028071	Jul 16, 2022	DS DP U-1004			
<u>PRALATREXATE - FOLOTYN</u>						
N022468 002	6028071	Jul 16, 2022	DS DP U-1004			
<u>PRASUGREL HYDROCHLORIDE - EFFIENT</u>						
N022307 001	>A> 8404703	Mar 02, 2022	U-1381			
<u>PRASUGREL HYDROCHLORIDE - EFFIENT</u>						
N022307 002	>A> 8404703	Mar 02, 2022	U-1381			
<u>PREDNISONE - RAYOS</u>						
N202020 001	8394407	Apr 23, 2024	DP U-1362		>A> M-128	Jul 26, 2015
<u>PREDNISONE - RAYOS</u>						
N202020 002	8394407	Apr 23, 2024	DP U-1362		>A> M-128	Jul 26, 2015
<u>PREDNISONE - RAYOS</u>						
N202020 003	8394407	Apr 23, 2024	DP U-1362		>A> M-128	Jul 26, 2015
<u>PREGABALIN - LYRICA</u>						
N022488 001					I-651	Jun 20, 2015
<u>RABEPRAZOLE SODIUM - ACIPHEX SPRINKLE</u>						
N204736 001	>A> 5045552	May 08, 2013	DS DP U-385		NDF	Mar 26, 2016
	>A> 5045552*PED	Nov 08, 2013			PED	Sep 26, 2016
<u>RABEPRAZOLE SODIUM - ACIPHEX SPRINKLE</u>						
N204736 002	>A> 5045552	May 08, 2013	DS DP U-385		NDF	Mar 26, 2016
	>A> 5045552*PED	Nov 08, 2013			PED	Sep 26, 2016
<u>REGORAFENIB - STIVARGA</u>						
N203085 001					I-667 ODE	Feb 25, 2016 Feb 25, 2020

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 4 - April 2013

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>RITONAVIR - NORVIR</u>						
N022417 001	>A> 8399015	Aug 25, 2024	DP			
	>A> 8399015*PED	Feb 25, 2025				
<u>RIZATRIPTAN BENZOATE - RIZATRIPTAN BENZOATE</u>						
A078173 001					PC	Jun 29, 2013
<u>RIZATRIPTAN BENZOATE - RIZATRIPTAN BENZOATE</u>						
A078173 002					PC	Jun 29, 2013
<u>ROPIVACAINE HYDROCHLORIDE - NAROPIN</u>						
N020533 001	5670524	Sep 23, 2014	DS DP U-833			
<u>ROPIVACAINE HYDROCHLORIDE - NAROPIN</u>						
N020533 003	5670524	Sep 23, 2014	DS DP U-833			
<u>ROPIVACAINE HYDROCHLORIDE - NAROPIN</u>						
N020533 004	5670524	Sep 23, 2014	DS DP U-833			
<u>ROPIVACAINE HYDROCHLORIDE - NAROPIN</u>						
N020533 005	5670524	Sep 23, 2014	DS DP U-833			
<u>RUXOLITINIB PHOSPHATE - JAKAFI</u>						
N202192 001	>A> 8415362	Dec 24, 2027	DS DP			
<u>RUXOLITINIB PHOSPHATE - JAKAFI</u>						
N202192 002	>A> 8415362	Dec 24, 2027	DS DP			
<u>RUXOLITINIB PHOSPHATE - JAKAFI</u>						
N202192 003	>A> 8415362	Dec 24, 2027	DS DP			
<u>RUXOLITINIB PHOSPHATE - JAKAFI</u>						
N202192 004	>A> 8415362	Dec 24, 2027	DS DP			
<u>RUXOLITINIB PHOSPHATE - JAKAFI</u>						
N202192 005	>A> 8415362	Dec 24, 2027	DS DP			
<u>SAPROPTERIN DIHYDROCHLORIDE - KUVAN</u>						
N022181 001	8318745	Nov 17, 2024	DP			
<u>SAQUINAVIR MESYLATE - INVIRASE</u>						
N020628 001					M-61 PED	Nov 30, 2015 May 30, 2016
<u>SAQUINAVIR MESYLATE - INVIRASE</u>						
N021785 001					M-61 PED	Nov 30, 2015 May 30, 2016
<u>SUMATRIPTAN SUCCINATE - SUMAVEL DOSEPRO</u>						
N022239 001	8343130	Oct 18, 2022	DP			
<u>SUMATRIPTAN SUCCINATE - ZECUITY</u>						
N202278 001	6745071	Feb 21, 2023	DP		NDF	Jan 17, 2016
	7973058	Apr 12, 2027		U-1328		
	8155737	Apr 12, 2027		U-1328		
	8366600	Apr 21, 2029		U-1327		
<u>TAPENTADOL HYDROCHLORIDE - NUCYNTA ER</u>						
N200533 001	8114383	Oct 10, 2024	DP		Y	
	>A> 8420056	Nov 20, 2023	DP			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 4 - April 2013

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TAPENTADOL HYDROCHLORIDE - NUCYNTA ER</u>						
N200533 002	8114383	Oct 10, 2024	DP	Y		
	>A> 8420056	Nov 20, 2023	DP			
<u>TAPENTADOL HYDROCHLORIDE - NUCYNTA ER</u>						
N200533 003	8114383	Oct 10, 2024	DP	Y		
	>A> 8420056	Nov 20, 2023	DP			
<u>TAPENTADOL HYDROCHLORIDE - NUCYNTA ER</u>						
N200533 004	8114383	Oct 10, 2024	DP	Y		
	>A> 8420056	Nov 20, 2023	DP			
<u>TAPENTADOL HYDROCHLORIDE - NUCYNTA ER</u>						
N200533 005	8114383	Oct 10, 2024	DP	Y		
	>A> 8420056	Nov 20, 2023	DP			
<u>TECHNETIUM TC-99M TILMANOCEPT - LYMPHOSEEK KIT</u>						
N202207 001					NCE	Mar 13, 2018
<u>TEDUGLUTIDE - GATTEX KIT</u>						
N203441 001	5789379	Apr 14, 2015	DS DP U-1320		ODE	Dec 21, 2019
	7056886	Sep 18, 2022	DP U-1320			
	7847061	Nov 01, 2025	U-1320			
<u>TELAVANCIN HYDROCHLORIDE - VIBATIV</u>						
N022110 001	>A> 6635618	Sep 11, 2023	DS DP U-728			
<u>TELAVANCIN HYDROCHLORIDE - VIBATIV</u>						
N022110 002	>A> 6635618	Sep 11, 2023	DS DP U-728			
<u>TELBIVUDINE - TYZEKA</u>						
N022011 001					M-124	Jan 28, 2016
<u>TELBIVUDINE - TYZEKA</u>						
N022154 001					M-124	Jan 28, 2016
<u>TESTOSTERONE - AXIRON</u>						
N022504 001	>A> 8419307	Feb 26, 2027	U-1386			
	>A> 8435944	Jul 05, 2027	U-1390			
<u>TESTOSTERONE - TESTOSTERONE</u>						
N203098 001					NP	Jan 31, 2016
<u>TESTOSTERONE - TESTOSTERONE</u>						
N203098 002					NP	Jan 31, 2016
<u>TESTOSTERONE - TESTOSTERONE</u>						
N203098 003					NP	Jan 31, 2016
<u>TIGECYCLINE - TYGACIL</u>						
N021821 001	8372995	Oct 08, 2030	DP			
<u>TOBRAMYCIN - BETHKIS</u>						
N201820 001	6987094	Sep 22, 2022	DP			
	7696178	Mar 17, 2023	DP			
	7939502	Jun 14, 2022	U-1324			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 4 - April 2013

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TOBRAMYCIN - TOBI PODHALER</u>						
N201688 001	>A> 7097827	Jun 27, 2021	DP		NP	Mar 22, 2016
	>A> 7368102	Dec 19, 2022	DP U-909			
	>A> 7442388	May 10, 2020	DP			
	>A> 7516741	Jan 11, 2024	DP			
	>A> 7559325	Oct 27, 2025	DP			
	>A> 8069851	Sep 24, 2024	DP			
	>A> 8349294	May 10, 2020	DP			
<u>TOLTERODINE TARTRATE - DETROL LA</u>						
N021228 001	>A> 6911217	Nov 11, 2019	DP U-544			
	>A> 6911217*PED	May 11, 2020	DP U-544			
<u>TRANEXAMIC ACID - TRANEXAMIC ACID</u>						
A202093 001					PC	Jul 02, 2013
<u>TRAVOPROST - TRAVATAN Z</u>						
N021994 001	8388941	Sep 20, 2027	DP			
<u>TROSPIUM CHLORIDE - TROSPIUM CHLORIDE</u>						
A091289 001					PC	Apr 10, 2013
<u>ULIPRISTAL ACETATE - ELLA</u>						
N022474 001	>A> 8426392	Jun 12, 2030	U-1389			
<u>UNOPROSTONE ISOPROPYL - RESCULA</u>						
N021214 001	6770675	Nov 24, 2018	DP U-1322			
<u>ZOLEDRONIC ACID - RECLAST</u>						
N021817 001	8052987	Oct 27, 2023	U-1199			

Footnote:

1. Patents are published upon receipt by the Orange Book Staff and may not reflect the official receipt date as described in 21 CFR 314.53(d)(5).
2. Patents listed prior to August 18, 2003 are flagged with method of use claims only as applicable and submitted by the sponsor. They may not be flagged with respect to other claims which may apply.

PATENT AND EXCLUSIVITY TERMS

Due to space limitations in the patent and exclusivity columns, abbreviations and references have been developed. Refer to the APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS, 33rd Edition for a full listing of patent and exclusivity terms (Abbreviations, Dosing Schedule, Indications, and Patent Use Codes).

The current complete list of patent terms is available at
<http://www.accessdata.fda.gov/scripts/cder/ob/docs/pattermsall.cfm>

The current complete list of patent terms is available at
<http://www.accessdata.fda.gov/scripts/cder/ob/docs/excltermsall.cfm>